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ErgamisoF +  5-FU.
The first adjuvant therapy proven to 
reduce recurrence by 41%.
LEVAMISOLE AND FLUOROURACIL FOR ADJUVANT THERAPY OF 
RESECTED COLON CARCINOMA
Abstract Twelve hundred ninety-six patients with resected 
colon cancer that either was locally invasive [Stage B2] or 
had regional nodal involvement (Stage C) were randomly 
assigned to observation or to treatment for one year with 
levamisole combined with fluorouracil. Patients with Stage 
C disease could also be randomly assigned to treatment 
with levamisole alone. The median follow-up time at this 
writing is 3 years (range, 2 to 5'/2).
Among the patients with Stage C disease, therapy with 
levamisole plus fluorouracil reduced the risk of cancer 
recurrence by 41 percent (P <  0.0001]. The overall death 
rate was reduced by 33 percent (P == 0.006], Treatment 
with levamisole alone had no detectable effect. The results 
in the patients with Stage B2 disease were equivocal and
too preliminary to allow firm conclusions. Toxic effects of 
levamisole alone were infrequent, usually consisting of 
mild nausea with occasional dermatitis or leukopenia, 
and those of levamisole plus fluorouracil were essentially 
the same as those of fluorouracil alone—i.e., nausea, 
vomiting, stomatitis, diarrhea, dermatitis, and leukopenia. 
These reactions were usually not severe and did not greatly 
impede patients’ compliance with their regimen.
We conclude that adjuvant therapy with levamisole and 
fluorouracil should be standard treatment for Stage C 
colon carcinoma. Since most patients in our study were 
treated by community oncologists, this approach should 
be readily adaptable to conventional medical practice. 
(N Engl J Med 1990; 322:352-8.]1
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QUILL ON SCALPEL
Early Gastric Cancer —  Making the 
Asymptomatic Better
N. Schmidt, MD, FRCSC
Member, Editorial Board, Canadian Journal o f  Surgery. Clinical Professor, Department o f 
Surgery, University o f  British Columbia, Vancouver, BC
Gastric cancer doesn’t seem to raise the same interest among 
surgeons it once did. This isn’t 
because the subject is uninteresting 
or inconsequential but because 
there is a sense of futility in treat­
ing a devastating disease with a 
uniformly poor outcome, unless the 
surgeon is fortunate enough to di­
agnose early gastric cancer (EGC).
Is EGC a distinct entity or is it 
merely the beginning of a spectrum 
of gastric mucosal neoplasia? 
Hampson and colleagues from Mc­
Gill University and the Montreal 
General Hospital address that ques­
tion in this issue (pages 349 to
352). Of their 199 cases of gastric 
carcinoma gathered between 1970 
and 1981, 26 by their definition 
(confined to mucosa or submucosa) 
were EGC. The authors correlate 
well the outcome of gastric cancer 
with depth of tumour penetration 
into the stomach wall; however, 
they do not totally address the 
question of whether EGC is a dis­
tinct entity, even though they be­
lieve it is merely part of a continu­
um of an advancing disease.
Because it may occur repetitively 
in family groups, may be indolent 
and may even recur in an early 
superficial and local manner, it is
still argued by some1 that EGC is a 
distinct gastric entity with a more 
favourable biologic nature than 
other forms of gastric cancer. Most 
workers — and here one must pay 
strict attention to the Japanese 
studies — consider EGC to be an 
early stage of progressive and ag­
gressive gastrointestinal malignant 
disease. As a result enormous ef­
forts have been made in Japan to­
ward screening for the early diagno­
sis of gastric carcinoma, which is 
the most common malignant dis­
ease in that country.
Early gastric cancer is indeed 
associated with a favourable statisti-
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cal survival rate. Takagi and 
Nakada2 studied 383 cases of EGC. 
Their 5-year survival was 94% in 
patients who had no lymph-node 
involvement, 74% in patients who 
had regional lymph-node involve­
ment, 64% in those who had sec­
ondary lymph-node involvement and 
26% in those who had remote me- 
tastases. Other large series3 from 
Japan have supported the optimistic 
figures of Takagi and Nakada. But 
the detection of EGC requires a 
screening program of immense 
complexity and cost. Nationwide 
screening for gastric carcinoma car­
ried out in 1985 in Japan alone 
involved 5 161 876 patients, and a 
positive diagnosis was made in only 
6240 patients (0.12%).
There is no doubt that screening 
for malignant disease has reduced 
the clinical severity of carcinoma of 
the cervix, breast and colon. 
Screening does not change the 
prevalence of a disease; it merely 
aims at early detection. However, if 
the incidence of a disease is de­
creasing, the benefits of a costly 
screening program are hard to doc­
ument, since the reduced morbidity 
and mortality may not be the end 
result of early detection through 
screening but of a decreasing preva­
lence of the disease. Since the inci­
dence of EGC is not rising in rela­
tion to advanced gastric carcinoma, 
EGC is most likely an early form of 
a disease with various biologic pre­
sentations and behaviour.4
How can gastric cancer be at­
tacked at a more treatable stage?
With such optimistic results from 
the treatment of EGC and such 
dismal ones from advanced gastric 
cancer, the answer can only come 
through screening programs for 
EGC. Unfortunately to organize a 
program such as this in Canada is a 
near impossibility. Mass screening 
through upper gastrointestinal ro­
entgenography and endoscopy with 
biopsy at a time when a patient is 
asymptomatic is almost impossible. 
The cost, inconvenience, small risk, 
lack of personnel and facilities, and 
failure of patient compliance has 
prevented even mass screening for 
colonic cancer with simple Hemoc­
cult testing, which bears no com­
parison with the complexity of an 
EGC screening program. In 1985 in 
Canada gastric carcinoma was diag­
nosed in 1833 men and 1077 wom­
en. If 1% of the patients had true 
EGC, only 28 patients could expect 
the favourable results of the Japa­
nese experience, if patients had no 
nodal involvement and if gastric 
cancer in Japan and Canada has 
similar biologic behaviour. The Ja­
panese detection rate of EGC of 
0.12% makes the likelihood of diag­
nosis in a Canadian screening pro­
gram even less. It is expected that 
in 1990 a similar number of cases 
of gastric carcinoma with be diag­
nosed, this number being only 3% 
to 4% of all diagnosed malignant 
disease, 14.3% of lung cancer in 
men and 16.7% of breast cancer in 
women. A national screening pro­
gram for detecting EGC with these 
statistics would hardly be cost effec­
tive and is unlikely to be health 
effective.5
What then do we do with gastric 
carcinoma? Massive screening pro­
jects are out of the question. Most 
people suffer epigastric symptoms 6 
to 9 months before gastric carcino­
ma is diagnosed and are sent for 
investigation of epigastric symp­
toms only after a period of initial 
therapy has failed. By being aware 
of the possibility of EGC and know­
ing the favourable results from 
treating it, primary physicians must 
send their patients for more thor­
ough assessment before the disease 
has a chance to become advanced. 
Premalignant conditions can be 
identified and EGC could fortuitous­
ly be found, and the asymptomatic 
patient could indeed be made to feel 
better.
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QUILL ON SCALPEL
Reproductive Conservation
John F. Jarrell, MD, FRCSC
Member. Editorial Board. Professor and Head. Department o f  Obstetrics and Gynecology. 
University o f  Calgary. Calgary. Alta.
One of the most powerful human needs is the need to 
reproduce. Although this is some­
times poorly understood, all cul­
tures share in the celebration of 
birth and the renewal of the life 
cycle. In medicine, disorders of fer­
tility are considered physical handi­
caps of the reproductive system 
and, although not life threatening, 
they take their toll on the individu­
al’s quality of life, particularly in 
cases of permanent sterility.
During the past decade new pro­
cedures have evolved, which are 
collectively known as the “assisted 
reproductive technologies”. These 
procedures are primarily indicated 
for established infertility, which 
may be due to disorders of semen, 
fallopian tubes or ovulation or to 
other abnormalities. They include 
almost all possible forms of interac­
tion of the human gametes alone or 
in combination. What is not gener­
ally appreciated is the extent to 
which these procedures may be 
used to prevent the loss of repro­
ductive capacity when it is vulnera­
ble to the effects of treatment for 
serious medical conditions such as 
cancer. In this editorial I describe 
briefly those assisted reproductive 
technologies that may benefit pa­
tients likely to become sterile as a 
result of cancer treatment.
What are these procedures and 
how do they affect the gynecolo­
gist’s clinical practice? For young 
men facing certain sterility, usually 
as a result of treatment for testicu­
lar cancers or various lymphomas, 
there are two main types of sup­
port, depending on the time frame.
Men who have been sterilized usual­
ly present to fertility clinics with a 
request for donor insemination. 
This technique has been substan­
tially modified in the past decade 
because of the risk of transmitting 
the human immunodeficiency virus 
through semen and blood products 
and the resultant need for quaran­
tine of the semen. In general recipi­
ents find this a satisfactory proce­
dure although, in addition to the 
small risk of acquired immunodefi­
ciency syndrome, there remains an 
unfortunate uncertainty and legal 
vacuum with respect to the legisla­
tion of parenthood.
The other possibility for young 
men may be considered at the time 
of diagnosis when there is a brief 
window of opportunity in which 
semen may be cryopreserved for use 
later when the need for progeny 
may be more appropriate. For this 
to be successful, those managing 
the condition that will render the 
man sterile should at least discuss 
the subject of semen cryopreserva- 
tion with the patient. Although 
some patients may be unable to 
produce a sample of semen, they 
appreciate the opportunity. There 
are concerns about the efficiency of 
this service in achieving the desired 
outcome, but it is reassuring that 
techniques enabling the insemina­
tion of a single spermatozoon into 
an oocyte are currently being devel­
oped in animal models using in- 
vitro techniques. These techniques 
may also help to offset the deleteri­
ous effects of serious diseases, par­
ticularly the lymphomas, on sper­
matogenesis.
With respect to young women, 
the therapy parallel to semen dona­
tion is oocyte donation. This may 
be done following treatment that 
has produced gonadal failure. It is 
possible to maintain pregnancy 
among such women by appropriate 
administration of estrogen and pro­
gesterone. The oocyte is commonly 
donated by either a friend or a 
relative or from an anonymous 
source, usually a patient at an in- 
vitro fertilization clinic. The treat­
ment can be quite successful, and 
for many the limiting factor is an 
acceptable source of oocytes. It is 
fortunate that access to the ovarian 
follicles has recently been facilitated 
by the ultrasonographic vaginal ap­
proach to follicle aspiration. This 
reduces the risk to the donor.
At present there is no technique 
to parallel the cryopreservation of 
semen. Cryopreservation is general­
ly considered to place the oocyte at 
risk because of the large size of the 
cell and the vulnerability of chroma­
tin during the final stages of meio- 
sis when the follicles are aspirated. 
Alternatively, young women suffer­
ing from a condition that will ren­
der them sterile can undergo a 
course of ovarian stimulation and 
oocyte recovery after which the 
oocytes may be fertilized by 
semen from the patient’s partner 
and the resultant embryos cryo­
preserved indefinitely. There is a 
concern that the time required for 
the stimulation cycle and oocyte 
recovery may extend from 2 to 4 
weeks and thereby cause additional 
risk from the original medical con­
dition. This may be alleviated in the
CJS. VOL. 33, NO. 5. OCTOBER 1990 337
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future as a result of recent reports 
that an oocyte may be induced to 
undergo maturation in vitro. Fur­
ther, the availability of ovarian per­
fusion techniques may decrease 
these concerns.
The new techniques are an im­
portant contribution to the holistic 
approach to the patient with cancer. 
They are becoming popular because 
of the failure of other methods,
such as ovarian repositioning before 
irradiation, and the uncertainty of 
the effectiveness of luteinizing hor­
mone releasing-hormone analogues 
in suppressing and maintaining go­
nadal function during chemothera­
py. For these new techniques to be 
effective, however, there must be 
improved communication between 
reproductive endocrine and oncolo­
gy services, improved patient aware­
ness of fertility and its relation to 
cancer and further study of the 
important changes in human rela­
tionships that may occur as a result 
of these treatments.
The recently announced royal 
commission directed to evaluate the 
new reproductive techniques in 
Canada will provide an opportunity 
to increase awareness of such thera­
pies and their implications.*
BOOK REVIEWS
THORACIC SURGERY. Edited by H. 
Pichlmaier and F.W. Schildberg. 460 
pp. Illust. Springer-Verlag New York, 
Inc., Secaucus, NJ, 1989. $375.00 
(US). ISBN 0-387-18464-3
This well-referenced book provides a 
descriptive account of general thoracic 
surgery. All of the chapters have sub­
headings, which makes it easy to find 
specific topics. The thrust of the book 
is toward the indications for specific 
general thoracic surgical procedures as 
well as detailed, practical aspects of the 
operative procedures themselves. Not 
enough emphasis is given to the patho­
physiology of disease processes.
The first chapters outline functional 
studies for assessing operability and 
describe the peri- and postoperative care 
of thoracic surgical patients. A discus­
sion of comparative outcomes of opera­
tive procedures in various disease states 
would have added stature to this book.
The chapter on trauma to the thorac­
ic wall and chest-wall disease is short 
on the pathophysiologic aspects of 
chest-wall injury, but operative proce­
dures and reconstruction of the thoracic 
cage are elegantly described with the 
aid of excellent diagrams. However, the 
book neglects to mention nonoperative 
management of thoracic wall trauma, 
and little mention is made of the devel­
oping use of myocutaneous flaps in 
chest-wall reconstruction, in terms of 
thoracic trauma, not enough emphasis 
is given to the emergency management
of life-threatening thoracic trauma in­
volving the lung parenchyma.
The section on the lung and tracheo­
bronchial tree is especially strong in 
defining the indications for surgery in a 
wide variety of pathologic conditions 
affecting the lung. Methods of surgical 
lung resection are precisely described in 
a step-by-step fashion, together with 
possible complications and ways to 
avoid them. Statements about out­
comes, again, are lacking.
The authors present a well-illustrat­
ed, detailed description and debate of 
the indications and relative merits of 
different approaches to surgical resec­
tion and reconstruction of the esopha­
gus for various disease states and oper­
ative conditions. They, quite rightly, 
favour the use of stomach over jejunum 
and colon as an esophageal substitute. 
In situations in which the stomach 
cannot be used as a substitute, they 
favour the use of colon over jejunum 
and limit the use of jejunum to replace 
the lower esophagus. The jejunum, 
however, can be used to replace the 
whole esophagus and can, in most 
patients, be elevated to the level of the 
neck. Although preparation of a jejunal 
segment for transposition to the neck is 
difficult and requires meticulous tech­
nique, its function is superior to that of 
colon. The technique requires dissect­
ing free the peritoneum overlying the 
arcades, defatting of the jejunal mesen­
tery and separate dissection and ligation 
of the mesenteric arteries and veins to
the selected segment to allow lengthen­
ing of the jejunal arcades.
In the chapter on the functional 
diseases of the esophagus, the authors 
stress that since surgery does not re­
store the normal motor function of the 
esophagus, accurate analysis of esopha­
geal function is essential when selecting 
patients for operative treatment. How­
ever, the authors failed to discuss the 
process of investigation and selection of 
such patients for operation. Good de­
scriptions of the technical aspects of 
surgery for esophageal diverticuli, dif­
fuse esophageal spasm, achalasia and 
gastroesophageal reflux are given, but 
again there is little information on the 
pathophysiology of these conditions 
and virtually no discussion 'of the out­
come of surgical management. In the 
section on gastroesophageal reflux and 
hiatus hernia, there are well-illustrated 
accounts of various antireflux surgical 
procedures. The authors favour the 
transabdominal approach, which I be­
lieve is the right one. It is not unusual 
to see patients completely free of symp­
toms of gastroesophageal reflux several 
years after a transthoracic procedure 
but complaining bitterly of post­
thoracotomy pain. The authors point 
out that the transthoracic approach is 
preferred in obese patients, in patients 
who have a short esophagus and in 
those who have recurrent gastroeso­
phageal reflux following a previous
continued on page 340
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CORRESPONDENCE
Classification Systems for 
Colorectal Carcinoma
To the editors. I read with interest 
Dr. Schubert’s history of the evolu­
tion of classification systems for 
staging cancer of the rectum (Can J 
Surg 1990; 33: 8-11). He has 
assembled and critically analysed all 
of the important staging systems 
except the newest and most impor­
tant. In 1987 a TNM (tumour- 
node-metastasis) staging classifica­
tion was put forward with the com­
bined efforts of the Union interna- 
tionale contre le cancer (UICC)1 and 
the American Joint Committee on 
Cancer (AJCC).2 Table I shows the 
similarity between the original 
Dukes’ stages and this classification 
system.
The primary purpose of a good 
classification system for cancer is 
not to ease one’s memory load but 
to stage patients with respect to 
prognosis and, possibly, further 
treatment. An example is the subdi­
vision of Stage III (Dukes’ C) into 
N1 (metastases in one to three 
pericolic or perirectal lymph nodes) 
and N2 (metastases in four or more 
pericolic or perirectal lymph nodes). 
The number of lymph nodes has 
been shown to have prognostic im­
Table I. Combined U ICC-AJCC 
Classification System for Staging of 
Colorectal Cancer Compared With Dukes’ 
Classification*
Stage Dukes’ stage TNM
1 A T1N0M0
T2N0M0
II B T3NOMO
T4NOMO
III C T (any) N1M0 
T (any) N2M0 
T (any) N3M0
IV T (any) N (any) M1
*UICC =  Union internationale contre le 
cancer, A JCC  =  American Joint Committee 
on Cancer, TNM =  tumour-node-meta­
stasis.
portance,3 although different break 
points have been used.
As physicians of different disci­
plines and nationalities become in­
volved in the multimodality treat­
ment of cancer, accurate staging 
becomes more important. A com­
mon language must be used. The 
UICC/AJCC TNM system satisfies 
these criteria. I would encourage its 
use throughout Canada.
D.R. McCready, MD, FRCSC
Department o f Surgery,
Women’s College Hospital,
University o f  Toronto,
Toronto, Ont.
M5S 1B6
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To the editors. Dr. McCready pro­
poses that my article “Dukes’ clas­
sification: American chaos versus 
British order” (Can J Surg 1990; 
33: 8-11) omits the “newest and 
most important” staging system, 
which he refers to as the UICC/ 
AJCC TNM (tumour-node­
metastasis) classification. The En­
glish translation of the Union inter­
nationale contre le cancer (UICC) is 
the International Union Against 
Cancer. This system’s classification 
was indeed referenced in my origi­
nal article in its English translation 
(reference 19).
In McCready’s opinion the break­
down into eight subcategories rath­
er than Dukes’ simple A, B and C 
classification would “stage patients
with respect to prognosis and possi­
ble further treatment” , and he pro­
poses that this gargantuan system 
would be a better classification to 
use as a national policy in Canada. 
Indeed, this is similar to the asser­
tion made by most of the authors of 
the 11 additional classification sys­
tems I have made reference to in my 
article. McCready’s argument would 
be stronger if he had proof, from 
studies or references, that patients 
in each of the UICC subcategories 
had a significantly different progno­
sis or required substantially differ­
ent treatment. The National Surgi­
cal Adjuvant Breast Project 
(NSABP), to which McCready re­
fers, concluded that there may be a 
“unique Dukes’ C subset of pa­
tients” with a prognosis “at least as 
good as Dukes’ B lesions” in which 
there was just partial tumour pene­
tration and “the presence of 1-4 
positive nodes” .1 This article goes 
on to “raise serious doubts con­
cerning the propriety of the newly 
proposed TNM classification 
schemes that fail to utilize the 
number of positive nodes as a pre­
dictive discriminant” . It was cer­
tainly satisfying to see that the 
authors of this NSABP report, 
which represented 75 prominent 
Canadian and United States institu­
tions, continued to use Dukes’ no­
menclature in their discussion. In 
their conclusions they stated, “ It is 
neither the intent nor the desire of 
this report to continue the assault 
on the Dukes’ classification, and it 
is quite evident that more than 
enough eponymous variants are in 
existence.”
I would like to renew my plea 
that surgeons resist the obsession 
to subdivide and subcategorize and 
that they not be seduced into using 
new classification systems by 
phrases such and “new and im­
proved” , “newest and most impor-
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tant” or even “international”, un­
less new systems have been scientif­
ically studied and proven superior 
to Dukes’ classification for patient 
management. In Dukes’ final up­
date, he reported on a series of 
2447 patients studied over 25 
years.2 I am unaware of any other 
study proposing a newer classifica­
tion system in which such large
BOOK REVIEWS
continued from page 338
transabdominal antireflux procedure.
The book puts in one package indica­
tions, techniques and practical hints for 
performing a wide variety of general 
thoracic surgical procedures. However, 
it lacks description of clinical aspects, 
pathophysiology and investigation of 
the disease processes for the surgical 
procedures. As such, it amounts to a 
“how to” book. Despite these short­
comings, it will be useful to both prac­
tising general thoracic surgeons and 
residents.
Hensley A.B. Miller, MB, BS, FRCSC
Division o f  General Surgery,
Sunnybrook Hospital,
University o f  Toronto,
Toronto, Ont.
SURGICAL MANAGEMENT OF 
RHEUMATOID ARTHRITIS. Edited 
by F. Howard Beddow. 194 pp. Illust. 
Butterworths, Stoneham, Mass. 1988. 
$160 (US). ISBN 0-7236-1007-X
This is a valiant attempt by F. Howard 
Beddow, an orthopedic surgeon from 
Liverpool, England, to tie together the 
various strands in the surgical manage­
ment of rheumatoid arthritis. It is based 
on 25 years of clinical experience and 
tutorials. The target audience is ortho­
pedic surgeons-in-training. Beddow has 
gathered eight worthy collaborators but 
has done most of the work himself.
The text is divided into sections on 
medical management, pathologic as­
pects, anesthesia and the surgical man-
340 CJS, VOL. 33, NO. 5, OCTOBER
numbers of patients have been stud­
ied and the 5-year survival has been 
evaluated.
Warren Schubert, MD
Department o f  Surgery,
University o f  Minnesota,
Box 122, Mayo Memorial Building,
Minneapolis, MN
55455
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agement of various regions commonly 
affected by rheumatoid arthritis.
The section on medical management 
is useful for orthopedic surgeons who 
may not have a good working relation­
ship with a rheumatologist. The days 
when rheumatologists saw their main 
role as protecting patients from ortho­
pedic “knuckle-walkers” is slowly pass­
ing, but surgeons should know a little 
about medical management.
The section on pathologic aspects is 
an interesting update, but many of the 
old standards such as pannus invasion 
and the primary role of the synovium 
are still included. No one knows the 
cause of rheumatoid arthritis, but as 
any surgeon can attest, once all the 
articular cartilage is gone, that joint 
will never again be involved in the 
arthritis process.
With respect to the surgical sections, 
most chapters are good, especially the 
one on the upper limb. Soutar’s section 
on the elbow is superb. I found the 
chapters on feet and hip disappointing. 
Almost the only forefoot operation de­
scribed is excision of all the metatarsal 
heads, which I was taught as a resident, 
but which I believe has a limited role.
The hip replacement section is dated; 
no mention is made of noncemented 
hips or of modern techniques of ce­
menting such as canal plugging, brush­
ing, lavage and pressure injection. The 
vast amount of cement distal to the 
prosthetic tip, shown in Fig. 10.13 
would do nothing to add to fixation and 
makes revision a nightmare. There is 
nothing at all on hip revision, which in
Canada is now exceedingly common 
because many patients with rheumatoid 
arthritis who had their hips replaced in 
the early 1970s are beginning to experi­
ence loosening of the prosthesis. Infec­
tion, both in the hip and knee, is dealt 
with superficially.
Overall, I liked this book. Most or­
thopedic surgeons who look after pa­
tients with rheumatoid arthritis will find 
something of value in it. Although it 
will not replace Campbell’s textbook as 
the bible for the orthopedic resident, 
this slim, 200-page book should be read 
by all orthopedic surgeons-in-training.
Hugh U. Cameron, MB, ChB, FRCSC
Ste. 318,
43 Wellelsley St. E,
Toronto, Ont.
TEXTBOOK OF LIVER AND BILI­
ARY SURGERY. William C. Meyers 
and R. Scott Jones. 489 pp. Illust. J.B. 
Lippincott Co., Philadelphia. 1990. 
$99.50 (US). ISBN 0-397-50774-7
This book is intended to be a compre­
hensive source of information for liver 
and biliary tract surgeons. The 12 sec­
tions cover the development of liver and 
biliary surgery, anatomy, physiology, 
signs and symptoms of hepatobiliary 
disorders, radiologic and other diagnos­
tic considerations, disorders of the liver, 
disorders of the biliary system, liver
continued on page 352
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HOW I DO IT
Bikini Appendectomy Incision as an 
Alternative to the McBurney Approach for 
Appendicitis
Walley J. Temple, MD, FRCS, FACS
W ith respect to appendectomy, a surgeon’s handiwork is 
often measured by the scar he 
leaves rather than by the quality of 
his surgery and the lifesaving 
judgements he makes. This is par­
ticularly true among the younger 
patients who spend a good deal of 
time in the sun, for whom some of 
the pleasures of an attractive phy­
sique will be marred by an abdomi­
nal scar. We tend to forget this at 
the start of surgery because of the 
overriding immediate concerns of a 
life-threatening problem, and we 
often forget it at the end of the 
procedure because we do not re­
member that it is important to leave 
as cosmetically attractive a scar as 
possible. Gynecologists have been 
sensitive to this need, using the 
Pfannenstiel incision for various 
pelvic operations. In this paper I 
describe a modified surgical ap­
proach to appendicitis — one that 
allows the scar to be completely 
hidden.
As one might guess this modified 
surgical approach was stimulated 
by experience with a patient, a 
20-year-old woman who presented 
in the middle of the Canadian win­
ter with a bikini tan obtained from a 
sojourn to the South. She was very
upset over having her expensive tan 
ruined by emergency surgery. 
Hence, I named the modified inci­
sion the bikini incision.
Method
All patients whom I saw with a 
diagnosis of appendicitis between 
1983 and 1984 are included in this 
report. Documentation of diagnosis, 
complications, technical difficulty, 
cosmetic results and days of hospi­
tal stay were tabulated. All but 
obese patients and those with signs 
of high retrocecal appendicitis were 
considered for the modified ap­
proach.
The Incision
A transverse incision is made in 
the superior pubic hairline through 
the skin and Scarpa’s fascia down 
to the external rectal sheath (Fig. 
1). The incision extends from just 
lateral to the midline for an average 
of 5 to 6 cm, as needed for subse­
quent exposure. A plane on the 
rectus fascia is easily created by 
sweeping the skin and subcutane­
ous tissues superiorly. With skin
retracted the external oblique fascia 
is incised approximately at McBur- 
ney’s point and the abdomen is 
entered through a standard muscle­
splitting approach. Depending on 
the body habitus, the area exposed 
on the abdominal wall is slightly 
more medial, and adequate expo­
sure occasionally requires the inci­
sion be extended medially into the 
rectus sheath. However, it is not 
necessary to transect the rectus 
muscle. If one must explore the
FIG. 1. Diagrammatic representation 
of “bikini” incision. A = muscle-split­
ting incision near McBurney’s point on 
abdominal wall. B = skin incision 
retracted to expose McBurney’s point 
on abdominal wall. Skin and subcuta­
neous tissue are easily mobilized off 
external oblique fascia. C =  site of 
appendectomy incision just above 
pubic hairline. This is extended to 
expose external oblique fascia.
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abdomen through this approach, 
the skin incision may be extended 
laterally and the abdominal incision 
enlarged as needed. The abdominal 
wall is closed in a standard fashion. 
No drains are left in the subcutane­
ous tissue tunnel. Two or three 
chromic catgut sutures are used to 
approximate the subcutaneous tis­
sue, and skin tapes are applied. 
When a drain is required because of 
an abscess it is brought out 
through the abdominal wall directly 
below the skin incision but with 
care taken to stay above the ingui­
nal canal.
Results
Of 28 patients operated on for
acute appendicitis, 16 (12 females, 
4 males) had the modified McBur- 
ney “bikini” incision. Twelve ap­
pendices were acute or suppurative, 
1 was perforated and 2 were nor­
mal. Two patients had associated 
abscesses that needed drainage. 
One normal appendix extended re- 
trocecally about as high as the 
gallbladder. Three incisions were 
extended to assist exposure. One 
wound infection occurred and 
healed by secondary intention but 
without an unsightly scar. Hospital 
stay ranged from 3 to 14 days 
(median 4 days, mean 5 days). In 
Table I, these results are compared 
with those in 12 patients whose 
appendices were removed by the 
standard McBurney incision.1 Cos­
metically the pubic hairline scars
were all judged as excellent and 
preferable to the usual paraumbili­
cal McBurney scar (Figs. 2 and 3).
Comments
The bikini incision is cosmetically 
superior to the standard McBurney 
incision. It is equally safe and is not 
associated with an increase in com­
plications or length of hospital stay. 
It is slightly more difficult to obtain 
adequate exposure than with the 
McBurney approach, but the inci­
sion can be extended for increased 
exposure while still resulting in a 
well-hidden scar. The subcutaneous 
tunnel and the potential for infec­
tion were not a problem. Although 
this incision has been used in al­
most every situation, it was avoided 
in obese patients, in those who had 
posterior flank signs and symptoms 
suggestive of a retrocecal appendix 
and in those who did not need a 
cosmetically superior incision.
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T a b le  1. Comparison of Findings in 28 Patients Who Underwent Appendectomy Using Either the 
“ B ik in i" or McBurney Incision
V aria b le B ikini
Inc is ion
M cB urney
No. of patients 14 12
Pathologic feature of appendix
Acute inflamm ation/suppuration 12 7
Gangrene 0 1
Perforation 1 4
Abscess 2 0
Normal 2 2
Wound infection 1 1
Hospital stay, d
Range 3 - 1 4 3 - 8
Mean 5 5
' 'iff
FIG. 2. Healed bikini appendectomy incision (6 weeks) at “tan 
line”, just above pubic hair line. FIG. 3. Modified appendectomy incision hidden by bikini.
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CANADIAN ASSOCIATION OF GENERAL SURGEONS
Presidential Address, 1989. Canadian 
General Surgery: Alive and Well
Fred G. Murphy, MD, FRCSC
N /
General surgery in Canada is alive and well because general surgeons remain 
versatile and adaptable. If this were not the case, the specialty of general surgery 
would go the way of the dinosaur.
The continuing evolution of general surgery can only be maintained by reviewing 
the following: (a) training; (b) continuing education; (c) maintenance of competence; 
(d) manpower and economic aspects; and (e) interaction of general surgeons with 
other surgeons and specialties.
The Canadian Association of General Surgeons will continue to play a vital role 
in maintaining liaison between all types of general surgeons across the country and 
help, in any way possible, to support the ever-changing face of general surgery.
La chirurgie generale au Canada vit et se porte bien parce que le chirurgien general 
a su maintenir des talents varies et demeurer souple. Si cela n’etait pas le cas, cette 
specialite subirait le sort qu’ont connu les dinosaures.
Le maintien de 1’evolution constante de la chirurgie generale depend des facteurs 
suivants: (a) l’enseignement; (b) la formation continue; (c) le maintien des 
competences; (d) la consideration des effectifs et de l’aspect economique; et (e) 
l’interaction des chirurgiens generaux avec les autres chirurgiens et autres 
specialites.
L’Association canadienne des chirurgiens generaux continuera de jouer un role 
vital dans le maintien d’un lien entre tous les types de chirurgiens generaux a 
travers le pays et aidera, dans la mesure du possible, a soutenir les virages constants 
de la chirurgie generale.
I can think of no greater honour and privilege than to be selected 
by my peers to be your president. 
As you know, our society is rela­
tively young, being 12 years old, 
but when I review the list of past 
presidents, I feel most proud that 
my name would be associated with 
such distinguished surgeons. This 
year, Dr. Bruce Tovee, our second 
president, passed away, and I think
Accepted for publication May 22, 1990
it is appropriate to bring his death 
to the attention of our association. 
It is because of such men as Dr. 
Tovee that our society, which 
brings together general surgeons 
from all over Canada, is in exis­
tence. My year as president has 
been an excellent learning experi­
ence, and had it not been for the 
helpful people about me — the 
executive, the committee chairmen
and the executive director — I 
would have found this an insur­
mountable task. My wife, too, al­
ways managed to correlate my per­
sonal and working life to allow me 
to attend meetings, conferences and 
teleconferences.
One of the privileges the presi­
dent of the association has is to 
address you. This meant reviewing 
other presidential addresses, which, 
generally, carry a message or give 
an overview of the “state of the 
union” for the year. After practis­
ing general surgery in a community 
hospital for 30 years, I have found 
that one of the most persistent, 
recurrent complaints is that general 
surgery is a disappearing specialty 
and that it is being hacked and 
dismembered, piece by piece, from 
inside, from outside, from top to 
bottom, so that soon there will be 
no specialty of general surgery. My 
good friend Dr. Roy from Quebec 
has even provided an obituary that 
was prepared for the Province of 
Quebec. Fortunately, as with politi­
cal forecasts, it should be taken 
with a grain of salt. It is my own 
feeling that, rather than becoming 
extinct like the dinosaur, we are an 
extremely active, adaptable, ver­
satile and vital group of first-line 
surgeons. As many of you know, 
one of my favourite pastimes is 
fishing for Atlantic salmon. Just as 
salmon fishing is the king of sport 
fishing, so, also, general surgery is 
the king of surgery because both, 
in their own way, share unparalleled 
excitement, anticipation and re­
ward.
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In the large centres, as Dr. Lang- 
er noted last year,1 the importance 
of surgical research and the results 
of research done by surgeons 
through the years has been tremen­
dous. Surgical research must be 
encouraged and kept moving for­
ward. At the other end of the scale, 
the king of the castle in small 
community hospitals is the general 
surgeon. He has to be extremely 
adaptable — he has a type of 
practice that very few of us can 
perform. Personally, I practise in a 
medium-sized, hospital with more 
than 500 beds and, having met 
surgeons at both ends of the scale, 
1 realize how few of us, after we 
have been in practice for 5 to 10 
years, could substitute for one an­
other. Consequently, it is important 
that, as a group, we have a deep, 
mutual respect for the type of prac­
tice which each association member 
has in this wide country. We must 
never forget that Canada starts at 
Newfoundland and extends through 
to Victoria, that the physical layout 
of Canada is such that centraliza­
tion of services is not feasible. It 
must also be realized that lay peo­
ple and politicians have dictated to 
physicians and surgeons much of 
how and where medical services will 
be made available. Therefore, even 
though medical personnel have 
input into what is or is not ideal, we 
must accept that we are not the 
masters of our house, that our 
houses are provided by the people 
of our country through the govern­
ment, and we must make every 
effort to provide the best possible 
surgical service for all arenas.
This leads to the many facets of 
surgical practice which the Canadi­
an Association of General Surgeons 
(CAGS) can influence through the 
activity of its members. It is impor­
tant that more members from all 
areas and types of practice should 
volunteer their services to help elu­
cidate the problems that face sur­
gery today, in order to keep it alive 
and well.
I have considered several parame­
ters upon which I intend to enlarge, 
which will help to keep us, as 
surgical leaders, viable, adaptable 
and versatile. These are: (a) the 
training of surgeons; (b) the contin­
uing education of surgeons; (c) the 
maintenance of competence; (d) 
manpower and economic aspects; 
(e) the interaction between general 
surgeons and other surgeons and 
physicians.
Training of Surgeons
The training for general surgery 
has just been extended to 5 years 
by the Royal College of Physicians 
and Surgeons of Canada. Indeed, it 
shows that the field of general 
surgery is not shrinking but, rather, 
it is expanding to the point where it 
needs more time for training than 
ever before. I would like to see at 
least 1 of these 5 years spent in 
surgical research, and the program 
of surgical research should be set 
so that it would be worthwhile to 
the nation and to surgeons in train­
ing in the development new tech­
nology and furthering medical 
progress. Also, equally important, 
the resident or fellow should be 
encouraged to develop a truly ana­
lytical mind. It is much too common 
in other specialties to have a sort of 
knee-jerk reaction to medical care, 
and the first thing reached for is 
another test, with an appropriate 
arrow pointing to the next step, to 
another arrow, to the next step. As 
Ravitch suggests, the surgeon be­
comes the end organ of some cere­
bral synapse elsewhere.2
I believe that a deductive type of 
thinking and logical process from a 
mind that has been helped by re­
search to understand pathophysi­
ologic processes will help to prevent 
that mind from developing a “lazy
brain syndrome”. It will also help 
develop a continuing, self-critical 
mind which keeps the surgeon 
learning through his or her lifetime. 
As Thomas Carlyle wrote: “the 
greatest of all faults is to be con­
scious of none”. All too often, I get 
a pert answer from a young intern 
who says that even though the 
patient looks like a facies of Hamil­
ton Bailey’s Textbook o f Surgery, 
his x, y and z tests are normal; 
therefore, the patient must be all 
right. I think that a well-trained 
surgeon must be a well-thinking 
surgeon, and there is no better 
place than a year or so of thought­
ful and worthwhile research.
The other aspect of a 5-year 
training program is that all pro­
gram directors and chairmen of the 
departments must, at all cost, con­
sider the primary purpose of a resi­
dency program to be education of 
the resident and not service to the 
hospital. Frank C. Spencer has elic­
ited some aspects of residency train­
ing, stating that (a) the primary 
purpose is education, (b) the on-call 
time must be reasonable and (c) the 
number of hours spent in “scut 
work” must be kept well under 
control.3 Thus, the extra time 
would be used to train a better 
surgeon and not to keep the appro­
priate manpower in the service of 
the program itself. As I listen to 
many general surgeons across Can­
ada, I realize that it would be 
impossible to train every surgeon 
for every situation for every hospi­
tal size in our country.
It seems to me that after some 
“core training”, there should be a 
trend to three types of general 
surgeon. One type would practise in 
a large teaching hospital and would 
require extra training in his or her 
special interest of surgery. Such a 
surgeon would become a leader in 
that particular aspect of general 
surgery. A second type would be 
the general surgeon in a medium-
A
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sized hospital who should be able to 
add to the surgical services provid­
ed by having a certificate of special 
competence or accreditation with­
out certification in such fields as 
thoracic, vascular and head and 
neck surgery, surgical oncology, 
critical care and trauma, thus en­
hancing the overall care of people 
in the region served. The third type 
would be a surgeon in a smaller 
hospital, who must have a good, 
broad basis with a thinking, deduc­
tive surgical mind, who soon learns 
his abilities and capabilities, his 
inabilities and his limitations, so 
that he can handle well the prob­
lems within his scope but recog­
nizes quickly the ones with which 
he needs further help. Again, an 
organization such as CAGS should 
be able to cement relationships 
among surgeons at various levels of 
hospitals and surgical care. It 
should always be considered an 
honour for any surgeon to be con­
sulted by another surgeon for spe­
cial expertise and help.
It is apparent that, after practis­
ing for many years, the surgeon 
tends to develop a certain degree of 
tunnel vision as to the best type of 
surgery and practice —- that theirs 
is the one and only type — and to 
feel sorry for the surgeon who is in 
a larger or smaller centre, who just 
doesn’t know what the real world is 
like. It might be conceived that 
many young surgical residents feel 
insecure in leaving the large centre, 
and it is suggested that the “role 
model” for surgeons to go out into 
smaller communities where the 
need is the greatest is not seen 
these large centres. Serious consid­
eration must be given to a rotation, 
of a reasonable period of time, to 
community hospitals to see what 
that type of surgical practice is like. 
Paul A. Ebert stated recently that 
“we continue to ask ourselves why 
subspecialization has become so 
popular, especially in general sur­
gery” .4 He stated that “it is only 
normal for students to imitate their 
teachers”. I think that anybody 
who trained in Montreal during the 
time of the late Dr. John Armour 
would have recognized his residents 
at the dining table because within 
weeks they had the same fiery lines 
and the same mannerisms as their 
chief, and these lasted through 
their whole residency. So contact 
with a “role model” seems essential 
in the enticement of general sur­
geons to communities where there 
is an acute shortage.
To all young surgeons, a word of 
wisdom written in 1711 by Alexan­
der Pope: “be not the first by whom 
the new is tried nor yet the last to 
lay the old aside”;5 or, as stated by 
another: “there are two types of 
fools; one says ‘this is old and 
therefore is good’; the other says 
‘this is new and therefore better’.”
Continuing Education of 
Surgeons
I feel that a well-trained general 
surgeon in a good surgical program 
must get the impetus to continue 
his education, and I think that 
CAGS has shown itself to be a 
leader among the national specialty 
societies that meet in conjunction 
with the Royal College meeting; 
CAGS produces a worthwhile pro­
gram that is informative and stimu­
lates continuing education. The un­
fortunate fact is that there are 
many members of our association 
who do not attend. I am sure that 
they must attend meetings else­
where. It is my opinion that our 
meetings should be across the na­
tion, as they have been, so that 
easterners who refuse to go west 
and westerners who refuse to go 
east get a chance to attend our 
meetings. The education committee, 
in the past and at present, has done 
a tremendous job. The postgradu­
ate courses have been increasing in 
attendance each year, and continu­
ing education will keep general sur­
geons from becoming an endan­
gered species. In the future CAGS 
may sponsor regional courses.
Maintenance of Competence
This is a question which CAGS 
must address. Already, the Royal 
College is becoming involved. Main­
tenance of competence is, at pres­
ent, a touchy political issue, but 
some realize that if surgeons do not 
become involved, then other 
groups, other people and other 
agents will become involved. I think 
that all of us, as we practise over 
the years, perform fewer procedures 
more often as we abandon one part 
of the body because of special inter­
est in another part. Though we 
have much in common, we also 
have much not in common; there­
fore, it seems appropriate to me 
that, when this form of maintain­
ing competence is programmed, 
each surgeon will have to identify in 
which aspect of medical and surgi­
cal practice he wishes to be 
considered competent. I agree that 
the basic aspect of surgery is com­
mon to all, but the search for a 
parathyroid tumour might interest 
only a very small percentage of us 
here today. The management of 
thoracic outlet syndromes would 
interest an even smaller percentage, 
so I see this as a very important, 
but complicated, problem which is 
going to be in the forefront of both 
the Royal College and our associa­
tion in the ensuing years.
Manpower and Economic 
Aspects
The manpower problem in Cana­
da has been more than amply cov­
ered in other presidential addresses.
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There is an acute shortage of gen­
eral surgeons in Canada, and sur­
geons have been criticized for leav­
ing general surgery and going into 
the more glamorous subspecialties. 
I realize that, at least, there is a 
maldistribution of general surgeons. 
Also, I am sure that subspecializa­
tion is a universal trend in all 
medical practices and that there is a 
certain desire to know more about a 
little throughout the medical field. 
This is not a bad concept. I believe 
that surgeons have done this of 
their own volition because of the 
type of practice that they feel they 
would be most comfortable doing. I 
have referred to some manpower 
problems along with those of train­
ing in my discussions with those 
who have practised in large commu­
nities with modem facilities and 
then have gone to the far north or 
the far east and have been aston­
ished at how quickly they needed to 
go back to their basic training to 
manage the new type of practice 
they have encountered.
Economics is also considered to 
be a factor associated with manpow­
er. I do not need to tell everyone 
here today that for what we do and 
the responsibilities and intensity of 
our work, we are not economically 
rewarded. Some of my old surgical 
friends have said to me that young, 
smart practitioners who have decid­
ed to go back to specialize told 
them: “ I like what you do in gener­
al surgery, but no way am I going 
to suffer the anxieties brought on 
by the tenseness of the work, the 
long hours of the work, for the 
economic return, when so many 
other specialties have a much better 
lifestyle and a much better econom­
ic return.” Saints and martyrs are 
good people, but they are not as 
popular as they once were. I think 
that this is probably a universal 
problem across our nation. The 
ongoing committee in CAGS has 
been working towards evaluating 
this problem.
Interaction Between General 
Surgeons and Other Surgeons 
and Physicians
There is continual interaction be­
tween the practice of general sur­
gery, other surgical subspecialties 
and physicians. Reviewing some of 
the recent presidential addresses of 
other societies, it is interesting to 
note that paranoia runs high at 
times. One of the main problems in 
general surgery is the attitude of 
general surgeons. The general sur­
geons seem to be thrilled by doing 
the biggest and most difficult proce­
dures in their area of practice or 
interest. They have, through the 
years, developed diagnostic proce­
dures which have been beneficial, 
but because they were more mun­
dane, they have let them trickle off 
to their physician friends. For ex­
ample, the diagnostic procedures 
associated with arteriography have 
been gladly referred to our radiolo­
gy friends, who now do them bet­
ter. When a field is given up, con­
trol over further developments is 
also surrendered, so that we now 
have interventional radiologists who 
suggest that a second opinion be 
obtained by them as to which vas­
cular problems should be managed 
by the surgeon. Another example is 
the field of endoscopy. Here CAGS 
has done a tremendous job to main­
tain endoscopy in the field of surgi­
cal training. However, the therapeu­
tic aspect of endoscopy is not pur­
sued by all surgeons. Young sur­
geons and those in training should 
make every effort to keep up with 
and look into the future of such 
“mundane procedures”. It is very 
easy to abandon a railway track, but 
it is nearly impossible to have it 
rebuilt; therefore, surgeons should 
take a keen interest in what they 
are abandoning.
The other interaction, of course, 
is between general surgeons and 
subspecialist or superspecialist 
groups. It seems that in medical
schools students have been taught 
that some diseases and treatments 
which general surgeons believe be­
long in their field belong to a 
subspecialist group. The solution 
here is that whatever a general 
surgeon decides to do in the area in 
which he practises, he must do well, 
he must keep up to date, be re­
spected and maintain overall compe­
tence to win out eventually. Many 
of the diseases treated by general 
surgeons 30 years ago have been 
abandoned, and this is kept fore­
most in our minds; however, there 
are many new procedures, new de­
velopments and new techniques 
which, if we maintain our adaptabil­
ity and versatility, will ensure that 
we will not become dinosaurs. This 
cannot be accomplished without a 
vibrant society like ours and a great 
deal of personal effort by the gener­
al surgeon. The avoidance of a 
“lazy brain syndrome”, by main­
taining a logical and self-critical 
mind, will and must prevail.
And so not to get caught up in 
too many words, again I refer to 
Alexander Pope:6 “Words are like 
leaves; and when they most abound 
much fruit of sense beneath is rare­
ly found.”
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Early Gastric Cancer: Is It a Distinct 
Clinical Entity?
Lawrence G. Hampson, MD, FRCSC, FACS;* Hani Shennib. MD, MSc, FRCSC;* John 0 . Lough, MD, 
FRCPC;t Gerald M. Fried, MD, FRCSC*
Of 199 patients with gastric cancer seen at The Montreal General Hospital between 
1970 and 1981, 104 were considered to have had a curative resection, and 26 of 
these were early gastric cancers (EGC). The authors compared early gastric cancers 
with advanced, but resectable, gastric cancers to determine whether EGC is a distinct 
entity or a stage in the progressive evolution of gastric cancer. They found that 
depth of invasion was the primary determinant of outcome, but that there was no 
discrete cut-off point between the depth of invasion associated with early and with 
advanced gastric cancers. The pathological features normally associated with a 
favourable prognosis in gastric cancer, such as absence of lymph-node metastases, 
an expanding growth pattern, intestinal metaplasia, and well-differentiated 
histologic features correlated highly with depth of invasion but did not appear to 
change abruptly between EGC and advanced resectable lesions.
The authors conclude that EGC is not a distinct pathological or clinical entity but 
a stage in the progressive growth of gastric cancer.
Des 199 patients souffrant d’un cancer gastrique vus a l’Hopital general de Montreal 
entre 1970 et 1981,104 ont subi une resection jugee curative, et 26 de ceux-ci 
etaient porteurs de cancers gastriques precoces (CGP). Les auteurs ont compare les 
cancers gastriques precoces et les cancers gastriques avances mais resecables afin de 
determiner si les CGP represented une entite distincte ou un stade dans revolution 
du cancer gastrique. Lis ont observe que la profondeur d’envahissement constitue le 
premier determinant de Tissue de la maladie mais ils n’ont pu etablir de profondeur 
critique permettant de distinguer cancers gastriques precoces et avances. Les 
caracteristiques pathologiques normalement associees a un pronostic favorable telles 
que Tabsence de metastases des ganglions lymphatiques, de caracteristiques 
devolution, de metaplasie intestinale, et les caracteristiques histologiques de 
differenciation offraient une forte correlation avec la profondeur d’envahissement 
mais elles ne paraissaient pas changer brusquement entre les CGP et les lesions 
resecables avancees.
Les auteurs concluent que les CGP ne represented pas une entite pathologique 
ou clinique distincte mais un stade de 1’evolution du cancer gastrique.
Early gastric cancer (EGC), de­fined as a tumour confined to 
the mucosa or submucosa of the 
stomach with or without nodal me­
tastases,1'2 is being diagnosed more
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frequently because of the increased 
availability and accuracy of diagnos­
tic techniques.
Since EGC was established as a 
distinct lesion, the remainder of
gastric malignant tumours have 
been referred to as advanced gastric 
cancers.1-3 Many regard EGC as a 
distinct clinical entity.4 The ques­
tion of whether it is a distinct entity 
or merely an earlier stage in the 
evolution of gastric cancer has not 
been resolved.
We carried out a retrospective 
study of gastric cancer at The Mon­
treal General Hospital over the 
11-year period from 1970 to 1981 
to assess our total experience with 
gastric cancer. From this study we 
were able to compare EGC with the 
more advanced forms. If early gastr­
ic cancer were truly a distinct enti­
ty, one would expect a distinct 
fall-off in survival and in those 
pathological features known to be 
associated with a favourable prog­
nosis when EGC is compared to 
advanced, but resectable, gastric 
cancer. Such pathological features 
include absence of lymph-node me­
tastases, well-differentiated histo­
logic features, presence o f intestinal 
metaplasia in the gastric mucosa 
and an expanding pattern o f tu­
mour growth.5
Patients and Methods
The clinical and pathological fea­
tures of 199 gastric carcinomas 
diagnosed at The Montreal General 
Hospital between 1970 and 1981 
were documented. Tumours were 
diagnosed by x-ray studies or en­
doscopy, or both. If surgery was 
carried out, the type and extent of 
the operation were noted. A judge­
ment was made as to whether the 
procedure was considered curative 
or palliative by the operating sur-
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Hospital and McGill University. Montreal. PQ
Presented at the 11th annual meeting o f  the Canadian Association o f General Surgeons, held in 
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geon. All patients had a pathologi­
cal diagnosis of gastric cancer, and 
pathology reports were reviewed 
and histological sections re­
examined by a single pathologist to 
establish the site, morphologic find­
ings, depth of invasion and the 
presence or absence of lymph-node 
metastases in each case. The degree 
of tumour differentiation was re­
corded and the pattern of tumour 
growth, either expanding or infil­
trating, was noted. In addition, the 
presence or absence of intestinal 
metaplasia in the gastric mucosa at 
a distance from the tumour itself 
was evaluated. Metaplasia was con­
sidered to be absent if the change 
was either absent or minimal, and 
present when the metaplastic 
change was moderate or marked.
As a means of comparing EGC 
with advanced gastric cancer, the 
primary tumours were classified by 
level according to the depth of 
penetration of the stomach wall as 
follows: A, tumours involving the 
lamina propria only; B, submucosal 
invasion; C, invasion into, but not 
through, the muscularis propria; 
and D invasion through the entire 
gastric wall. Levels A and B tu­
mours were considered as EGC and 
C and D as advanced disease.
All patients were followed up for 
at least 5 years or until death. 
Actuarial survival was calculated 
from the data for each level of 
invasion of the primary tumour, and
for the group as a whole. Linear 
regression analysis was then used 
to test for a linear relation between 
depth of tumour invasion and sur­
vival, lymph-node involvement, tu­
mour differentiation, intestinal 
metaplasia and tumour growth pat­
tern. Data were considered statisti­
cally significant when p < 0.05.
Findings
Of the 199 patients examined, 26 
had EGC. Twenty-one patients had 
no operation and 74 were consid­
ered to have had palliative proce­
dures; the remaining 104 patients, 
including all those who had EGC, 
were considered to have had poten­
tially curative operations.
Demographics
The patients ranged in age from 
26 to 90 years (mean 65 years) and 
there was no significant difference 
in the mean age between those with 
EGC and advanced resectable gastr­
ic cancers. Superficial tumours 
tended to be diagnosed with equal 
frequency in men and women, but 
more deeply invading lesions were 
more likely to be diagnosed in men 
(Table I).
Location
The distribution of tumours with­
T a b le . Age and S ex D is tr ib u tio n  o f 1 0 4  G a s tr ic  C ancers A cco rd in g  to  Leve l o f Invas ion
L e v e l M e a n  a g e , y r M a le ,  n o . F e m a le ,  no.
A 66 5 6
B 64 8 7
C 60 13 7
D 67 42 16
T a b le  II. L o ca tio n  o f T u m o u rs  in  E arly  G a s tr ic  C a n ce r (EGC) and A dvanced  G a s tric  Cancer
L o c a tio n E a r ly , % A d v a n c e d , %
P ro x im a l 12 26
B o d y 27 24
D is ta l 61 50
in the stomach was similar for both 
early and advanced cancers, except 
for a slightly increased likelihood of 
proximal gastric cancers in patients 
with more advanced tumours (Table 
H ) .
Pathological Features
The degree of tumour differentia­
tion is shown in relation to depth of 
invasion in Fig. 1. Tumours tended 
to be progressively more poorly 
differentiated at deeper levels of 
penetration, but there was no 
abrupt change between the early 
and advanced tumours. Depth of 
invasion correlated highly with tu­
mour differentiation (r = 0.99, p < 
0.01).
The relationships between depth 
of invasion and pathological fea­
tures of intestinal metaplasia, tu­
mour growth pattern and lymph- 
node metastases are shown in Fig. 
2. There was a highly correlated 
linear relation between depth of 
invasion and each of these features 
(intestinal metaplasia: r = 0.98, p < 
0.01; tumour growth pattern: r = 
0.98, p < 0.01; lymph-node metas­
tases: r = 0.98, p < 0.01). Lymph- 
node involvement increased pro­
gressively with the level of invasion. 
No nodal involvement was seen un­
less the primary tumour had pene­
trated deep to the muscularis muco­
sae. If patients with levels A, B and
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FIG. 1. Percentage of patients with 
histologically well-differentiated tu­
mours, according to level of invasion.
EARLY GASTRIC CANCER
C are pooled together, the survival 
was not affected by the lymph-node 
status of the patient. Patients with 
lymph-node involvement had a 
mean survival (± SEM) of 4.25 ± 
0.47 years, compared with 4.44 ± 
0.22 years in those without nodal 
metastases. Even in level D pa­
tients, survival was 2.89 ± 0.32 
years when nodes were involved 
with tumour compared with 2.94 ± 
0.41 years in patients without nodal 
metastases.
Surgical Procedures
The type of operation used in the 
104 patients operated upon for cure 
is shown in Table III. Total gastrec­
tomy was not required for the resec­
tion of EGC in this study.
FIG. 2. Percentage of patients with 
intestinal metaplasia (I.M.+), expand­
ing pattern of tumour growth (Exp) 
and absence of lymph-node metastases, 
according to level of invasion.
FIG. 3. Actuarial survival rates from 
time of surgery, according to level of 
invasion.
Survival
Actuarial 5-year survival was also 
seen to decrease with depth of 
invasion (Fig. 3). There was little 
difference in survival curves be­
tween levels A, B and C. Levels A 
and B are considered “early” gastr­
ic cancers, whereas level C is not. 
The only appreciable fall off in 
survival was seen with level D tu­
mours.
Four of 26 patients with EGC 
failed to survive 5 years. One (level 
B) died of metastatic carcinoma. 
The others died of unknown causes, 
although one was known to have 
had a metastatic renal cell carcino­
ma at the time of operation. One of 
two patients with EGC who had 
lymph-node involvement survived; 
the other had associated metastatic 
renal cell carcinoma. Three of five 
level C patients with nodal involve­
ment survived, a rate similar to that 
observed in patients without nodal 
involvement. Ten of 31 level D 
patients with lymph-node involve­
ment lived 5 years, a survival rate 
only marginally worse than that for 
patients who were free of involved 
nodes.
Discussion
From this study it appears that 
gastric cancer begins in the mucosa 
of the stomach and progresses in a 
relatively orderly fashion through 
the gastric wall. The earliest lesions 
involve the lamina propria only and 
are infrequently associated with 
lymph-node involvement. Excision 
of these lesions results in cure in a 
high percentage of cases. Nodal 
involvement is more frequent as
tumours invade the submucosa,67 
and is increasingly likely as the 
primary tumour invades the gastric 
wall more deeply.
Intestinal metaplasia, histologi­
cally well-differentiated tumours 
and an expanding growth pattern 
have previously been shown to be 
associated with a good prognosis in 
patients with gastric cancer.5 We 
found these favourable pathological 
features to be present in a high 
proportion of patients with EGC, 
but less evident as depth of tumour 
invasion progressed. Furthermore, 
there was a progressive gradual 
increase in the likelihood of lymph- 
node metastases and a concomitant 
decrease in survival as tumour inva­
sion progressed. All these changes 
occurred in a linear or progressive 
fashion with increasing depth of 
tumour invasion, without any dis­
cernible cut-off to distinguish early 
from advanced gastric cancer. The 
survival curves were also found to 
be linear and not biphasic. These 
data suggest that to segregate 
those lesions called EGC as a dis­
tinct entity would be an arbitrary 
distinction, rather than one based 
on biologic behaviour. Gastric can­
cers do not appear to behave any 
differently from colonic cancers 
when depth of invasion in the wall 
of the bowel is an important deter­
minant of outcome, but early colon­
ic cancer has not been designated a 
distinct entity, except in the case of 
polyps.
It has been suggested4 that the 
depth of gastric wall invasion, and 
not metastases to regional lymph 
nodes, appears to be the primary 
determinant of prognosis in gastric 
cancer. Our data certainly support 
this concept. Although we found an
T a b le  II I .  Surgical Procedures Performed in Patients W ith EGC and Advanced Gastric Cancer
P rocedure E arly  no. A d vanced  no.
Partial gastrectomy 23 51
Total gastrectomy 0 11
Esophagogastrectomy 3 16
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increasing incidence of lymph-node 
involvement with increasing depth 
of invasion, there was no demon­
strable difference in survival, at 
each level, whether or not nodes 
were involved.
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BOOK REVIEWS
continued from page 340
resection, transplantation, hepatobiliary 
trauma, diseases of infancy and child­
hood, and liver and biliary diseases in 
pregnancy. The largest sections are 
those covering disorders of the liver and 
the biliary system, which are divided 
into separate chapters covering differ­
ent entities.
This readable, well-written book has 
a consistent style, is accurate and up to 
date and contains many useful illustra­
tions. Another good feature is that the 
bibliography is organized into separate 
sections following each chapter. This 
allows the researcher to pursue certain 
topics in detail. The references are to 
current as well as classic and historical 
articles.
The first chapter, which is dedicated 
to the development of liver and biliary 
surgery, gives a historical review of 
how this subspecialty evolved. The 
chapter on anatomy is well illustrated 
and the important features of the surgi­
cal anatomy of the liver as described by 
Couinaud are considered. In the chapter 
on liver resection the use of the ultra­
sonic dissector is discussed.
Although this book is shorter than 
Blumgart’s extensive, classic, two- 
volume Surgery o f the Liver and Biliary 
Tract, it covers the subject matter in a 
concise, yet complete manner.
I highly recommend this book for all 
serious practitioners of hepatobiliary 
surgery. For students and residents it 
provides sufficient information present­
ed in a concise but highly readable and 
consistent style. For more senior practi­
tioners it summarizes the topics well
and provides an organized bibliography 
that can be used as a basis for further 
reading and research. It is a must for 
university and hospital libraries.
Sherif Hanna, MB, FRCSC, FACS
Trauma Unit,
Sunnybrook Medical Centre,
2075 Bay view Ave.,
Toronto, Ont.
AN ATLAS OF SURGICAL EXPO­
SURES OF THE UPPER EXTREMI­
TY. Raoul Tubiana, Christopher J. 
McCullough and Alain C. Masquelet. 
Illustrations by Leon Dorn. 359 pp. 
Illust. J.B. Lippincott Co., Philadel­
phia. 1990. Price not stated. ISBN 0~ 
397-58316-8
This beautifully illustrated atlas repre­
sents a notable contribution to the 
literature on upper extremity surgery. 
The great strength of this work is the 
quality, clarity and accuracy of Dorn's 
artwork. There clearly has been close 
collaboration between the surgeon- 
authors and their illustrator. The atlas 
is organized along anatomic lines with 
additional chapters focusing on expo­
sure of peripheral nerves, arteries and 
veins, Dupuytren’s contracture, infec­
tions, compartment syndromes and skin 
flaps.
The introduction is succinct and con­
tains many gems that are universally 
applicable to upper extremity expo­
sures. Each exposure is discussed ac­
cording to its indications, the patient’s
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position, the incision and the details of 
the exposure. In general the chapters 
are comprehensive, although the anteri­
or exposure of the elbow is not dis­
cussed, nor are there detailed instruc­
tions on reattachment of the triceps 
after its reflection from the olecranon. 
One might also question the utility of 
including an axillary approach to the 
shoulder joint as a method of treating 
shoulder instability, a subdeltoid ap­
proach to the proximal humerus and 
the use of an oblique dorsal skin inci­
sion to expose the scaphoid and the 
lunate. The chapters are not referenced, 
although a list of selected references is 
included at the end of the book. The 
chapters organized along nonanatomic 
lines (i.e., compartment syndromes) 
would, in particular, benefit from more 
extensive referencing.
Although some fault may be found 
with certain segments of the text the 
overwhelming strength of the illustra­
tions makes this a very worthy volume. 
Trainees, in particular, will find the 
lavish illustrations especially useful in 
enhancing their understanding of surgi­
cal anatomy. This book deserves a place 
in the library of every institution and 
individual performing any type of upper 
extremity surgery.
Robin R. Richards, MD, FRCSC
Associate Professor,
Division o f Orthopedic Surgery,
Department o f Surgery,
St. Michael’s Hospital,
University o f Toronto,
30 Bond St.,
Toronto, Ont.
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Management of Pyogenic Liver Abscess 
in the Era of Computed Tomography
Carol J. Swallow, MD;* Ori D. Rotstein, MD, FRCSC
The advent of high-resolution imaging has allowed earlier diagnosis of pyogenic 
liver abscess. Because radiologically guided percutaneous drainage (PCD) of liver 
abscesses is controversial, the authors studied 40 patients with liver abscess 
admitted to the Toronto Hospital between 1982 and 1987 to determine the role of 
PCD versus operative drainage (OD). The diagnosis of pyogenic liver abscess was 
made at autopsy (4 patients), at laparotomy (6) or by radiologically guided aspiration 
of pus (30). Ultrasonography and computed tomography were highly sensitive (85% 
and 96% respectively) in detecting liver abscess.
Of the 36 patients treated for liver abscess all received antibiotics intravenously; 
31 also underwent a drainage procedure. Treatment with antibiotics alone was 
associated with a success rate of 80% and a death rate of 20%. The success rate for 
those who had PCD was 75% with a death rate of 13%; 2 patients in this group of 16 
subsequently required OD for cure. In the 15 patients initially treated with OD, 
success and death rates were 87% and 13% respectively. For solitary abscesses, 
success rates were comparable for PCD and OD (86% and 90% respectively). For 
unilobar multiple abscesses the success rate was 100% for both PCD and OD, but for 
bilobar multiple abscesses the rates were only 40% and 67% respectively. 
Complication rates were similar for both methods of drainage. The authors conclude 
that pyogenic liver abscess can now be safely and efficaciously managed with a 
combination of antibiotics and PCD.
La venue des techniques d'imagerie a haute resolution ont permis un diagnostic 
plus precoce des abces hepatiques pyogenes. Comme le drainage percutane (DPC) 
des abces hepatiques sous controle radiologique est conteste, les auteurs ont etudie 
40 patients qui ont ete regus a l’Hopital de Toronto entre 1982 et 1987, afin de 
determiner quel est le role du DPC par rapport au drainage operatoire (DO). Le 
diagnostic d’abces hepatique pyogene fut etabli a l’autopsie (4 patients), a la 
laparotomie (6) ou par aspiration de pus sous controle radiologique (30). L’echogra- 
phie et la tomographie axiale ont ete tres sensibles (85% et 96% respectivement) 
pour deceler les abces hepatiques.
Les 36 patients qui furent traites pour abces hepatiques regurent tous une 
antibiotherapie intraveineuse; 31 eurent aussi un drainage. L’antibiotherapie seule 
eut un taux de guerison de 80% et une mortalite de 20%. Le taux de succes de ceux 
qui eurent un DPC fut de 75% et la mortalite de 13%; 2 des 16 patients de ce groupe 
necessiterent un DO pour assurer la guerison. Des 15 patients initialement traites 
par DO, les taux de guerison et de mortalite ont ete, respectivement, de 87% et de 
13%. Dans les cas d’abces solitaires, les taux de guerison etaient comparables pour 
le DPC et le DO (86% et 90%). Dans les cas d’abces unilobaires multiples, le taux de 
guerison fut de 100% aussi bien pour le DPC que pour le DO; toutefois, pour les 
abces bilobaires multiples, les taux de guerison furent de 40% et de 67%, 
respectivement. Les taux de complications furent similaires pour les deux methodes 
de drainage. Les auteurs concluent que les abces hepatiques peuvent maintenant 
etre traites de fagon sure et efficace en associant antibiotherapie et DPC.
I n their classic paper published in 1938, Ochsner, DeBakey and 
Murray1 reported a 78% death rate 
in patients with pyogenic liver ab­
scess. Over the ensuing decades,
despite the introduction of broad- 
spectrum antibiotics, death rates re­
mained as high as 70% in unselect­
ed series.2' 5 The advent of more 
sophisticated imaging techniques in
the 1980s has facilitated earlier 
diagnosis of liver abscesses, and the 
death rate has concomitantly been 
reduced to between 11% and
21%.6~9
Current controversy over the 
management of pyogenic liver ab­
scesses is focussed on the optimal 
technique of abscess drainage, that 
is the role of operative drainage 
(OD) versus percutaneous drainage 
(PCD). From the Mayo Clinic series 
published in 19866 it was concluded 
that PCD should be the initial 
drainage procedure when no con­
comitant surgery is planned. By 
contrast, Klatchko and Schwartz8 
concluded that “surgical drainage 
remains the standard” initial man­
agement because of a high initial 
failure rate in patients treated by 
PCD.
The purpose of our study was to 
review the management and out­
come of patients who had a diagno­
sis of pyogenic liver abscess after 
the introduction of computed to­
mography (CT) in our institution,
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particularly with respect to the role 
of PCD.
Methods
The charts of all 40 patients who 
had a final diagnosis of pyogenic 
liver abscess at the Toronto Hospi­
tal between January 1982 and De­
cember 1987 were reviewed. The 
diagnosis was confirmed at autopsy, 
at laparotomy, or by radiologically 
guided aspiration. The criterion for 
a diagnosis of pyogenic abscess was 
aspiration of purulent material but 
not necessarily a positive result on 
Gram’s staining or culture of the 
abscess contents. Amoebic abscess­
es were excluded. For PCD, a no. 
10 to 18 French catheter was ins­
erted by the Seldinger technique 
under local anesthesia and connect­
ed to closed suction drainage. Fre­
quent follow-up imaging was done 
to ensure adequacy of drainage. For 
OD, needle aspiration was used to 
locate abscesses not apparent from 
the surface of the liver. Abscesses 
were widely unroofed, loculations 
were broken down and a soft drain 
was left in the cavity; earlier in the 
study open drainage was often 
used, but recently closed suction 
drainage has been used exclusively. 
Data were collected on patient and 
abscess characterisics, diagnosis, 
treatment, outcome and duration of 
hospital stay.
Findings
Patient Characteristics
The 40 patients ranged in age 
from 20 to 91 years (median 63 
years). The male to female ratio was 
26:14, a finding typical of most 
reported series.4’8-10 The median du­
ration of symptoms before diagnosis 
was 11.5 days. In 23 of the 36 
patients who were treated for liver
abscess, the diagnosis was not 
made before admission; for them 
the mean duration of hospitaliza­
tion from the time of admission to 
diagnosis was 1 day for those ad­
mitted to medical wards (12 pa­
tients) and 2 days for those admit­
ted to surgical wards (11). The 
diagnosis was made at autopsy in 4 
patients, at laparotomy in 6 and 
radiologically, based on aspiration 
of pus from the identified lesion, in 
30.
Etiology
The most common source of in­
fection was the biliary tree (15 
patients); spread by way of the 
portal vein, chiefly due to diverticu­
litis, was second in frequency (8 
patients). In five patients, liver ab­
scesses were judged to be second­
ary to disseminated septicemia with 
bacteria (three) or fungi (two). Liver 
abscesses developed in two patients 
after blunt trauma. One had a hyda­
tid cyst which became secondarily 
infected. Twenty percent of abscess­
es were cryptogenic, a rate consis­
tent with that reported in recent 
series.6-911-13
Clinical Presentation
As has been reported in most 
series, symptoms fell into three 
main categories (Table I). Constitu­
tional symptoms included fever and 
anorexia in 73% and 50% of pa­
tients, respectively. Abdominal 
symptoms consisted chiefly of epi­
gastric or right upper quadrant 
pain, or both, which was present in 
53% of patients. Chest symptoms 
were reported by a small group of 
patients. Physical findings fell into 
the same three categories. Three- 
quarters of the patients had a docu­
mented fever with a body tempera­
ture greater than 38°C. The most 
common abdominal findings were 
tenderness and hepatomegaly, al­
though these were found in only 
58% and 35% of patients, respec­
tively. Only 15% of patients present­
ed with abdominal pain, tenderness, 
hepatomegaly and fever, a clinical 
complex considered classic for pyo­
genic liver abscess.
Laboratory Findings
The leukocyte count was elevated 
in 73% of patients, and individual 
liver function test (LFT) results 
were elevated in up to 85% (Table 
II). To determine whether underly­
ing biliary tract disease per se was 
responsible for the elevation in 
LFTs, patients with biliary versus 
nonbiliary sources of infection were 
compared. For each LFT evaluated, 
at least 50% of the abnormal values 
occurred in patients whose liver 
abscess was nonbiliary in origin. 
These data suggest that pyogenic 
liver abscess per se can cause an 
elevation of LFT values, but that 
the diagnosis of liver abscess can­
not be ruled out if the LFT results 
are normal. From the lack of sensi-
T a b le  1. C lin ica l P re se n ta tio n
S ym p tom /s ign No. (% )
Fever a n d /o r  c h ills 29  (7 3 )
A no re x ia , w ith  o r  w ith o u t w e ig h t
lo ss 20 (50 )
General m a la ise 1 6 (4 0 )
A b d o m in a l pain 21 (53 )
N a u s e a /v o m it in g 2 ( 5 )
C hest pa in 5 ( 1 3 )
D yspnea 4 ( 1 0 )
C ough 1 0 )
S ho u lde r pa in 1 (3 )
Severe  headache 1 (3)
A s y m p to m a tic 1 (3 )
Fever ( >  3 8 ° C ) 30  (75 )
Jaund ice 11 (28 )
Low ered  leve l o f  co n s c io u sne ss 1 2 (3 0 )
W e a k n e s s /le th a rg y 3 ( 8 )
S y s to lic  b lo o d  p ressu re
<  9 0  m m  Fig 1 0 (2 5 )
A bd o m in a l te n de rne ss 23  (5 8 )
H ep a to m e ga ly 14 (3 5 )
A bd o m in a l m ass 2 ( 5 )
D ecreased ch e s t expansion 6 ( 1 5 )
C hest te n d e rn e s s 2 ( 5 )
E levated h e m id ia p h ra g m 1 ( 3 )
H yp o th e rm ia 1 (3 )
G rand m a l se izu res 1 ( 3 )
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tivity and specificity of symptomatic 
complaints, physical examination 
and laboratory findings, it is evident 
that clinical presentation is unreli­
able in the diagnosis of liver ab­
scess.
Imaging Studies
The most useful radiologic mo­
dalities for detecting pyogenic liver 
abscesses were ultrasonography 
(US) and computed tomography 
(CT). Ultrasonography identified ab­
scesses in 81% of patients (25 of 
31), whereas CT was more sensi­
tive, identifying abscesses in 96% of 
patients (24 of 25). The diagnosis 
was made at laparotomy in one
Table II. S e le c te d  L a b o r a to r y  D ata
Measurement
No./no. tested 
(»/»)
L e u k o c y te  c o u n t, 
>  1 0 .0  X  10 9/ L 2 9 / 4 0  (73)
B il ir u b in ,  >  2 0  ^ m o l/ L 1 9 / 3 9  (49)
A lk a l in e  p h o s p h a ta s e ,  
>  1 0 0  U / L 3 4 / 4 0  (85)
S e ru m  a sp a r ta te  
t ra n s fe ra s e ,  > 4 0  U / L 21 / 3 6  (58)
P ro th r o m b in  t im e , >  2  s  
o v e r  c o n t ro l 1 1 / 3 3  (33)
P a r t ia l t h r o m b o p la s t in  t im e , 
> 5  s  o v e r  c o n t ro l 9 / 3 3  (27)
patient whose abscess was not de­
tected on CT. In those with multiple 
abscesses, both US and CT were 
sensitive in detecting the multiplici­
ty (13 of 16, and 12 of 13 patients, 
respectively). A chest x-ray film was 
insensitive, showing an abnormality 
in only 28% of patients. Liver/ 
spleen scanning and angiography 
were done in seven and three pa­
tients, respectively, and were posi­
tive -in all. However, all of these 
patients also had a positive US or 
CT scan.
Abscess Characteristics
The incidence of single versus 
multiple abscesses was approxi­
mately equal; 21 patients had single 
abscesses (17 in the right lobe) and 
19 had multiple abscesses. In those 
who had multiple abscesses, they 
were confined to one lobe in 7 
patients (unilobar multiple abscess­
es, Fig. 1); the remaining 12 had 
bilobar abscesses.
Abscess cultures were positive in 
80% of patients and blood cultures 
were positive in 46%, rates consis­
tent with those reported in other 
series.6' 8-11-15 The majority (17 of
28) of isolates were monomicrobial. 
The specific organisms isolated (Ta­
ble III) were most commonly facul­
tative gram-negative rods, especially 
Escherichia coli and Klebsiella spp. 
Gram-positive aerobes were isolated 
from 11 abscesses; Streptoccoccus 
faecalis was the predominant spe­
cies (5 of 11). Fungi (Candida or 
Aspergillus) were recovered from 
the abscesses of three patients.
Deaths
The overall death rate in our 
series was 23%; when patients in 
whom the diagnosis was made at 
autopsy were excluded, the rate was 
14%. In all patients who died, in­
cluding those whose liver abscesses 
were diagnosed at autopsy, death 
was primarily attributed to liver 
abscess or associated septicemia, or 
both. Because increasing age and 
number of abscesses have been as­
sociated with increased mor­
tality,UU2-16"18 the influence of 
these factors on all patients and on 
treated patients (n =  36) was as­
sessed. The death rate was in­
creased in patients over the of age 
60 years compared with those
FIG. 1. Computed tomography scan demonstrating multiple pyogenic abscesses in right hepatic lobe.
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under 60 (33% versus 11%). Howev­
er, the four untreated patients (di­
agnosis made at autopsy) were all 
over 60 years old. When treated 
patients alone were analysed, the 
difference in death rate was re­
duced, being 18% and 11% in the 
over- and under-60 groups, respec­
tively. Similarly, the overall death 
rate was greater in those with mul­
tiple abscesses (32%) than in those 
with single (14%) abscesses, when 
the entire patient population was 
considered. Once again, however, 
the four untreated patients had 
multiple abscesses, and when they
were eliminated from the analysis, 
the death rates were similar for 
those with single and with multiple 
abscesses (14% and 13%, respective­
ly). The death rate did not differ in 
treated patients admitted to medical 
wards (7%, 1 of 15) and surgical 
wards (8%, 1 of 12), but was higher 
in patients admitted to the intensive 
care unit (33%, 3 of 9).
Treatment and Outcome
All of the 36 patients in our 
series who were treated for pyo­
genic liver abscess received broad-
spectrum antimicrobial therapy and 
in all but 5, some type of drainage 
procedure was performed. Treat­
ment success was defined as clinical 
and radiologic resolution of liver 
abscesses, followed by hospital dis­
charge.
Five patients received intrave­
nously administered antibiotics 
alone; in three blood cultures were 
positive, and in one abscess cultures 
were also positive. The latter was 
an immunosuppressed patient with 
disseminated candidiasis who expe­
rienced clinical and radiologic reso­
lution of his liver abscess after
Table III. Microorganisms Recovered From Abscess and Blood Cultures*
Monomlcrobial Polymicrobial Totals
Organisms Abscess Blood Abscess Blood Abscess Blood
Gram-negative aerobes
Escherichia coli 4 2 3 2 7 4
Klebsiella spp 3 3 4 3 7 6
Proteus mirabilis 1 1 1 1
Morganella morgan/i 1 1 1 1
Citrobacter aerogenes 2 2
Aclnetobacter sp 1 1
Pseudomonas aeruqinosa 1 1
Eikenella corrodens 1 1
Haemophilus influenzae 1 1
Totals 8 5 14 7 22 12
Gram-positive aerobes
Streptococcus faecalis 1 5 2 5 3
Streptococcus v/ridans 2 1 2 1
Streptococcus pyoqenes 1 1 1 1
Streptococcus bovis 1 1 1 1
Staphylococcus aureus 1 1 2
Totals 1 3 10 3 11 5
Gram-negative anaerobes
Bacteroides fraqilis 1 2 2 1
Bacteroides sp 1 1 1 1
Eubacterium sp 1 1
Fusobacterium nucleatum 1 1
Totals 2 2 2 1 4 3
Gram-positive anaerobes
Microaerophilic Streptococcus 5 1 1 1 6 2
Peptostreptococcus 1 1 2
Clostridium perfrinqens 1 1
Totals 6 1 3 1 9 2
Fungi
Asperqillus 1 1
Candida 1 1 1 1 2 2
Totals 2 1 1 1 3 2
'Figures are the number of patients from whom a particular microorganism was isolated.
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intravenous amphotericin therapy. 
In one man a diagnosis of chronic 
cholecystitis was made 2 weeks 
after he had undergone cholecystec­
tomy, and a swab of the gallbladder 
was positive for E. coii and Klebsiel­
la. A 12 X 8 cm right intrahepatic 
abscess developed from which pus 
was aspirated, but a drainage cathe­
ter was not left in. He improved 
with broad-spectrum antibiotic ther­
apy and his abscess eventually re­
solved. A third patient presented 
with a 12-month history of low- 
grade fever and was found to have a 
7 X 6 cm abscess in the right lobe 
which was aspirated; no drain was 
left in. She, too, improved on broad- 
spectrum intravenous antibiotic 
therapy. Those three patients were 
treated on medical wards, and the 
surgical service was not consulted. 
Two patients refused drainage: in 
one, the diagnosis of liver abscess 
was made after a long course of 
antibiotic treatment during which 
the patient improved clinically; he
continued to improve and his ab­
scess resolved. The other patient 
who refused drainage was an 
87-year-old woman with cholangitis 
who subsequently died of septic 
shock. The overall success rate for 
medical treatment alone was there­
fore 80% (4 of 5) with a death rate 
of 20% (Table IV). It is noteworthy 
that two of the survivors had a 
single percutaneous aspiration of 
their abscesses.
Comparison o f PCD and OD
Demographic characteristics of 
patients initially treated with PCD 
were compared with those of pa­
tients initially treated with OD (Ta­
ble V). The patients in each group 
were comparable with respect to 
age and duration of symptoms be­
fore treatment. The chief demo­
graphic difference between patients 
treated with PCD and those treated 
with OD was in the year of admis­
sion. The majority of patients treat­
ed with PCD were admitted between 
1985 and 1987 (11 of 16) whereas 
most of the patients who underwent 
surgical drainage (10 of 15) were 
admitted between 1982 and 1984. 
It was difficult to determine what 
the rationale for the chosen mode 
of treatment had been. There was a 
trend toward treating patients who 
had recently undergone laparotomy 
(within 6 months) with OD (five of 
seven patients). Of the five patients 
treated by OD between 1985 and 
1987, the diagnosis was made at 
laparotomy in three, one had re­
cently undergone laparotomy and 
one had a post-traumatic liver ab­
scess.
Outcome parameters including 
treatment success, death and com­
plication rates, and duration of hos­
pital stay, were compared in pa­
tients managed with PCD and OD. 
Although the demographic charac­
teristics of these two groups were 
similar, a statistical analysis of re­
sults was not considered appropri­
ate, since entry into the two groups 
had been nonrandom. Sixteen pa­
tients underwent PCD as their ini­
tial therapy with a success rate of 
75% (Table IV). Of the four patients 
in whom PCD failed, two died and 
two recovered after subsequent OD. 
Open drainage was the initial proce­
dure in 15 patients, with a success 
rate of 87%; the 2 patients in whom 
OD failed died of sepsis and multi­
ple organ failure.
Since multiplicity of abscesses 
has been considered a predictor of 
poor outcome,1'1 U2'16-18 we analysed 
the success rates of PCD and OD in 
cases of single and multiple ab­
scesses. Single abscesses were well 
treated by either modality, with suc­
cess rates of 86% with PCD versus 
90% with OD. For patients with 
multiple abscesses, OD appeared at 
first glance to be a superior mode of 
therapy with a success rate of 80% 
compared with the PCD rate of 
67%. However, when the patients
T a b le  IV. Treatment and Outcome
S uccess, D eath .
T re a tm e n t No. no. (% ) no. (% )
Antibiotics alone 5 4 (8 0 ) 1 (20)
Antibiotics and PCD 16 12 (75 ) 2 (1 3 )
Antibiotics and 0D
Initial 15 13 (87 ) 2 (1 3 )
After failure of PCD 2 2 (100) 0
Totals 17 15 (88 ) 2 (1 2 )
PCD =  percutaneous drainage, 0D =  operative drainage.
T a b le  V . Comparison of Patient Characteristics: 
Percutaneous Drainage (PCD) Versus Operative Drainage (0D)
C haracteris tic PCD 0 D
No. o f patients 16 15
Age, yr
Range 2 0 - 8 7 20 -  91
Median 56 59
Sex, M:F 13:3 9:6
Median duration o f symptoms, d 8.5 11
Year of admission
1982 -  1984 5 10
1985 -  1987 11 5
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with multiple abscesses were subdi­
vided into those with unilobar and 
those with bilobar multiple abscess­
es, an interesting difference in out­
come emerged. Patients with unilo­
bar multiple abscesses achieved 
100% treatment success whether 
treated with PCD or with OD; those 
treated with PCD (four patients) 
were all managed with a single 
catheter only (Fig. 2). Overall suc­
cess rates were much lower for 
bilobar multiple abscesses, although 
higher for OD (67%) than for PCD 
(40%). In only two of the five 
patients with bilobar multiple ab­
scesses was treatment with PCD 
successful. In these two patients, 
multiple drainage catheters were re­
quired to achieve satisfactory drain­
age. In contrast, only a single cath­
eter had been used for the three 
patients in whom PCD failed. Fail­
ure to employ multiple drainage 
catheters in these three patients 
may have been responsible for treat­
ment failure.
Complication rates were similar 
for PCD (2 of 16, 13%) and OD (3 
of 15, 20%). In one patient perito­
neal signs developed the day after 
PCD, and OD was performed to 
drain both the liver abscess and the 
contaminated peritoneal cavity; the 
patient’s recovery was uncomplicat­
ed. Another patient suffered a he­
mothorax after percutaneous cathe­
ter insertion; this was adequately 
treated by insertion of a chest tube. 
Of the three patients who experi­
enced complications after OD, one 
had serious intraoperative hemorrh­
age from the liver which required 
packing and repeat laparotomy, 
which was followed by a successful 
recovery. A second patient had mul­
tiple pulmonary emboli and required 
heparinization. The third patient 
suffered an upper gastrointestinal 
hemorrhage and followed a progres­
sive course of sepsis, multiple organ 
failure and death.
Patients treated with PCD were 
assessed for resolution of abscesses 
using US or CT, or both, before 
drainage catheters are removed. Me­
dian duration of catheter drainage 
in these patients was 4 weeks. Typi­
cally, patients were discharged from 
hospital with the drainage catheter 
in place. Catheters were removed 
after abscess resolution had been 
confirmed by US, CT or sinography.
Some authors have reported a 
significantly prolonged hospital stay 
in patients who have undergone 
PCD compared with OD.68 Indeed, 
those managed with OD had a 
shorter mean hospital stay (Table 
VI), both total and following the
initiation of appropriate therapy 
(i.e., antibiotics and drainage). The 
difference was most marked in pa­
tients admitted to surgical wards. 
The mean duration of hospital stay 
following initiation of treatment 
was longest for patients treated 
with antibiotics alone (34 days).
Discussion
Although pyogenic liver abscess 
is not a frequent diagnosis (ranging 
from 9 to 15 per 100 000 hospital 
admissions81112), the high death 
rate when it is left untreated1218"20 
makes it an important clinical enti­
ty. The impact of early diagnosis on 
outcome in pyogenic liver abscess is 
illustrated by the marked decline in 
death rates since the advent of 
readily available US and CT (accom­
panied by prompt drainage) in the 
early 1980s.7-91018 This appears in 
part to be related to an increased 
antemortem diagnosis rate. Of the 
40 patients in the present series, 
the diagnosis made at autopsy in 
only 4, and they were seen during 
the early part of the review period 
(1982 and 1983). In contrast, be­
fore the introduction of high-resolu- 
tion imaging techniques, only 50% 
to 70% of liver abscesses were diag-
FIG. 2. Follow-up scan and sinogram 1 week after institution of percutaneous catheter drainage demonstrate resolving abscess 
cavities. Interconnections between cavities can be seen in sinogram.
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nosed ante mortem.1219~2! Similarly, 
early diagnosis and highly accurate 
localization have probably con­
tributed to improved outcome in 
our own and other recent series.
Ultrasonography and CT should 
probably be viewed as complemen­
tary modalities in the investigation 
of suspected liver abscess. Their 
reported sensitivity rates are compa­
rable but, as in this series, are 
slightly higher for CT (95% to 
100%)7 11 12-22-23 than for US (80% to 
90%).7101112 Although US has the 
advantage of being noninvasive and 
mobile, its usefulness can be limited 
by obesity, excess gastric or colonic 
gas, interoperator variability and 
the difficulty in detecting small ab­
scesses located near the hemidia- 
phragm.79 Computed tomography 
is superior in detecting abscesses in 
this location. Both modalities are 
also useful in assessing the results 
of therapy; in our patients, collapse 
of the abscess cavity as judged by 
US and CT was used as one of the 
criteria for removing drainage cath­
eters.
Follow-up imaging is crucial to 
ensure that the original abscess 
cavities have been drained and to 
investigate for the development of 
new abscesses or the presence of 
previously unrecognized collec­
tions. Frey and colleagues9 24 em­
phasized that failure to drain one of 
several abscesses was as lethal as 
not draining a solitary abscess. 
Such failure has likely been respon­
sible for the higher death rates 
traditionally reported for multiple
abscesses. This point is illustrated 
by the five patients in this series 
with bilobar multiple abscesses 
treated by PCD: the two in whom 
PCD was successful were treated 
with multiple (three and four) drain­
age catheters, and the three in 
whom PCD failed were treated with 
a single catheter only.
In contrast to the requirement for 
multiple catheters for bilobar ab­
scesses, all four patients with unilo­
bar “multiple” abscesses treated by 
PCD had resolution of the abscess­
es with insertion of a single drain­
age catheter only. This result sup­
ports the notion that such unilobar 
“multiple” abscesses are usually 
multiloculated single abscesses with 
free communication between the lo- 
cules25 (Fig. 2). Effective drainage 
can therefore be achieved with a 
single drain, whether inserted per- 
cutaneously or at laparotomy. With 
treatment of multiple abscesses 
based upon the above principles, 
Farges, Leese and Bismuth10 report­
ed a comparable prognosis for pa­
tients with multiple and solitary 
hepatic abscesses. Similarly, in our 
series, the death rates were compa­
rable in treated patients who had 
solitary (14%) and multiple (13%) 
abscesses.
The overall success rate in pa­
tients treated with antibiotics and 
drainage (either PCD or OD) in the 
present series was 87% (27 of 31). 
The success and complication rates 
for PCD (75% and 13%, respective­
ly) were comparable to those for OD 
(87% and 20%) and approximate
those achieved with PCD in other 
recent series (success in 65% to 
90%,6-8’10'25-26 complications in 4% 
to 20%.7’10-25-27' 29 With equivalent 
overall results using either PCD or 
OD, other factors require consider­
ation in formulating the relative 
roles of PCD and OD in the optimal 
management of pyogenic liver ab­
scesses. Clinical scenarios favouring 
OD include: (a) the need for addi­
tional concomitant surgery (e.g., 
drainage of the biliary tree), (b) the 
inability to drain the infection per- 
cutaneously due to the presence of 
infected necrotic tissue rather than 
pus and (c) failure of PCD. Failure 
of PCD to achieve clinical improve­
ment within 24 hours should be an 
indication for radiologic reassess­
ment. If additional abscesses have 
developed, these should be drained 
promptly.
In their review of 33 cases of 
pyogenic liver abscess seen between 
1979 and 1985, Klatchko and 
Schwartz8 concluded that operative 
drainage should remain the primary 
mode of treatment. This conclusion 
was based on the high rate of 
treatment failures (6 of 11) in pa­
tients initially managed with PCD. 
However, PCD was used as a sec­
ondary treatment in 6 patients, with 
success in all, so that of a total of 
17 PCD drainage procedures, 11 
were successful. This compares 
with a failure rate of 33% (6 of 18) 
in those patients initially treated 
with operative drainage, and a total 
of 20 operative drainage proce­
dures, 14 of which were successful.
One major objection raised 
against PCD is that it prolongs 
hospital stay. Bertel, van Heerden 
and Sheedy6 reported that in pa­
tients treated with PCD the mean 
duration of hospital stay was 37 
days compared with 26 days for 
those treated operatively. More re­
cently, Attar, Levendoglu and Cuas- 
say26 reported a mean stay of 21 
days in 15 patients treated with
T a b le  V I. L e ng th  o f H o sp ita liza tio n  (M e a n  +  S E M ) in S u rv iv in g  P a tie n ts
H osp ita liza tio n P C D . d (no .) 0 D , d (no.)
T o ta l s ta y 3 5  ± 6  (1 4 ) 2 7  ± 4 ( 1 3 )
F o llo w in g  in it ia l th e ra p y
O ve ra ll 2 9  ±  4  (1 4 ) 2 2  ± 3 ( 1 3 )
P a tie n t lo c a tio n :
ICU th e n  su rg ica l w ard 4 2  ±  5  (4 ) 3 8  ±  5 (2)
M ed ica l w a rd 2 2  ±  6  (6 ) 2 9  ±  3  (4)
S u rg ica l w a rd 3 0  ±  8  (4 ) 12  ± 2 ( 7 )
PCD =  p e rcu ta n e o u s  d ra inage , OD =  opera tive  d ra in a g e , ICU = in te n s iv e  care u n it.
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PCD. In our own series, both total 
stay and stay after the initial drain­
age procedure were approximately
I week longer for PCD than OD 
patients. The reason for this dis­
crepancy is not understood. In our 
series, however, it did not relate to 
the clinical service on which the 
patient was treated. Another possi­
bility may be the severity of illness 
when treatment is initiated,. We are 
currently undertaking a prospective 
study of patients with the diagnosis 
of pyogenic liver abscess which will 
include determination of APACHE
II scores before therapy. This may 
assist in determining whether sever­
ity of underlying illness or mode of 
drainage is a more important deter­
minant of length of stay. Stratifica­
tion according to severity of illness 
may also provide information which 
will help optimize the selection of 
therapy for an individual patient.
Conclusions and 
Recommendations
The clinical presentation of pyo­
genic liver abscess, including labo­
ratory findings, is nonspecific. Any 
suspicion of the diagnosis warrants 
early radiologic investigation.
Both CT and US are sensitive 
modalities in the diagnosis of liver 
abscesses. Should US fail to detect 
an abscess where it is clinically 
suspected, CT should be done. One 
or both of these modalities should 
be used to assess adequacy of ab­
scess drainage.
Percutaneous drainage and oper­
ative drainage appear to be equally 
efficacious in the treatment of soli­
tary pyogenic liver abscesses and 
unilobar multiple abscesses.
Bilobar multiple abscesses are 
more difficult to manage and carry 
a correspondingly higher death rate 
than that for single or unilobar 
multiple abscesses. Bilobar multiple
4
abscesses can probably be success­
fully managed by either OD or PCD, 
as long as multiple drainage cathe­
ters are used in the latter case. 
Follow-up imaging should be done 
frequently to rule out the presence 
of undrained or newly evolved ab­
scess cavities.
We thank Dr. Bryce Taylor for his 
critical reading of the manuscript.
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When choosing an antibiotic for nosocomial infections,
LOOK BEYOND 
THE PRICE TOG.
Look at the 
safety profile 
and total cost 
of treatment.
ROUSSEL
ROUSSEL CANADA INC. 
MONTREAL. QUEBEC
Significant biliary excretion o f antibiotics can have a very disruptive effect on 
intestinal flora, which may promote the emergence o f resistant strains o f bacteria and 
cause diarrhea.12 This can add substantially to the cost o f treatment.3
CLAFORAN (cefotaxime sodium) has an excellent safety profile. With only 5% biliary 
excretion, Claforan has little effect on intestinal flora, thus reducing the risk o f 
diarrhea and bacterial resistance.14 And Claforan provides excellent coverage o f 
major nosocomial pathogens.
Over a complete course o f therapy, if one looks at the average cost per patient, 
Claforan makes good sense.5
1 . GuggenbichlerJP el at. J Antimicrob Chemother 1984;14(Suppl B):pg. 67-70.
2. Hooker KD, Dipiro JT. Clin Pharm 1988;Vol 7:pg. 878-888.
3. Gladen HE el al. Infect Surg 1986;5(10):559-572.
4. Alcock SR. Update in Intensive Care and Emergency Medicine 1989;7:102-108.
5. Bivens BA et al. Diag Microbiol Infect Dis 1989;12:113-118.
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P R E S C R IB IN G  IN F O R M A T IO N  
Action
In vitro studies indicate that the bacterial action of Claforan (cefotaxime sodium) a semi-synthetic cephalosporin 
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible 
strains of the designated micro organisms in the diseases listed below.
Lower respiratory trac t in fec tions : pneumonia and lung abscess caused by Streptococcus pneumoniae 
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, eg. S. faecalis), Straphylococcus 
aureus (penicillinase and non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including 
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract in fe c tio n s : caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae), 
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated 
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
Bacteremia /  S e p ticem ia : caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens. 
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing, S. epidermidis, 
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdom inal in fe c tio n s : caused by Escherichia coli, and unspecified Klebsiella species.
Gynecological in fe c tio n s : including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by 
E. coli, Group A streptococci and Staphylococcus epidermidis; anaerobic bacteria including unspecified Peptococcus 
and Peptostreptococcus strains and some strains of Bacteroides (ragitis. In several cases, although clinical cures 
were achieved, bacteriological follow up was not available.
Central nervous system in fec tions: meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria 
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active 
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in 
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci.
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy 
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative 
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility 
studies are known; antibiotic treatment should be re evaluated once these results become available.
Prophylactic U s e : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively) 
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal 
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or 
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative 
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain 
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as 
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism 
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin 
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous 
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with 
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be 
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an 
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents 
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudomembranous colitis has been reported w ith  the use of cephalosporins (and other broad spectrum  
antib io tics); therefore, it is im po rtan t to  consider its diagnosis in patients who develop diarrhea during 
the adm inistration o f Claforan. This co litis  can range from  mild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit 
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium 
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic. 
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic 
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy 
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).
Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro­
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women 
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child bearing potential requires that the anticipated benefits be weighed against the 
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is 
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the 
patient's condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures 
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended, 
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended 
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and 
prolonged serum antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals during treatment with the cephalosporin group of 
antibiotics, including cefotaxime sodium.
In laboratory tests a falso positive reaction to glucose may occur with reducing substances but not with the use 
of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are :
H ype rsensitiv ity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous 
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%): Colitis, 
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan 
treatment. Hem ic and Lymphatic System ( <  1%): Mild, reversible leukopenia, granulocytopenia and thrombo­
cytopenia have been reported. Some patients developed positive direct Coomb's test during treatment with 
Claforan. Genitourinary System ( <  1%): Moniliasis, vaginitis. Liver ( <  1%): Transient elevations in SGOT, SGFT,
serum LDH and serum alkaline phsphatase levels have been reported. Kidney ( <  1%): Increased serum creatinine 
and BUN have occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or 
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table 
with recommended mode of reconstitution according to route of administration).
Adults
The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection 
and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)
Type of Infection
Daily Dose
(g) Frequency and Route
Uncomplicated Gonorrhea 1 1 g IM (single dose)
Uncomplicated infections 2 1 g every 12 hours IM or IV
Moderately severe to severe infections 3-6 1-2g every 8 hours IM or IV
Vfery severe infections (eg. septicemia. CNS) 6-8 2 g every 6-8 hours IV
Life-threatening infections up to 12 2g every 4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are 
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate 
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional 
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery 
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses 
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates: 0-1 week of age 50 mg / kg IV q 12 h
1-4 weeks of age 50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is 
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe 
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or 
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for 
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or 
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary 
tract infections and may be required for several months after therapy has been completed; persistent infections may 
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 the dose of Claforan should be 
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient) 
may be used to convert these values into creatinine clearance.
Males: Weight (kg) x  (140 -  age)
72 x  serum creatinine 
Females: 0.85 x  above value
Administration
In tram uscu la r: Claforan should be injected well within the body of a relatively large muscle such as the upper 
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a 
blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia, bacterial spticemia, or other severe 
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from 
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if 
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes. 
Using an infusion system, it may also be given over a longer period of time through the tubing system by which 
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this 
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue 
temporarily the administration of other solutions at the same site.
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a 
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or 
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP 
Stability
Solutions of Claforan reconstituted in 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP in the 
ADD-Vantage* flexible containers maintain satisfactory potency for 12 hours at room temperature.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium 
(expressed as acid on a dry basis).
S torage: Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
*Reg’d TM of Abbott Laboratories.
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Ex-Vivo Microvascular Reconstruction 
Before Renal Allograft and Autograft 
Transplantation
Joseph L. Chin, MD, FRCSC
Microvascular reconstruction was performed ex vivo on 50 kidneys that had vascular 
anomalies or had sustained vascular injury during procurement before allograft 
transplantation or autotransplantation. The authors review the various surgical 
techniques used to facilitate the in-situ vascular anastomoses during transplantation 
and to salvage otherwise an unusable allograft. The complications associated with 
the microvascular repair were negligible. The authors conclude from the results of 
their study that ex-vivo microvascular reconstruction is a valuable adjunct to renal 
transplantation.
Une microreconstruction vasculaire a ete pratiquee ex-vivo sur 50 reins qui 
presentaient des anomalies vasculaires ou qui avaient subi des lesions vasculaires au 
cours du prelevement en vue d’une allogreffe ou d’une autogreffe. Les auteurs 
passent en revue les diverses techniques chirurgicales utilisees pour faciliter une 
anastomose vasculaire in situ, durant la transplantation, et pour preserver une 
allogreffe qui serait, autrement, inutilisable. Les complications reliees a la microchi- 
rurgie vasculaire sont negligeables. Les auteurs concluent des resultats de leur 
etude que la microreconstruction vasculaire ex-vivo est un appoint therapeutique 
utile a la transplantation renale.
M icrovascular bench surgery was used to reconstruct the 
vasculature of 50 kidneys before 
renal allograft transplantation. All 
kidneys had vascular anomalies (in­
cluding a renal artery aneurysm) or 
vascular injury sustained during 
procurement. The purpose of the 
repair was to facilitate the in-situ 
vascular anastomosis in the recipi­
ent or to salvage an otherwise “un-
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usable” allograft. Although utiliza­
tion of the Carrel patch is the 
procedure of choice for donor kid­
neys with multiple vessels, its use is 
sometimes precluded (e.g., in live 
donors, when kidneys are harvested 
without an aortic patch or when the 
arteries have remote aortic origins). 
The value of adjunctive microvascu­
lar reconstruction is also illustrated 
in this paper.
Patients and Methods
Between January 1985 and June 
1989, 35 cadaveric kidneys and 13 
kidneys from living-related donors 
were repaired and transplanted into 
48 patients with end-stage renal 
failure. Two patients underwent 
renal autotransplantation after ex- 
vivo microvascular repair. The kid­
neys from cadaveric donors were 
harvested en bloc with in-situ perfu­
sion whenever possible. Vascular 
repair was performed in a basin of 
iced saline. Optical magnification 
was provided by either the Zeiss 
operating microscope (10X magnifi­
cation) or optical loupes (2.5X mag­
nification), depending on vessel 
size. Standard microsurgical instru­
ments and monofilament nonab­
sorbable 8-0, 9-0 or 10-0 sutures 
were used.
Surgical Technique
Multiple Vessels
Two basic microvascular anasto­
moses were used, either alone or in 
combination, depending on the vas­
cular problem of each kidney. Ves­
sels of comparable calibre were 
anastomosed side to side with run­
ning suture to create a single osti­
um from the two vessels (Fig. 1). 
Small polar vessels were anas­
tomosed end to side to the main 
artery with interrupted sutures after
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excision of a patch of vessel wall 
sufficient to accommodate the small 
vessel (Fig. 2). A small, plastic 
intravenous cannula was used as an 
intraluminal stent, safeguarding 
against injury to the posterior wall 
of the vessel during the anastomo­
sis.
Vascular Injury
When the vessels had been in­
jured during procurement and the 
kidneys were otherwise usable, indi­
vidual vascular reconstruction was 
performed. An end-to-end anasto­
mosis with interrupted sutures was 
feasible when the vessels had been 
cleanly severed without loss of 
length. If a substantial length of the 
vessel had been lost (usually from 
an unsuspected polar branch), the 
polar vessel was anastomosed end 
to side to the main artery at a new 
site near the renal hilum, providing 
a tension-free anastomosis. In two 
kidneys with extensive vascular in­
jury harvested at a non-transplant 
centre a combination of the tech­
niques was used. The end-to-end 
technique was used in two other 
kidneys with a severed polar vessel.
Short Renal Vein
Kidneys having a very short renal 
vein were reconstructed by incorpo­
rating the proximal inferior vena 
cava as part of the renal vein in a 
manner previously described1 (Fig. 
3). Usually a 7-0 nonabsorbable 
monofilament running suture was 
used. The renal vein length was 
increased two- to threefold in all 
cases.
Renal Artery Aneurysm
The renal arteriogram on a live 
donor revealed a solitary renal ar­
tery bilaterally. When the kidney 
was harvested, a renal artery aneu­
rysm, 1.6 cm in diameter, was dis­
covered at the bifurcation of the 
main artery and a lower pole 
branch. Standard donor nephrecto­
my was completed and microvascu- 
lar repair performed before trans­
plantation into the recipient. The 
aneurysm was excised and the de­
tached lower pole vessel was anas­
tomosed end to side to the ostium 
of the aneurysm after appropriate 
spatulation.
FIG. 1. Vessels of comparable calibre 
were anastomosed side to side with 
running suture to create single osti­
um. Note splitting of arterial wall in B.
FIG. 2. Small polar vessel was anas­
tomosed end to side to main artery 
with interrupted sutures after creating 
arteriotomy on main vessel.
Renal Autotransplantation
One patient had a long impass­
able ureteral stricture secondary to 
previous ureteroscopic instrumenta-
FIG. 3. Short right renal vein was 
elongated by incorporating inferior 
vena cava. Cava is incised obliquely 
either along line indicated by solid 
arrows in A with reconstruction illus­
trated in B or along line indicated by 
open arrow in A with reconstruction 
illustrated in C. Running 7-0 nonab­
sorbable monofilament suture is used.
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tion. Autotransplantion was under­
taken to salvage the obstructed 
kidney, which had an accessory 
artery at its lower pole. Standard
end-to-side microanastomosis was 
performed (lower pole to main ar­
tery) and the graft was autotrans- 
planted with a single in-situ arterial
FIG. 4. (A) Renal cell carcinoma in solitary kidney. (B) Mid-pole branch ligated and 
divided and tumour excised ex vivo. Renal pelvis was closed. (C) Artery was 
reanastomosed end to end with interrupted 8-0 sutures after determining extent of 
blood supply by arterial branch. Tumour bed was closed with interrupted matress 
sutures.
Tab le  1. P a tie n t Data
A natom ic arran g em en t T y p e  of anastom osis No. of g ra fts
A llo g ra fts
S in g le  a n a s to m o s is
P o la r a rte ry End to  s ide 20
D up lica ted  a rte ries C o n jo in t a rte rie s 11
D up lica ted  ve in s C o n jo in t v e in s 1
S h o rt renal ve in Caval e x te n s io n 4
M u lt ip le  a n a s to m o ses
D up lica ted  a rte ries , ve in s C o n jo in t a rte rie s , ve in s 1
P o la r a rte ry , s h o rt ve in E n d -to -s id e  a rte ry ; cava l e x te n s io n 1
D up lica ted  a rte ry , s h o r t  ve in S id e -to -s id e  a rte ry ; cava l e x te n s io n 1
3 a rte ries  (2  m a in , 1 p o la r) P olar end to  s id e  to  m ain ; 2  m a in  s id e  to
side 2
3 a rte ries  (2  m a in , 1 p o la r), 2  m ain  on  C arre l pa tch ; p o la r end to  s id e  to
dup lica te d  ve in s m a in ; c o n jo in t  ve in s 1
5 a rte ries 2  a rte ries b o th  end to  s ide  to  m a in ; 2  s m a ll
a rte rio le s  lig a ted 1
D am aged d u rin g  p ro c u re m e n t C o m b in a tio n  o f end to  s ide , s ide  to  s id e ,
end to  end 4
Renal a rte ry  a n e u rysm E xc is ion  o f  a n e u rysm ; end to  s ide , p o la r to
m ain a rte ry 1
A u to g ra fts  
S ing le  a n a s to m o s is
P o la r a rte ry End to  s ide 1
E arly b ranch  s u p p ly in g  tu m o u r,
m id d le  zone End to  end 1
and venous anastomosis. The sec­
ond patient had a centrally located 
renal cell carcinoma in a solitary 
kidney. The carcinoma measured 5 
cm in diameter and directly abutted 
on the renal pelvis. The renal arteri­
ogram suggested a very early ante­
rior branch supplying the tumour 
(Fig. 4). On the assumption that it 
supplied the tumour primarily, the 
branch was identified intraopera- 
tively, ligated and divided before the 
standard radical nephrectomy was 
carried out. The tumour was ex­
cised ex vivo with adequate margins 
of normal renal tissue, confirmed by 
random frozen-section examina­
tions. The collecting system was 
repaired and the arterioles and ven­
ules, which were identified by indi­
go carmine infusion through the 
main renal artery and vein, were 
sutured. Infusion of indigo carmine 
through the previously severed end 
of the anterior arterial branch re­
vealed that the branch supplied 
much more normal parenchyma in 
the middle zone of the kidney than 
anticipated. To minimize the risk of 
fistula and renal ischemia, the divid­
ed vessel was anastomosed end to 
end with interrupted 8-0 sutures. 
Standard autotransplantion into the 
right iliac fossa was performed after 
closure of the renal tumour bed 
(Fig. 4).
Results
Of the 48 patients who received 
allografts, 37 had a single anasto­
mosis and 11 required multiple re­
constructive procedures, including 
one aneurysm excision and repair 
(Table I). In both cases of autotran­
splantation, the patients required a 
single microanastomosis, end to 
side in one and end to end in the 
other. All reconstructed kidneys re­
quired a single arterial and venous 
anastomosis in situ. For the grafts 
with a short renal vein, the length
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of the renal vein was routinely 
doubled or tripled by incorporating 
part of the vena cava, thus facilitat­
ing the in-situ exposure and anasto­
moses.
The average duration for the 
bench surgery was 35 minutes for a 
single arterial anastomosis, 15 min­
utes for a single venous reconstruc­
tion and 60 minutes for multiple 
procedures. The median warm isch­
emic (rewarm) time for the in-situ 
arterial and venous anastomoses 
was 27 minutes for the 45 trans­
plants I performed. Three of the 45 
grafts had a warm ischemic time 
exceeding 45 minutes because of 
technical problems unrelated to the 
microvascular reconstruction.
Two of the 50 reconstructed kid­
neys had a minor leak along the 
anastomotic suture line when the 
arterial clamp was released; one 
graft required a single hemostatic 
suture (8-0) at the leakage site, and 
in the other, bleeding was stopped 
with topical application of an ab­
sorbable Gelfoam pad. Satisfactory 
blood flow was observed through 
the reconstructed vessels with cor­
responding good parenchymal per­
fusion in all allografts and auto­
grafts as confirmed by nucleotide 
renal scanning 1 day postoperative- 
ly. There were no postoperative 
complications, such as hemorrhage 
or renal or ureteral devasculariza­
tion, related to the microsurgery 
per se.
Nuclear scanning was repeated 
regularly only when indicated by 
persistent oliguria or anuria, a sud­
den rise in the serum creatinine 
level or a decline in urine output. 
Blood flow was uniform in all re­
constructed kidneys and there were 
no detectable perfusion defects. In 
selected patients, renal arteriogra­
phy was performed because of post­
operative hypertension, an audible 
bruit over the area of the iliac 
vessels or declining renal function. 
One patient had stenosis at the
allograft renal artery and host inter­
nal iliac artery anastomosis, remote 
from the end-to-end microanas­
tomosis.
There were two deaths periopera- 
tively, due to an intraoperative myo­
cardial infarction in one patient and 
overwhelming sepsis in the other. 
Transplant nephrectomy was per­
formed in three patients because of 
irreversible acute rejection; in each 
case the microanastomosed vessels 
were patent. Three patients suffered 
chronic rejection with a steady dete­
rioration in renal function. The 
other 40 allografts and 2 autotrans­
plants have maintained good renal 
function to date (median follow-up 
26 months).
Discussion
Approximately 25% of donor kid­
neys have unilateral multiple renal 
vessels and 10% have bilateral vas­
cular variations.2 Whenever possible 
the Carrel aortic patch should be 
used to salvage such kidneys for 
transplantation. However, the use 
of the aortic patch is contraindicat­
ed in live donors, and the procedure 
is not technically feasible in some 
circumstances. Several macroscopic 
anastomotic techniques have been 
proposed to handle kidneys with 
multiple arteries,3 although the 
techniques are cumbersome and in- 
situ exposure is usually suboptimal.
Microvascular reconstruction 
would greatly facilitate the in-situ 
vascular anastomoses, since excel­
lent exposure and accurate anasto­
mosis can be achieved with a mini­
mum of technical errors. A conjoint 
“double-barrelled” artery has the 
theoretical hemodynamic advantage 
over two smaller vessels anas­
tomosed individually to the recipi­
ent artery. Revascularization of 
multiple vessels in situ would pro­
long the rewarm time compared 
with a single arterial anastomosis 
and might adversely affect subse­
quent allograft function, since 
warm ischemic damage has been 
shown to be more crucial to subse­
quent allograft function than cold 
ischemia.4 Kidneys that would be 
exposed to cyclosporine as part of 
the immunosuppression regimen 
are particularly vulnerable because 
prolonged warm ischemia appears 
to exacerbate the nephrotoxic effect 
of cyclosporine.5 In addition to 
using kidneys with complicated vas­
culature, microvascular surgery has 
facilitated the use of some kidneys 
in which the vessels have been 
damaged during procurement. The 
surgeon might hesitate to use an 
immunologically compatible live 
donor with multiple renal arteries 
bilaterally if complicated in-situ 
anastomoses are required. However, 
with microvascular repair ex vivo, 
the subsequent in-situ anastomoses 
are much simpler.
Complications arising from the 
microvascular repair were negligible 
in this series of patients. Microvas­
cular repair has several theoretical 
and technical advantages over other 
methods of handling allografts with 
multiple vessels and is a valuable 
adjunct to renal transplantation. 
The same microsurgical techniques 
are applicable in selected cases of 
renal autotransplantation.
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Reconstitution 
For Intramuscular Use
Reconstitute ‘Rocephin’ powder with the appropriate diluent:
• Sterile Water for Injection • Bacteriostatic Water for Injection
• 0.9% Sodium Chloride Injection • 1 % Lidocaine Solution
• 5% Dextrose Injection 
Reconstitute as follows:
Reconstitution Table (IM)
Vial Size
Volume to be 
added to vial mL
Approximate 
available 
volume mL
Approximate
average
concentration g/mL
0.25 g 0.9 1 0.25
0.5 g 1.8 2 0.25
i.0 g 3.6 4 0.25
2.0 g 7.2 8 0.25
Shake well until dissolved.
NOTE: SOLUTIONS PREPARED FOR INTRAMUSCULAR USE OR ANY SOLUTION CONTAINING 
LIDOCAINE OR BACTERIOSTATIC WATER FOR INJECTION SHOULD NEVER BE ADMINISTERED 
INTRAVENOUSLY.
For Intravenous Use
Reconstitute only with Sterile Water for Injection.
Reconstitute as follows:
Reconstitution Table (IV)
Vial
Size
Volume to be 
added to vial 
mL
Approximate
available
volume
mL
Approximate
average
concentration
g /m l
0.25 g 2.4 2.5 0.1
0.5 g 4.8 5.0 0.1
1.0 g 9.6 10.0 0.1
2.0 g 19.2 20.0 0.1
Shake well until dissolved. The prepared solution may be further diluted to the desired volume with any of the 
“Solutions for IV Infusion” listed below.
Solutions for IV Infusion
0.9% Sodium Chloride Injection, 5% Dextrose Injection, Dextrose and Sodium Chloride Injection.
Pharmacy Bulk Package Reconstitution for Preparation of Intravenous Infusion Solutions
The closure of the pharmacy bulk vial shall be penetrated only one time after reconstitution, using a suitable 
sterile transfer device or dispensing set which allows measured dispensing for the contents.
Reconstitution Table for Bulk Pharmacy Package
Volume to be Approximate Approximate
Vial added to vial available volume average concentration
size mL mL g/mL
10 g 95 100.0 0.1
Shake well until dissolved. Withdraw the required amount and dilute with one of the “Solutions for IV 
Infusion". Any unused solution remaining within a period of 8 hours should be discarded.
Stability of Solutions - Storage
For complete stability and storage information, consult the Product Monograph.
Incompatibility:
‘Rocephin’ should not be physically mixed with other antim icrobial agents.
‘Rocephin’ should not be added to blood products, protein hydrolysates or amino acids.
'Rocephin' should not be added to solutions containing calcium.
DOSAGE FORM
Availability: ‘Rocephin’ is available in vials containing dry substance equivalent to 0.25 g, 0.5 g, 1 g or 2 g of 
ceftriaxone and as a pharmacy bulk vial containing the equivalent of 10 g ceftriaxone (not for direct 
administration). The availability o f the Pharmacy bulk vial is restricted to hospitals with a recognized intravenous 
admixture program.
Storage: Rocephin’ sterile powder should be stored at a controlled room temperature (between 15° and 30°C) 
and protected from light.
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Comparison of Automated and Manual 
Methods for Islet Isolation
Garth L. Warnock, MD, MSc, FRCSC; Norman M. Kneteman, MD, MSc, FRCSC; 
Mark G. Evans, MD, MSc, FRCSC; Kelly D. Dabbs, MD; Ray V. Rajotte, MSc, PhD
The authors used the principal features of a collagenase perfusion technique and an 
automated dissociation technique to determine if islets could be isolated from the 
large mammal pancreas and to compare the effects of the two methods on isolated 
islets. The pancreases of 16 dogs were cannulated and perfused with collagenase at 
4°C, then warmed to 37°C. Group 1 (eight) pancreases were perfused at 37°C until 
digested, then dissociated manually by teasing and trituration. Group 2 (eight) 
pancreases were transferred to a closed chamber for continued collagenase digestion 
and dissociation at 37°C. Islets were purified using identical Ficoll gradients. 
Aliquots were stained with dithizone and evaluated for number, size and purity. 
Total islet volume was calculated.
Group 2 pancreases were thoroughly digested leaving only a few residual ducts, 
but undigested fragments persisted in group 1 pancreases. Islet size was similar in 
both groups. There was a greater islet volume before and after Ficoll purification in 
group 2, but the difference was not significant. Purity was greater than 90% in both 
groups. Perifusion with 28 mM glucose elicited a biphasic insulin release from islets 
in both groups.
The data show that the combined protocol enables mass isolation of purified islets 
from the canine pancreas. Compared with the manual technique, the automated 
protocol for pancreas dissociation tends to improve the yield of islets without 
compromising islet size and viability. It provides the advantages of a closed system 
with increased control over the extent of collagenase digestion.
Afin de determiner si les tlots pancreatiques pouvaient etre isoles du pancreas des 
gros mammiferes et d’apprecier les effets des techniques manuelle et automatisee 
d’isolation des ilots, les auteurs ont associe les principales caracteristiques d’une 
technique de perfusion a la collagenase mise au point dans leur laboratoire et une 
technique automatisee. Les canaux pancreatiques de 16 chiens ont ete canules et 
perfuses avec de la collagenase a 4°C, avec rechauffement subsequent a 37°C. Les 
(huit) pancreas du groupe 1 ont ete perfusees a 37°C jusqu’a digestion complete, 
puis dissocies manuellement par effilochage et trituration. Les (huit) pancreas du 
groupe 2 ont ete transferes en vase clos pour la poursuite de la digestion a la 
collagenase combinee a une dissociation a 37°C. Les ilots ont ensuite ete purifies a 
l’aide de gradients Ficoll identiques. Des aliquotes ont ete colorees a la dithizone 
puis exminees pour en evaluer le nombre, la taille et la purete. Le volume total 
d’Tlots fut aussi calcule.
Les pancreas du groupe 2 etaient completement digeres, ne laissant que quelques 
canaux residuels, alors que des fragment non digeres persistaient dans le groupe 1. 
La distribution selon la taille etait semblale pour les deux groupes. Le volume des 
ilots avant et apres purification par gradients Ficoll ne differait pas de fa$on 
importante. La purete etait superieure a 90% dans les deux groupes. Une perifusion 
a l’aide 28 mM de glucose a provoque une liberation biphasique d’insuline dans les 
deux cas.
Ces donnees demontrent qu’il est possible d’isoler de grandes quantites d’ilots 
purifies de pancreas canin a l’aide de ce protocole combine. Comparativement a la 
technique manuelle, le protocole automatise de dissociation pancreatique a augmen­
ts le rendement d’isolation des ilots sans compromettre leur taille ou leur viabilite, 
bien que cette augmentation n’ait pas ete significative. Cette methode offre les 
avantages d’un systeme ferme avec un meilleur controle du degre de digestion a la 
collagenase.
Progress in the isolation of islets of Langerhans from the pancre­
as of adult human organ donors1-3 
has promoted studies of pancreatic 
islet transplantation in insulin- 
dependent diabetes mellitus.4-5 How­
ever, results of renewed trials sug­
gest that yields of islets must be 
optimized to reverse the insulin- 
dependent state. Improvements can 
be made in three key steps that 
form the basis for islet isolation 
protocols: collagenase digestion of 
the fibrous connective tissue stroma 
of the pancreas; gentle mechanical 
dissociation of islets from exocrine 
constituents; and purification. Al­
though the optimal protocol to be 
followed has not been defined, two 
recently described methods for col­
lagenase digestion appear promis­
ing. We have perfused collagenase 
through canine or human pancreat­
ic ducts, gently dissociated the pan­
creas with manual teasing and tritu-
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ration and purified islets with Ficoll 
gradients.2-6
Ricordi and colleagues3 have re­
ported success with human islet 
isolation using an automated tech­
nique that simultaneously subjects 
the pancreas to collagenase diges­
tion and dissociation. In the present 
study we combined the principal 
features of the collagenase perfu­
sion method with the automated 
digestion technique. The canine 
pancreas was used because its 
structure and collagen distribution 
approximate those observed in the 
human pancreas. Our aim was to 
determine if islets could be isolated 
from the canine pancreas using this 
combined protocol and to compare 
the effects of manual or automated 
isolation on the size, viability, puri­
ty and yield of canine islets.
Material and Methods
Islet Isolation
The pancreases of 16 dogs were 
mobilized, preserving all major vas­
cular connections. Both main 
branches of the pancreatic duct 
were cannulated in situ using 
20-gauge cannulas. The gland was 
then excised and weighed. A third 
cannula was inserted into the left 
duct 5 cm from the tip of the gland. 
Hanks’ solution (50 ml) containing 
collagenase (Sigma Type XI; Sigma 
Co., St. Louis, Mo., 1100 U/ml at 
4°C) was injected slowly into each 
cannula. For digestion, each cannu­
la was connected to a perfusion 
device and perfused with collage­
nase solution (6 m l/g of original 
pancreas weight, 1100 U/ml) at 
4°C for 10 minutes. The perfusate 
was warmed at a rate of 3°C/min 
to 37°C. Figure 1 summarizes the 
two types of protocols that were 
followed for subsequent islet isola­
tion.
Group 1 (eight) pancreases were
perfused until the gland became 
mucoid (approximately 10 to 12 
minutes after commencement of 
warming). The pancreas was then 
cooled to 4°C and dissociated by 
teasing and trituration. Group 2 
(eight) pancreases were transferred 
to an oscillating chamber (3 Hz) for 
digestion with collagenase (same 
dose as above) and dissociation at 
37 °C. Islets that were liberated in 
the chamber were continuously col­
lected from the effluent of solution 
that flowed through the chamber 
and cooled to 4°C.3 Final purifica­
tion was performed with Ficoll 
using gradient densities of 1.045, 
1.075 and 1.085 as previously de­
scribed.7-8
Quantification o f Islets
Aliquots of the islet suspension 
were stained with dithizone and
FIG. 1. Comparison of two protocols. All pancreases were initially perfused with 
collagenase through three cannulas inserted into pancreatic ducts. Pancreas was 
then dissociated by manual (group 1, teasing and trituration) or automated (group 
2, digestion chamber) method. In each case, islets were purified using Ficoll 
gradients.
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examined microscopically. The 
numbers of islets in each size range 
of 60 to 99 Mm, 100 to 149 pm, 
150 to 199 /am, 200 to 249 Mm and 
greater than 250 Mm in diameter 
were counted with the aid of an 
optical graticule and converted to a 
number of islets with a standard 
diameter of 150 Mm. The number of 
islets equivalent to 150 Mm in diam­
eter was multiplied by a volume 
constant to calculate the volume of 
islets. Purity was estimated by com­
paring the quantity of dithizone 
stained and unstained tissue at mi­
croscopy.
Viability o f  Islets
Islet viability was assessed in 
vitro by measuring the insulin se­
cretory response during perifusion 
with low (2.8 mM), and high (27.8 
mM) glucose levels. In addition, 
islets from five group 1 isolations 
and from one group 2 isolation 
were autografted to the spleen by 
venous reflux.
Results
Pancreas Digestion and Dissociation
Group 2 pancreases were thor­
oughly digested into fine particles, 
leaving a few residual ducts but no 
exocrine particles. In contrast, 
group 1 pancreases were dissociat­
ed into coarse particles which re­
quired trituration with 14-gauge 
needle (three times), a 16-gauge 
needle (three times) and an 
18-gauge needle (twice). Undigested
fragments persisted, comprising 
22% of the original pancreas 
weight.
Islet Size and Viability
Table I shows that the size range 
of the islets is similar in both 
groups, the majority of the islets 
being in the lower range (60 to 
99 Mm diameter), but in group 2 
a larger proportion of islets were 
identified in the upper size range 
(more than 150 Mm). Islets from 
both groups responded to an in­
crease in perifusate glucose with a 
biphasic pattern of insulin release 
and a threefold increase in insulin. 
The magnitude of insulin secretion, 
both basal and stimulated, was less 
in islets isolated by the automated 
method.
Islet Yield
Table II shows the islet recovery 
before and after Ficoll purification 
in both groups. The number of 
islets yielded per gram of pancreas 
tended to be higher when the auto­
mated isolation procedure was used, 
although the increase did not reach 
statistical significance (Mann-Whit­
ney test). Similarly, when the islet 
yield was expressed in terms of
volume, the automated technique 
appeared to provide a greater yield, 
although again statistical signifi­
cance was not achieved. Ficoll puri­
fication resulted in a 52% reduction 
of islet volume in group 1 compared 
with a 42% reduction in group 2. 
Purity was greater than 90% in 
both groups.
Weight-Corrected Islet Yields and 
Implantation
The final mean (± standard error) 
pure islet volume [pL/kg donor 
body weight) was 4.4 ± 1.5 in 
group 1 compared with 7.6 ± 1.6 
in group 2. Normoglycemia ensued 
when more than 4 pL/kg  of puri­
fied islets were autoimplanted after 
preparation with the manual (five 
pancreases) or automated (one pan­
creas) technique.
Discussion
Initial clinical experience with 
islet transplantation suggests that 
an adult patient with insulin- 
dependent (type I) diabetes will re­
quire more than 3710 islets of 
mean diameter 150 pm/kg  body 
weight to reverse insulin depen­
dence.5 This represents an estimat-
Table II. Yields of Islets Isolated With Manual or Automated Methods*
No. of islets, X 103/g Volume of islets, nL/g
Group No. Pre-Ficoll Post-Ficoll Pre-Ficoll Post-Ficoll
Manual 8 4.8 ± 1.0 3.0 ± 0.7 4.2 ± 1.0 2.0 ± 0.7
Automated 8 7.3 ± 1.0t 3.7 ± 0 .7 t 6.2 ±  1.4t 3.6 ± 0.8+
'Mean ±  SEM.
tN ot significant versus manual.
Table 1. Size and Viability of Islets Isolated With Manual or Automated Methods*
Islet size, (% of islets) Insulin secretion, ^U/islet - min1
Group No. 60-99 100-149 150-199 >200 Basal Stimulated
Manual 8 64 ± 3 32 ± 2 4 ± 1 0.4 ± 0.3 0.03 ±0.01 0.11 ±0.02+
Automated 8 61 ± 6 29 ± 4 8 ± 3 2 ± 1 0.01 ± 0.003 0.03 ± 0.007+
'Mean ±  SEM.
tThreefold rise over basal level.
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ed islet volume of more than 6.5 
#iL/kg. The quantity may need to 
be augmented further to provide 
the critical mass of /8-cells,7 as well 
as to overcome the potential delete­
rious effects of reduced viability, 
immunosuppressive drugs,9 the dia­
betic state,10 the site chosen for 
implantation11 and rejection or au­
toimmune phenomena. Islet yields 
of this magnitude have recently 
been reported.23 However, recovery 
continues to vary in different isola­
tions, and the optimal method for 
islet preparation needs to be de­
fined.
In earlier studies we found that 
collagenase perfusion through the 
pancreatic duct was superior to 
ductal injection for isolating islets 
from the human pancreas.2 Perfu­
sion appeared to enhance the deliv­
ery of collagenase to the intralobu­
lar exocrine compartment of the 
pancreas, thereby improving the 
cleavage of connective tissue stro­
ma, which binds the islets. Ricordi 
and colleagues3 used a duct injec­
tion technique, then developed an 
automated method to liberate large 
quantities of human islets. Among 
the advantages they cited were min­
imal trauma to the islets, continu­
ous liberation from collagenase, 
which protects islets from excessive 
digestion, and minimal human inter­
vention. In this study, we combined 
the advantages of both perfusion 
and automation. The result was 
successful isolation of mass quanti­
ties of islets from the canine pancre­
as, which compares favourably with 
results of other studies, including 
our own.6 812 The quantity of pure 
islets provided per unit body weight 
of donor (7.6 pL/V.g) is well in 
excess of that which we found 
necessary for consistent reversal of 
hyperglycemia (more than 4.5 mU 
after autoimplantation.7 This quan­
tity also compares favourably with 
the quantity of islet tissue that we 
predict is necessary to induce nor-
moglycemia in human recipients.
Comparison of results of the 
manual and automated methods of 
islet isolation revealed that the 
quantity of islets isolated was con­
sistently better using the latter 
method, although the improvement 
in yields did not reach statistical 
significance. A comparison of mor­
phology and viability of the islets 
isolated revealed that islets of simi­
lar size can be obtained by either 
method, and the response to perifu- 
sate glucose showed a threefold rise 
in each case. Although the quantity 
of insulin released was less in the 
automated studies, this could be 
attributed to such factors as a re­
duced size of the islets in the 
sample subjected to perifusion.2
Some additional factors regard­
ing the combined procedure are 
noteworthy. First, the digestion 
chamber augments the activity of 
collagenase delivered to the in­
tralobular environment by incubat­
ing the periphery of undigested par­
ticles for longer. Thus, we found 
that the duration of exposure to 
collagenase at 37°C could be in­
creased from 10 minutes to more 
than 25 minutes, which may have 
freed more entrapped islets. Second, 
the automated procedure provided 
the advantage of a closed system, 
which reduced the likelihood of 
bacterial or fungal contamination. It 
should also be noted that the quan­
tity of collagenase solution needed 
to operate the digestion chamber 
was twice that used for the perfu­
sion method alone.
In summary, these data show 
that the combination of an automat­
ed digestion protocol and collage- 
nase ductal perfusion enabled mass 
isolation of purified islets from the 
canine pancreas. Comparison of the 
manual and automated protocols 
shows that automation tends to 
improve yields of islets without 
compromising islet morphology and 
viability, although the yields are not
significantly higher. The modifica­
tion provides the advantages of a 
closed system with control over the 
extent of collagenase digestion. 
This protocol may provide improved 
isolation of islets from the human 
pancreas.
We thank Dixie Untch for technical 
assistance and Colleen Gardner for pre­
paring the manuscript.
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New Mesasal:
Because in 5-ASA therapy, 
the difference is the delivery 
mechanism13
◄ pH-mediated release delivers 5-ASA to distal 
small bowel and throughout colon4 5
◄ Buffering adjuvants help ensure rapid, fine 
dispersion at classic inflammation sites4 5
◄ Slow transit through colon documented 
in IBD patients4-5
New Mesasal: pH-mediated 
release mechanism for 
unsurpassed delivery6
Because Mesasal’s enteric coating dissolves at 
pH 6 or above, it delivers 5-ASA to the distal small 
bowel, as well as dispersing throughout the 
colon.1-4 6 Gamma scintigraphy confirms that 
Mesasal delivers 5-ASA to key sites of 
inflammation -  quickly and reliably.4 6
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New Mesasal: 
induces remission- 
and maintains it6 7
Clinical studies prove patients treated with Mesasal 
achieve a high rate of remission ,6 And Mesasal 
therapy helps ensure remission is maintained.7 New 
Mesasal is currently indicated for both active and 
quiescent ulcerative colitis.
Controlling Active Disease 
In patients with active mild to moderate ulcerative 
colitis, Mesasal is a generally well-tolerated, 
effective treatment.6
Maintaining Remission
Mesasal is an effective treatment for maintaining 
ulcerative colitis remission and is associated with 
fewer side effects than equivalent doses of 
sulfasalazine.7
Because in 5-ASA therapy, the 
difference is the delivery mechanism
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PHARMACOLOGICAL CLASSIFICATION
Lower Gastrointestinal Anti-inflammatory
ACTIONS AND 
CLINICAL PHARMACOLOGY
5-aminosalicylic acid (5-ASA) is considered 
to be the active component of sulfasalazine. 
Although its mode of action has not been 
definitely elucidated, 5-ASA is thought to 
have a topical anti-inflammatory effect which 
is produced by inhibition of prostaglandin 
and/or leukotriene synthesis.
Mesasal™ tablets have an acrylic based resin 
coating which is specifically designed to 
release 5-ASA in the terminal ileum and 
colon. Urinary recovery studies have shown 
that 35% of the 5-ASA is absorbed. The 
absorbed 5-ASA is rapidly acetylated and 
excreted mainly by the kidney.
Detectable plasma levels of 5-ASA were 
seen 4 hours after a single oral dose of 
tablets (2 x 250 mg). Peak plasma levels 
of 5-ASA and l\l-acetyl-5-ASA were 1.2 
and 1.9 prg/mL, respectively, and occurred 
6.5 - 7 hours post-dosing. Mean steady- 
state plasma levels of 5-ASA and 
N-acetyl-5-ASA using a 500 mg t.i.d. 
dosage schedule are 0.7 and 1.2 gg/mL, 
respectively.
Except for a delay of 1.5 - 3 hours in time to 
peak of 5-ASA and N-acetyl-5-ASA plasma 
levels, Mesasal™ pharmacokinetics are 
essentially the same in fasted and fed 
subjects.
INDICATIONS
Mesasal™ (5-aminosalicylic acid) tablets are 
indicated in the management of acute 
ulcerative colitis, and for the prevention of 
relapse of active ulcerative colitis.
CONTRAINDICATIONS
Mesasal™ (5-aminosalicylic acid) is 
contraindicated where there is a history of 
hypersensitivity to salicylates.
Mesasal™ is contraindicated in cases of 
hemorrhagic diathesis.
Mesasal™ is contraindicated in patients with 
existing gastric and duodenal ulcers. 
Mesasal™ is contraindicated in patients with 
urinary tract obstruction.
WARNINGS
In cases of severe liver and kidney disorders, 
caution should be exercised.
Use in Pregnancy:
In the first three months of pregnancy, 
treatment is recommended only if potential 
benefits outweigh the possible risks. 
Pediatric Use:
There is no experience with respect to the 
use of this drug in children; potential 
benefits should be weighed against possible 
risks.
PRECAUTIONS 
Drug Interactions:
The blood-sugar reducing effect of sulfonyl 
ureas may be enhanced. Interactions with 
coumarins, methotrexate, probenecid, 
sulfinpyrazone, spironolactone, furosemide 
and rifampicin cannot be excluded. 
Potentiation of undesirable glucocorticoid 
effects on the stomach is possible.
In long term therapy, periodic urinalysis 
should be conducted. Caution should be 
exercised when therapy is first initiated in 
patients known to be allergic to 
sulfasalazine.
ADVERSE REACTIONS
In controlled clinical trials in 395 patients 
who received 5-ASA, the following adverse 
reactions were reported: headache (3.04%),
A
BECAUSE IN 5-ASA ' «
THERAPY, THE DIFFERENCE > 
IS THE DELIVERY MECHANISM
◄
nausea (2.03%), abdominal pain (1.52%), V 
and diarrhea (1.52%). Other adverse effect^ 
common to salicylates, including 
hypersensitivity reactions, may be expected 
to occur rarely. There have been a few ^ 
spontaneous reports of pancreatitis, acute t 
and chronic interstitial nephritis and 
pericarditis, associated with 5-ASA therapy’
SYMPTOMS AND 4
TREATMENT OF OVERDOSAGE
There is no specific antidote. Gastric lavage' 
should be employed, followed by promotion v  
of diuresis by the intravenous infusion of an 
electrolytic solution. i
DOSAGE AND ADMINISTRATION A
During the acute inflammatory stage and in  ^
long-term maintenance therapy, Mesasal™ 
(5-aminosalicylic acid) must be taken 
reliably and consistently by the patient in *  
order to ensure therapeutic success.  ^
Although symptomatic relief may be seen as 
early as three to twenty-one days, therapy 4 
should be continued depending on clinical^ *- 
findings. A
The following dosage regimens are 
recommended: 4
A dults *
Tablets: For the management of acute w j 
ulcerative colitis: 1.5 g to 3 g daily in 
divided doses. For prevention of relapses *  
of acute ulcerative colitis: 1.5 g daily in 
divided doses.
AVAILABILITY AND STORAGE 
Tablets
Mesasal™ enteric coated tablets, 250 mg 
and 500 mg, are available in amber glass 
bottles of 100 tablets. Mesasal™ tablets 
should be swallowed whole before meals 
with plenty of fluid.
ORIGINAL ARTICLES
Vagotomy and Antrectomy Revisited
C. Kotwall, MD, MSc, FRCSC; H.T.G. Williams, MD, FRCS, FRCSC
A retrospective review of 185 patients who underwent truncal vagotomy and 
antrectomy for duodenal ulcer disease was carried out to determine the mortality and 
morbidity of the procedure. There were no deaths within 30 days of operation and 
only one patient died while in the hospital (0.54%). Twenty-one patients (11.4%) 
suffered early morbidity, 3 of them requiring a second operation. Follow-up was 
obtained in 83 patients and averaged 13.5 years. According to Visick’s classification 
75 patients (90.4%) were in class I or II; 5 patients (6%) were in class III and 3 
patients (3.6%) in class IV.
A recurrent ulcer developed in 2 of the 83 patients. In contrast, after highly 
selective vagotomy, the literature supports an unacceptable incidence of recurrent 
ulcer. Therefore, we must not prematurely cast aside vagotomy and antrectomy; it 
still remains a safe and acceptable procedure for duodenal ulcer disease.
Cette etude retrospective de 185 patients, qui ont subi une vagotomie tronculaire 
avec antrectomie pour ulcere duodenal, a ete realisee dans le but d’etablir la 
mortalite et la morbidite reliees a cette intervention. Aucun deces n’a ete enregistre 
dans les 30 jours qui ont suivi l’operation et un seul patient (0.54%) est decede 
durant son hospitalisation. Vingt-et-un patients (11.4%) ont souffert d’une morbidite 
precoce, 3 d’entre-eux necessitant une seconde operation. Un suivi a pu etre obtenu 
pour 83 patients et sa duree moyenne a ete de 13.5 annees. Soixante-quinze patients 
(90.4%) appartenaient aux classes I et II de la classification de Visick; 5 patients 
(6%) etaient dans la classe III et 3 (3.6%) dans la classe IV.
Une recidive de l’ulcere est apparue chez 2 des 83 patients. En comparaison, la 
litterature medicale rapporte une incidence inacceptable d’ulceres recidivants apres 
vagotomie tres selective. II ne faut done pas rejeter prematurement la vagotomie- 
antrectomie; elle demeure une operation sure et acceptable pour l’ulcere duodenal.
The place of truncal vagotomy and antrectomy in the modern- 
day treatment of duodenal ulcer 
disease is unclear. There is a pletho­
ra of reports in the literature attest­
ing to the advantages of highly 
selective vagotomy over any other 
ulcer operation, in both prospective­
ly randomized1-6 and retrospective 
studies.7-13 But all these studies 
report an incidence of recurrent 
ulcer ranging from 3.5% to 30%, 
with varying periods of follow-up.
Accepted for publication Aug. 11. 1989
Dissatisfaction with highly selec­
tive vagotomy has led to such inno­
vative procedures as proximal gastr­
ic vagotomy and mucosal antrecto­
my.14 In addition, the advent of 
H2-receptor antagonists has altered 
the role of surgical therapy.
In this study we review the mor­
tality, morbidity (early and long­
term) and incidence of recurrent 
ulcer in truncal vagotomy and an­
trectomy, done by a single surgeon 
(H.T.G.W.) over a 16-year period. In
Edmonton, Alta.
St. Michael's Hospital.
the light of highly selective vagoto­
my, we will then try to reassess the 
role of vagotomy and antrectomy in 
duodenal ulcer disease.
Patients and Methods
We reviewed retrospectively 185 
consecutive patients (135 men, 50 
women) with duodenal ulcer disease 
who underwent truncal vagotomy 
and antrectomy between 1960 and 
1976. The mean age of the patients 
was 47.4 years. All patients with 
gastric ulcer were excluded. Preop­
erative investigations included bari­
um studies in most patients; gastric 
acid analysis was performed in no 
more than 15%. Forty-one patients 
(22.2%) were identified as having 
undergone 43 previous surgical 
procedures for their duodenal ulcer 
diathesis (Table I). The most com­
mon antecedent surgical procedure 
was a Rosco-Graham patching for a 
perforated duodenal ulcer. The av­
erage interval between the previous 
surgical procedure and vagotomy 
and antrectomy was 6.2 years. Indi­
cations for vagotomy and antrecto­
my included intractability in 113
T a b le  1. Surgical Procedures Performed
Prior to Vagotomy and Antrectomy
Procedure N o. o f p ro c e d u res
Perforated duodenal
ulcer (patching) 20
Partial gastrectomy with
Billroth II 10
Billroth 1 2
Vagotomy and
pyloroplasty 8
Gastrojejunostomy 2
Vagotomy and
gastrojejunostomy 1
Total 43Reprint requests to: Dr. C. Kotwall. Division o f  General Surgery. 
University o f Toronto. 30 Bond St.. Toronto. Ont. M5B 1W8
From the Department o f Surgery. University o f  Alberta Hospital.
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(61.1%), bleeding in 34 (18.4%), 
obstruction in 28 (15.1%) and per­
foration in 2 (1.1%).
The operative technique is as 
follows: after a nasogastric tube has 
been inserted, a bilateral truncal 
vagotomy is performed. The left 
triangular ligament of the liver may 
be incised to retract the lateral 
segment of the left lobe for addi­
tional exposure, but the use of a 
Weinberg retractor is usually suffi­
cient. The esophagus is mobilized 
on the right and left aspects, care­
fully retaining the dorsal attach­
ment of “mesoesophagus” in which 
lies the posterior vagus trunk. Slid­
ing this tissue between the finger 
and thumb, working anteriorly from 
the aorta, makes identification of 
the posterior vagus relatively easy. 
Metal clips are placed on it, approx­
imately 3 cm apart, and the inter­
vening segment is sent for patho­
logical examination. Traction is 
then placed on the esophagus with 
a Penrose drain, and the left (anteri­
or) vagal trunk is identified lying on 
the anterior esophageal muscula­
ture; in similar fashion, a segment 
is sent for examination. A meticu­
lous search is then made for any 
other accessory vagal fibres which, 
if found, are divided.
Attention is then turned to the 
stomach where the distal one-half 
of the greater curvature is mobi­
lized from the gastroepiploic ves­
sels. The gastrohepatic ligament is 
divided in an avascular place and 
the descending branches of the left 
gastric artery are identified, doubly 
ligated proximally and divided. The 
right gastric artery is similarly ligat­
ed and divided. The line of transec­
tion of the stomach is from the 
mid-point of the greater curvature 
to a point just below the descending 
branch of the left gastric artery 
(approximately 3 cm above the 
gastric notch) to include the 
“tongue of antrum”, which extends 
for a variable distance along the
X
lesser curvature of the stomach 
(Fig. 1). A crushing clamp is then 
placed across the stomach at the 
line of transection. The stomach is 
divided 5 mm proximal to the 
clamp, first cutting down (with a 
new blade) to the vascular plexus in 
the submucosa, clamping the ves­
sels and then dividing into the lu­
men. The divided stomach, with 
bleeding accurately controlled, is 
closed with a single layer of 3-0 silk 
interrupted sutures, starting at the 
lesser curvature and leaving a 7-cm 
opening at the greater curvature.
The duodenum is mobilized just 
beyond the pylorus and divided at 
this level, controlling the vessels in 
the submucosa. A finger is passed 
down the duodenum to assess any 
fibrous stenosis associated with the 
ulcer and to identify the ampulla of 
Vater. Any stenosis is relieved with 
a 5-cm incision down the an­
teromedial aspect of the duodenum. 
Gastroduodenostomy is then per­
formed using a single layer of inter­
rupted silk sutures and taking the 
greater curvature of the stomach to 
the apex of the anteromedial inci­
sion. A large posterior penetrating 
ulcer is entered when the duode­
num is mobilized beyond the pylo-
FIG. 1. Diagram of stomach showing 
line of transection from midpoint of 
greater curvature toward lesser curva­
ture just below descending branch of 
left gastric artery. 1 =  left gastric 
artery, 2 =  right gastroepiploic artery, 
3 = left gastroepiploic artery, 4 =  
right gastric artery, 5 =  splenic artery.
rus. The ulcer is excluded by using 
the distal margin for part of the 
anastomosis.
Follow-up was obtained in 83 of 
the 185 patients (44.9%). The aver­
age duration of follow-up was 13.5 
years. The method of follow-up was 
by telephone conversation between 
the junior author (C.K.) and the 
patient or, if the patient was not 
available or had died, a relative. 
Specific questions involved those 
related to dumping, diarrhea, 
weight loss, recurrent ulcer and 
overall success of the operation. A 
modified Visick score was used to 
categorize the patient’s postopera­
tive status: grade I — was no 
postoperative symptoms; grade II 
— mild symptoms that were con­
trolled with dietary change and did 
not interfere with life-style; grade 
III — moderate symptoms requiring 
diet change and treatment, with 
incomplete control of the symptoms 
but with no serious change in life­
style and grade IV — severe symp­
toms incompletely controlled by any 
treatment and with a major change 
in life-style; this category included 
all recurrent ulcers.
Results
After truncal vagotomy and an­
trectomy, gastroduodenostomy was 
performed in 175 (95.7%) patients; 
the remaining 8 had Billroth II 
gastrojej unostomy.
There were four incidental sple­
nectomies (2.2%).
Complications
There were 21 major complica­
tions in 185 patients, an overall 
morbidity of 11.4% (Table II). Three 
of these complications required an­
other operative procedure. The pa­
tient with gastric outlet obstruction 
subsequently required a gas­
trojejunostomy; in another patient a
4
V
4
4
-4
376 CJS, VOL. 33, NO. 5, OCTOBER 1990
VAGOTOMY AND ANTRECTOMY
Billroth II stomal obstruction devel­
oped secondary to twisting of the 
afferent and efferent loops, requir­
ing operative intervention. The 
third patient had an anastomotic 
leak and required drainage of a 
subhepatic abscess. This patient 
was on hyperalimentation when 
Candida sepsis developed; this was 
followed by jaundice then subacute 
hepatic necrosis and she died 147 
days after the vagotomy and antrec­
tomy. Overall mortality was there­
fore 0.54%; however, there were no 
deaths within 30 days of operation.
Visick Scores
Table III lists the Visick scores 
for the 83 patients who were avail­
able for follow-up; 90.4% of the 
patients were placed in Visick 
grades I and II. Six patients had 
diarrhea and four had postoperative 
dumping. Of these 10 patients, 3 
were Visick grade II, 5 were grade 
III and 2 were grade IV. One of the 
grade IV patients had Visick grade 
III diarrhea, but was changed to 
Visick IV when a recurrent ulcer 
developed. A second patient who 
was taking nonsteroidal anti-inflam­
matory medication suffered recur­
Table II. Morbidity of Vagotomy and 
Antrectomy
M orbidity No.
Splenectomy 4
Wound infection 4
Pneumonia 4
Pulmonary embolism 4
Anastomotic leak 2
Gastric outlet obstruction 1
Pancreatitis 1
Billroth II stomal obstruction 1
Total 21
Table III. Visick Score (Modified)
Visick grade No. °/o
I 56 67.5
II 19 22.9
III 5 6.0
IV 3 3.6
Total 83 100.0
rent ulceration 14 years after the 
vagotomy and antrectomy; a 3-cm 
ulcer developed on the posterior 
wall of the gastroduodenostomy. 
The ulcer healed with cimetidine 
therapy, but gastric outlet obstruc­
tion developed necessitating gas- 
troduodenoplasty. The rate of ulcer 
recurrence in these 83 patients was 
therefore 2.4%.
Discussion
There was no 30-day operative 
mortality in this study, but one 
patient died 147 days after surgery, 
and death was directly attributable 
to the gastric resection, giving an 
overall in-hospital mortality of 
0.54%. This is somewhat lower 
than the 30-day operative mortality 
rates reported by Palumbo and 
Sharpe15 and Hubert and col­
leagues16 of 2.2% and 1.1% respec­
tively, and the combined in-hospital 
and 30-day rate reported by Her­
rington, Sawyers and Scott17 of 
1.6% in 3584 patients. The majority 
of studies of highly selective vagot­
omy report no mortality;1-8101213 
Herrington, Davidson and Shum- 
way9 and Kennedy11 cited rates of 
0.7% and 0.3%, respectively, in a 
total of 435 patients who under­
went highly selective vagotomy. It 
would appear that highly selective 
vagotomy is the operation of choice 
if mortality is the only end-point.
It is unfortunate that less than 
50% of our patients could be con­
tacted for follow-up after vagotomy 
and antrectomy. Reasons may in­
clude the retrospective nature of 
the study, the length of follow-up 
with an average of over 13 years, 
the lack of a need for continued 
medical visits (unlike carcinoma) 
and the transient nature of the 
population. Nevertheless, in our 
opinion it is important to report our 
recurrence rate and Visick status, 
realizing that over 50% of the pa­
tients could not be contacted.
The recurrence rate in this study 
for 83 patients who underwent va­
gotomy and antrectomy and were 
followed for an average of 13.5 
years was 2.4%. One of these pa­
tients suffered a recurrence 14 
years after operation, stressing the 
importance of long-term follow-up. 
Low recurrence rates after truncal 
vagotomy and antrectomy have 
been confirmed in three large series, 
comprising 4661 patients, with an 
ulcer recurrence rate ranging from 
0.6% to 0.7%.15-17 The follow-up of 
this large group of patients was 
approximately 10 years. In contrast, 
recurrent ulcer rates after highly 
selective vagotomy are variable and 
significantly higher than those after 
vagotomy and antrectomy. Hoff­
mann, Olesen and Jensen7 from Co­
penhagen prospectively followed up 
106 patients after parietal cell va­
gotomy; 30% of the patients had 
proven recurrent ulcers and a fur­
ther 9% had suspected recurrence. 
Of the 32 proven ulcer recurrences, 
10 developed within 5 years, 9 
within 5 to 10 years and 13 devel­
oped 10 to 17 years after surgery. 
In addition, this report is from one 
of the institutions that pioneered 
highly selective vagotomy in 
1970.18 Vagotomy and antrectomy, 
therefore, remains clearly the opera­
tion of choice if ulcer recurrence is 
the only end-point.
Regarding postoperative seque­
lae, 90.4% of patients in our study 
were classified as Visick grade I or 
II. Excluding the 2 patients with 
recurrent ulcers, 7 of 83 patients 
(8.4%) were Visick grade III or IV. 
One patient had severe dumping 
(Visick IV) and the other six pa­
tients had Visick III dumping or 
diarrhea. The retrospective nature 
of this study may well have under­
estimated the Visick scores, but it is 
doubtful that a telephone interview 
would have overlooked a grade III 
or IV post-gastrectomy complica­
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tion. This is in agreement with the 
findings of Herrington, Sawyers and 
Scott17 that 94% of the patients had 
excellent to good follow-up results, 
with 1% having severe diarrhea and 
no severe symptoms of dumping. 
The Mayo Clinic study16 with a 
follow-up of 290 patients had a 
grade IV incidence of diarrhea and 
dumping of 1.0% and 0.7% respec­
tively. In 542 patients followed up 
by Palumbo and Sharpe,15 moderate 
to severe diarrhea and dumping 
were found in 3.1% and 0.4% re­
spectively. Vagotomy and antrecto­
my, therefore, has a small but im­
portant rate of serious postopera­
tive adverse effects. Highly selective 
vagotomy is, however, not without 
side-effects. In the study reported 
by Hoffmann, Olesen and Jensen,7 
excluding the 32 patients with re­
current ulcers who were placed in 
Visick IV, 10.7% of patients had 
grade IV symptoms consisting 
mostly of dyspepsia with dumping 
or dyspepsia alone; none of the 
patients had grade IV diarrhea. Jor­
dan and Thornby1 and Donahue and 
associates,2 similarly, reported no 
severe diarrhea in their patients, but 
5% of patients in Donahue’s series 
had either severe dysphagia or 
dumping. From these three studies 
totalling 375 patients, it is apparent 
that severe diarrhea is extremely 
uncommon following highly selec­
tive vagotomy, but there is still a 
low incidence of significant dump­
ing. Review of four randomized 
studies comparing highly selective 
vagotomy with vagotomy and an­
trectomy1-2'56 revealed consistently 
better results with highly selective 
vagotomy with a greater percentage 
of patients in Visick grades I and II. 
Nevertheless, a small but important 
number of patients did experience 
grade IV complications after both 
operations.
Hoffmann and colleagues19 re­
cently completed a prospective ran­
domized trial comparing truncal,
selective and highly selective vagot­
omy in the elective treatment of 
duodenal ulcer. The rate of ulcer 
recurrence after highly selective va­
gotomy (11- to 15-year follow-up) 
was 39.3%; this rate was not signifi­
cantly different in any of the three 
groups. The rates of severe post­
vagotomy sequelae were similar in 
all groups, except for dumping, 
which was significantly less fre­
quent following highly selective va­
gotomy. Taking into consideration 
medical and surgical treatment for 
ulcer recurrence, Hoffmann and as­
sociates concluded that none of 
these forms of vagotomy could be 
recommended as standard operative 
treatment for duodenal ulcer.
How should recurrent ulcers be 
managed? Those few occurring 
after vagotomy and antrectomy 
should first be treated with H2- 
receptor antagonists, because the 
cholinergic and gastrin phases of 
acid secretion have already been 
interrupted. Those resistant to med­
ical treatment will need a repeat 
vagotomy or gastric reresection, or 
both. Recurrent ulcers after highly 
selective vagotomy should also be 
managed medically first. Ten 
studies have been reviewed that 
address surgical management of 
ulcer recurrence after highly selec­
tive vagotomy.1-3-6-13 A total of 76 
(43.4%) of 175 recurrent ulcers 
were managed surgically, with the 
operation of choice being an antrec­
tomy with or without a truncal 
vagotomy. In performing these pro­
cedures, there will undoubtedly be a 
risk of injury to the esophagus and 
also difficulty in mobilizing the less­
er curvature of the stomach, with a 
possible increase in morbidity and 
mortality.
It is our opinion that the wide­
spread use of Hr receptor antago­
nists may lead to more refractory 
duodenal ulcers. Christensen, Bous- 
field and Christensen20 and Bardhan 
and associates21 have shown that
the introduction of H2-receptor an­
tagonists has not altered the inci­
dence of perforated and bleeding 
duodenal ulcers. No longer will in­
tractability be the prime indication 
for operative intervention; obstruc­
tion and hemorrhage will assume 
increasing importance in the surgi­
cal management of duodenal ulcer 
disease. In this setting, highly selec­
tive vagotomy may have prohibitive 
recurrent ulcer rates, and a more 
definitive acid-reducing procedure 
may be needed.
Blackett and Johnston12 stated 
“the incidence of recurrent ulcer­
ation after highly selective vagoto­
my is strongly influenced by the 
operating surgeon”. This raises an­
other issue, namely, the training of 
surgeons to perform near-perfect 
highly selective vagotomy. In the 
face of an absolute decrease in the 
surgical treatment of duodenal 
ulcer disease, adequate training of 
all prospective general surgeons 
may be very difficult.
Conclusions
Vagotomy and antrectomy offers 
acceptable mortality, morbidity and 
a relatively low incidence of Visick 
grade IV scores; its outstanding 
feature is the virtual freedom from 
recurrent ulceration over an extend­
ed period of follow-up that is opera­
tor-independent. Conversely, highly 
selective vagotomy has a slightly 
lower incidence of mortality and 
Visick IV scores but a significantly 
higher incidence of recurrent ul­
cers. These recurrent ulcers are 
operator-dependent and appear to 
increase with continued follow-up. 
Unfortunately, there is still no ideal 
operation for duodenal ulcer dis­
ease, and research should be direct­
ed toward a procedure that com­
bines the advantages of both vagot­
omy and antrectomy and highly 
selective vagotomy. Until that time,
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vagotomy and antrectomy should 
still remain in the surgeons’ arma­
mentarium for the management of 
duodenal ulcer disease.
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SESAP VI Question
Item 24
All of the following could be related to the genesis of peptic ulcer EXCEPT
(A) increased parietal cell mass
(B) increased sensitivity to gastrin
(C) elevated vagal tone
(D) reduced somatostatin
(E) elevated prostacyclin (PGI2)
For the incomplete statement above select the best of the five completions.
For the critique of Item 24 see page 413
(Reproduced by permission from SESAP VI Syllabus; Surgical Education and Self-Assessment Program No. 6. 
For enrolment in the Surgical Education and Self-Assessment No. 6, please apply to the American College of 
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Ductal Adenoma of the Breast
S.E. O’Brien, MD, FRCSC, FACS;* J.M. Kay, MD, FRCPC, FRCPath;t 
Vicky S. Chen, MB, BS, FRCPCt
Ductal adenoma is a recently described benign tumour of the breast that can be 
mistaken for carcinoma in both frozen and paraffin sections. Such a case is 
presented. Fortunately a mastectomy was not performed, but the patient did undergo 
axillary node dissection. Surgeons and pathologists should familiarize themselves 
with this lesion so that patients do not have to undergo unnecessary mastectomies 
and axillary node dissections.
L’adenome canaliculaire est une tumeur benigne decrite recemment qui peut etre 
prise pour un carcinome, aussi bien dans les coupes en congelation qu’en bloc de 
paraffine. On decrit un tel cas. Heureusement, on n’avait pas eu recours a la 
mastectomie mais la patiente avait subi une dissection axillaire. Chirurgiens et 
pathologistes devraient se familiariser avec cette lesion afin d’eviter aux patientes 
une mastectomie et une dissection axillaire inutiles.
In 1984 Azzopardi and Salm1 published details of 24 cases of a 
previously undescribed benign 
breast tumour which they named 
“ductal adenoma” . Three of the 
cases were derived from their own 
institution, and 21 were seen in 
patients referred for consultation. It 
is important to recognize this tu­
mour because it may mimic carcino­
ma. In some of the cases reviewed 
by Azzopardi and Salm, the patient 
had been subjected to mastectomy 
because of an erroneous diagnosis 
of malignancy made usually, but 
not exclusively, on frozen-section 
examination. Only one further case 
has been reported in the pathology 
literature.2 Since it is important that 
both surgeons and pathologists be
Accepted fo r publication July 18, 1989
aware of this lesion we describe the 
clinical and pathological features of 
a further case.
Case Report
A 63-year-old woman was discov­
ered to have a mass in her right 
breast during a routine physical 
examination carried out by her fam­
ily physician. She had not noted a 
nipple discharge. Twenty-nine years 
previously she had undergone a 
biopsy of the left breast for benign 
fibrocystic disease. Eighteen years 
previously she had received radio­
therapy for carcinoma of the cervix 
with no recurrence to date. Physical 
examination revealed a firm, irregu­
lar, nontender mass in the upper 
quadrant of the right breast, mea­
suring approximately 2 cm in diam­
eter. It was not attached to the 
overlying skin or underlying pecto­
ral muscles. There was slight re­
traction of the nipple which the 
patient stated had been present for 
many years. No lymph nodes were 
palpable in the axilla. The left 
breast and axilla were normal.
Bilateral xeromammograms (Fig. 
1) demonstrated a fairly smooth, 
marginated lesion (2 cm in diame­
ter) in the 12 o’clock position of the 
right breast with no associated cal­
cification. The radiologist felt this
FIG. 1. Xeromammogram showing fair­
ly smooth, noncalcified, marginated le­
sion with partial halo. Nipple is re­
tracted.
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lesion was probably benign, repre­
senting a fibroadenoma or cyst. 
Fine-needle aspiration of the mass 
yielded no fluid. Cytologic examina­
tion (Fig. 2) revealed a cellular 
aspirate consisting of slightly over­
lapping sheets of epithelial cells 
with occasional dissociated ones. 
Some nuclei had one or multiple 
nucleoli. The cytologic findings 
were interpreted as “suspicious for 
malignancy”.
The patient was advised that the 
lesion was probably malignant. 
Treatment options were discussed 
and she elected to undergo a seg­
mental mastectomy and axillary dis­
section if the malignant nature was 
confirmed by frozen section. A pre­
operative chest film showed no evi­
dence of metastatic disease. At sur­
gery, a wide excision of the mass 
was carried out with a good margin 
of surrounding normal breast tis­
sue. Grossly, the lesion was well 
circumscribed, homogeneous, grey­
ish and suggestive of a medullary
® t?
*
FIG. 2. Fine-needle aspirate. Slightly 
overlapping sheets of epithelial cells 
with occasional dissociated cells at top. 
Most nuclei include one or two nu­
cleoli (Papanicolaou stain, original 
magnification X 500).
carcinoma. A frozen section was 
reported as carcinoma. Axillary 
lymph-node dissection was then 
performed using a separate incision. 
The postoperative course was un­
complicated.
Pathological Findings
The specimen consisted of an 
oval mass of adipose tissue ( 6 X 5  
X 4 cm). In the centre of the tissue 
was a well-circumscribed oval nod­
ule of firm, grey tissue measuring 2 
X 1.5 X 1.5 cm. Microscopic exam­
ination showed a lobulated adeno­
matous lesion surrounded by dense 
hyalinized collagen with some elas­
tic tissue consistent with the wall of 
a distended duct. In the centre of 
the nodule was a stellate fibrous 
scar (Fig. 3). The nodule was com­
posed of glandular tubules made up 
of two cell types, epithelial and 
myoepithelial (Fig. 4). A small pro­
portion of the epithelial cells
FIG. 3. Ductal adenoma of breast. 
Lesion is lobulated and surrounded by 
dense hyalinized collagen consistent 
with wall of distended duct (arrow). 
There is central pale, stellate fibrous 
scar (s) (hematoxylin and eosin, origi­
nal magnification X 7).
showed apical snouts. The glandu­
lar tubules were small. Most were 
empty, but some contained eosino­
philic secretion. Occasional tubules 
contained small circular foci of cal­
cification. Most of the tubules were 
round, but some were elongated 
and branching. The epithelial tu­
bules were supported by a sparse 
collagenous stroma with scanty 
elastic fibrils. The epithelial cells 
showed no significant pleomor- 
phism or hyperchromatism. Mitotic 
figures were rare and morphologi­
cally normal. In some areas, the 
fibrous tissue surrounding the ade­
nomatous nodule was attenuated, 
and glandular tissue was protruding 
into the duct wall. In some micro­
scopic fields glandular tissue ap­
peared to be entrapped within the 
wall of the duct simulating an inva­
sive malignant lesion. The lesion 
was diagnosed as ductal adenoma of 
the breast. The sections were re­
ferred to J.G. Azzopardi who con­
firmed the diagnosis. The axillary
FIG.4. Ductal adenoma of breast. Glan­
dular tubules composed of epithelial 
and myoepithelial cells in collagenous 
stroma. At top glandular tissue ex­
tends into wall of duct simulating 
invasive malignant lesion (hematoxylin 
and eosin, original magnification X 
200 ) .
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dissection included five small be­
nign lymph nodes.
Discussion
Twenty-five cases of ductal ade­
noma of the breast have been de­
scribed in the literature.1,2 We pres­
ent an additional case. All the pa­
tients in the literature were women 
ranging in age from 26 to 76 years 
(mean 52 years). Twenty of the 25 
patients were older than 40 years. 
All had presented with a palpable 
breast lump that had been present 
for periods ranging from several 
weeks to several years. All lesions 
were unilateral. Eleven tumours 
were discrete solitary nodules, 14 
were multiple. In the patients with 
multiple nodules, most of the tu­
mours formed compact aggregates, 
but in some cases they were sepa­
rated by up to 1 cm. The multiple 
nodules mostly appeared to involve 
different parts of the same duct 
system. The lesions varied from 0.5 
and 3 cm in maximum diameter.
Clinically and radiologically duc­
tal adenoma can simulate a malig­
nant lesion because of its occur­
rence in older patients, the hardness 
and irregularity of many lesions and 
the frequency of microcalcification. 
Cytologically, a cellular aspirate and 
the presence of nucleoli indicate a 
proliferative lesion. In older women 
these features tend to raise concern 
for malignancy. The relative cohe­
siveness of the cells and the ab­
sence of definite malignant nuclear 
criteria are helpful hints that the 
lesion may be benign. Fibrous scle­
rosis with resulting distortion of the 
glandular elements and entrapment 
of glandular elements within the 
wall of the duct may simulate carci­
noma in both frozen and paraffin 
sections. Recognition that the le­
sion is composed of both epithelial 
and myoepithelial cells is the most 
reliable criterion in identifying this
lesion as benign. Unfortunately, the 
quality of frozen sections is such 
that it is not always possible to 
recognize such subtle features of 
cellular differentiation.
Ductal adenoma constitutes the 
third major type of adenoma in the 
breast, in addition to the already 
widely recognized nipple adenoma 
and tubular adenoma. Ductal ade­
nomas differ from duct papillomas 
in that the latter occur in the major 
ducts under the areola and are 
usually associated with nipple dis­
charge. Duct papillomas are tiny 
and rarely palpable. They have an 
arborescent fronded structure. Duc­
tal adenomas on the other hand 
seem to occur in the more peripher­
al ducts. They are palpable and 
solid and they do not present with 
nipple discharge. On morphologic 
grounds, Azzopardi and Salm1 con­
sidered that ductal adenoma arose 
from medium-sized and small ducts 
but not major areolar ducts. Guster- 
son and colleagues2 carried out im- 
munocytochemical studies in one 
case and found that the cells mak­
ing up the lesion carried the pheno­
type of cells derived from a terminal 
ductal lobular unit, rather than 
those of a larger duct.
Our patient was fortunate in that 
a mastectomy was not performed, 
although she did have unnecessary 
dissection of the axillary nodes. 
Recognition of this lesion by both 
surgeons and pathologists could 
prevent unnecessary mastectomies 
and axillary node dissection.
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Antibiotic Handbook and Pre-printed 
Perioperative Order Forms for Surgical 
Antibiotic Prophylaxis: Do They Work?
M.J. Girotti, BSc, MD, FRCSC; S. Fodoruk, BScPharm;* J. Irvine-Meek, BSc, PharmD;t O.D. Rotstein, 
MD, MSc, FRCSC
The authors attempted to compare the value of two strategies — an educational 
(antibiotic handbook) and a control (perioperative pre-printed physician order form, 
which contained antibiotic orders) — in modifying physicians’ patterns of antibiotic 
prophylaxis for preventing infection in patients who undergo elective surgery. They 
reviewed the charts of 240 such patients on five different surgical services in one 
teaching hospital. Use of the antibiotic handbook (educational strategy) increased 
overall compliance with the recommended regimens from 11% to 18% (p = 0.06). 
The control strategy (perioperative pre-printed physician order form) increased 
compliance from 17% to 78% (p < 0.01).
Les auteurs ont tente de comparer le succes de deux strategies — pedagogique (a 
l’aide d’un livre de reference sur les antibiotiques) ou dirigee (avec un feuillet 
d’ordonnance preimprime renfermant des instructions sur les antibiotherapies 
peroperatoires) — visant a modifier les habitudes des medecins dans leur choix 
d’une antibiotherapie preventive pour les patients devant subir une chirurgie non 
urgente. Ils ont passe en revue les dossiers de 240 patients des cinq differents 
services chirurgicaux d’un hopital universitaire. L’emploi du livre de reference sur 
les antibiotiques (l’approche pedagogique) a fait passe le taux de conformite aux 
traitements recommandes de 11% a 18% (p = 0.06). L’approche dirigee (le feuillet 
d’ordonnance preimprime) a ameliore le taux de conformite de 17% a 78% (p <
0 .01).
A ntimicrobial use has increased markedly since the early 1970s 
and currently accounts for up to 
25% of the total drug inventory of 
major hospitals. In the United 
States and Canada, it is believed 
that almost 20% of all dollars spent
on ethical drug products are for 
antibiotics.12 The recognized bene­
fit and expanded use of antibiotics 
for both prevention and treatment 
of postoperative sepsis have con­
tributed substantially to this escala­
tion in drug use.23 Well-designed
clinical trials have demonstrated the 
clinical benefit of perioperative pro­
phylactic antibiotic regimens with 
both elective and emergency sur­
gery.45 However, for perioperative 
antimicrobial prophylaxis to be clin­
ically effective, several principles for 
its use must be adhered to. The 
antimicrobial agent must be present 
in high tissue concentrations during 
the operative procedure and should 
be discontinued in the early postop­
erative period.
Continued pressure on the health 
care system to provide both effica­
cious and cost-effective patient care 
has resulted in the introduction of 
various strategies into hospital- 
based medical practice aimed at 
modifying physicians’ patterns of 
drug usage. To this end, our hospi­
tal established an Antibiotic Com­
mittee which reports directly to the 
Pharmacy and Therapeutics Com­
mittee.6 The representatives to this 
committee were chosen from the 
major clinical departments, hospital 
administration, pharmacy and the 
medical/surgical housestaff. This 
Antibiotic Committee assumed re­
sponsibility for both the formulary 
control of all antimicrobial agents 
and surveillance of antimicrobial us­
age. Several strategies (e.g., re­
stricted drug list, limited microbial 
sensitivity reporting, periodic phar­
macy bulletins) had been tried but 
had failed to improve the pattern of 
use of antibiotics for surgical pro-
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phylaxis. In 1987, a pocket size 
“antibiotic handbook”, based on 
recently published clinical trials, 
was developed by this committee in 
an effort to modify the perioperative 
pattern of physician drug use. This 
handbook recommended guidelines 
for antimicrobial prophylaxis in the 
area of surgical wound infection. 
During the development and institu­
tion of these guidelines, a single 
surgical service decided to incorpo­
rate these guidelines for surgical 
procedure prophylaxis into a com­
prehensive pre-printed perioperative 
physician order form. A similar sys­
tem had been in use on another 
surgical service for over 1 year. 
Employing a chart review in a be- 
fore-and-after study design on se­
lected surgical services, we com­
pared the impact of an educational 
strategy (the antibiotic handbook) 
and a control strategy (pre-printed 
physician order form) designed to 
modify physician prescribing habits 
in elective surgical prophylaxis.
Methods
The study was conducted on five 
selected surgical services (A to E) of 
the Toronto General Hospital, a 
1000-bed teaching hospital with 
more than 100 attending surgeons 
and 175 surgical housestaff (in­
terns, residents and fellows). Most 
(more than 95%) antibiotic orders 
are written by the surgical houses­
taff. The information concerning 
surgical antibiotic prophylaxis and 
contained within the antibiotic 
handbook and on the pre-printed 
physician order forms was based on 
a literature review and input from 
the individual surgical divisions.
The handbook, which also con­
tained general educational material 
on infectious disease, was distribut­
ed to attending surgical staff and 
housestaff with a covering letter 
from the Antibiotic Committee, indi­
cating that the recommendations 
contained in the handbook were to 
be followed for the perioperative 
use of antimicrobial agents. The 
impact of the handbook on antimi­
crobial use was examined on ser­
vices A, B and C, and the effect of 
the pre-printed physician order form 
was investigated on services D and 
E. Service D had been using such a 
form for over 1 year before this 
review. Service E introduced the 
pre-printed perioperative order form 
at approximately the same time as 
the antibiotic handbook was circu­
lated. The pre-printed order forms 
did offer the physician limited op­
tions when ordering perioperative 
antimicrobial agents.
The study design was of a before- 
and-after chart review. The first 
review occurred 1 year before the 
introduction of the antibiotic hand­
book or the pre-printed physician 
order form on service E. For each 
surgical service studied, a list of 
possible study patients was generat­
ed from consecutive daily operative 
lists. A period of 4 weeks was 
chosen within which case records 
were examined for possible inclu­
sion in the study. In a similar 
fashion, a second review occurred 6 
months after distribution of the 
handbook or order form so as to 
accumulate an identical number of 
patient case records for review with­
in each surgical service.
A patient was included in the 
study if the chart indicated the 
performance of a selected elective 
surgical procedure for which pro­
phylaxis guidelines were outlined in 
the antibiotic handbook. Antibiotic 
usage was considered to be thera­
peutic and the patient was therefore 
excluded from the study when the 
chart indicated any of the following: 
antibiotic treatment of an intercur­
rent infection within the week pre­
ceding surgery; a major intraopera­
tive problem which converted the 
procedure to a contaminated one;
prophylaxis for bacterial endocardi­
tis.
The prophylactic antibiotic regi­
men recommended in the antibiotic 
handbook or the pre-printed physi­
cian order form was compared with 
the patient medication records and 
the intraoperative anesthesia re­
cords of the patients selected for 
study. The prophylactic antibiotic 
regimen prescribed was analysed for 
antibiotic choice, dosage, route, fre­
quency of ordered drug administra­
tion, necessity of intraoperative an­
tibiotic dosing and, finally, duration 
of use. A prophylactic antibiotic 
regimen was considered appropriate 
(i.e., no drug error) if all of the 
above, excluding actual time of ad­
ministration of first dose (a nursing- 
dependent factor) corresponded to 
the recommendations. The rate of 
appropriate usage for the individual 
surgical services was calculated. 
Differences between study periods 
for the antibiotic handbook and the 
pre-printed physician order form 
were compared using x2 analysis. 
The results were further analysed to 
identify specific components of the 
antibiotic orders that were contrary 
to the recommendations for surgi­
cal prophylaxis. Dollar costs or ad­
verse reactions of the prophylactic 
antibiotic regimens were not ad­
dressed.
Results
A total of 230 patient charts were 
reviewed. For the statistical evalua­
tion, services A, B and C (anti­
biotic handbook) were collectively 
analysed, but services D and E were 
examined both as single services 
and as a combined second group. 
For services A, B and C, overall 
compliance increased from 11% to 
18% (p = 0.06) after the introduc­
tion of the antibiotic handbook. On 
service D, which had been using a 
pre-printed physician order form
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previously, overall compliance did 
not improve significantly during the 
study period. After the introduction 
of the pre-printed physician order 
form, service E experienced a sig­
nificant increase in compliance rate 
from 17% to 78% (p < 0.001). The 
overall compliance rate for the com­
bined services D and E following 
the introduction of the pre-printed 
physician order form was 84%.
Specific practices of antimicrobial 
prophylactic drug prescribing are 
detailed in Table I. Before the intro­
duction of the antibiotic handbook 
on services A, B and C, the choice 
of antimicrobial agent and the tim­
ing of drug administration (duration 
and frequency) were the most com­
monly observed drug errors. The 
introduction of the antibiotic hand­
book did not improve these aspects
of drug use. Service D, which had 
been using a pre-printed physician 
order form, reduced the wrong-fre­
quency drug errors after the circu­
lation of the antibiotic handbook 
and a re-emphasis of the pre-printed 
order forms. Service E significantly 
reduced observed drug errors with 
respect to frequency and duration 
after the introduction of the pre­
printed physician order forms.
A comparison of the control or 
educational strategies for modifying 
physician prescribing habits in the 
perioperative use of antimicrobial 
agents indicates that the pre-printed 
physician order form containing an 
antibiotic component was better 
than the antibiotic handbook (over­
all compliance rate of 84% versus 
18% after the introduction of the 
strategy, p < 0.001).
Discussion
On the basis of internal reviews 
such as ours, the majority of clini­
cal and pharmacy departments have 
adopted drug utilization programs 
which have resulted in the introduc­
tion of various strategies in an 
attempt to modify physician pre­
scribing habits.7 These attempts can 
be generally classified as either edu­
cational or control strategies.8 Ex­
amples of educational mechanisms 
include pharmacy bulletins and 
newsletters, lectures and confer­
ences, peer review of drug usage, 
handbooks (such as the antibiotic 
handbook) and pharmaceutical or 
academic drug detailing. Control 
strategies include direct formulary 
control, mandatory consultation 
with infectious disease experts or 
clinical pharmacists, pre-printed an­
tibiotic order forms, automatic anti­
biotic stop orders and controlled 
antibiotic sensitivity reporting from 
the microbiology laboratory. These 
measures of antibiotic control have 
not been evaluated rigorously until 
recently. Table II2'9-23 summarizes 
the results of these studies. Few 
reports specifically address the 
issue of controlling antibiotic use in 
the perioperative prophylaxis of 
elective surgical procedures. The 
present study investigates the effi­
cacy of two of these strategies in 
this setting. Our results indicate 
that the introduction of a purely 
educational strategy in the form of 
an antibiotic handbook provided 
only a marginal improvement in the 
overall compliance with our recom­
mendations on three surgical ser­
vices. However, the introduction of 
a control strategy through the use 
of a pre-printed physician order 
form in the perioperative period 
resulted in a dramatic improvement 
in compliance with the recommend­
ed antibiotic regimens. Employing a 
similar handbook, D’Eramo and col­
leagues17 reported a short-term im-
Table I. Specific Drug Error Rates Observed on Individual Surgical Services*
Surgical service
A + B + C  D E D + E
Drug error (n =  166) (n =  40) (n =  24) (n =  64)
Wrong drug 55/51 0/0 8/0 3/0
Wrong dose 17/13 0/0 8/8 3/3
Wrong frequency 22/18 2 0 /5 t 6 4 /8 t 36/6
Wrong duration 31/28 0/0 40/16+ 16/6+
(too long) 
Intraoperative dose 11/6 0/0 0/8 0/3
’ Numbers indicate % before/% after, 
tp  < 0.05 by x 2 analysis, before versus after.
Table II. Comparison of Drug Utilization Strategies
Method Series Impact
Educational
Weekly lectures, CME courses, 2,9,10 Minimal positive effects, failed to
bulletins, newsletters control costs
Pharmaceutical detailing 2,11 No data available, obvious company 
bias
Academic detailing 12,13 Short- and long-term positive impact 
on use and costs
Peer review 14-16 Educational component high, resource 
intensive, positive impact on use
Handbook 17 Short-term benefit only
Control
Controlled formulary 18 Reduced cost and inventories
Selective reporting of sensitivity 18 No data available
testing
Automatic stop order policy 2,18 Effective control for prophylaxis and 
empiric therapy
Mandatory consultation (service or 
MD)
Antibiotic order form
2,19,20 Reduced costs, improved drug use
21-23 Reduced drug errors and drug costs
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provement (less than 3 months) 
when the handbook was introduced 
into a hospital setting in an attempt 
to modify the patterns of physician 
drug use for empiric therapy.
The single most impressive edu­
cational strategy affecting physician 
drug use appears to be “academic 
detailing”, which is a labour-inten­
sive program of ongoing one-to-one 
pharmacist to physician counsel­
ling. This mechanism has been 
demonstrated to influence physician 
prescribing patterns both in the 
short- and long-term assessment of 
drug utilization.1213 In this regard, 
our study could be criticized for the 
omission of a program of regular 
reminders from the clinical and 
pharmacy attending staff to the 
physicians most often prescribing 
perioperative antimicrobial agents 
that the antibiotic handbook recom­
mendations must be adhered to. 
This is a key element in any educa­
tional strategy.2
Several recent, well-designed 
studies have addressed the use of 
specialized pre-written antibiotic 
order forms, which provide the phy­
sician with clear choices and direc­
tions for either prophylaxis, empiric 
or directed therapy, as well as auto­
matic antibiotic stop orders. Such 
programs effectively reduced drug 
errors, lowered drug-dollar costs 
and were not perceived as interfer­
ing with patient care or educational 
objectives in teaching hospitals.21-23 
The results of this study indicate 
that the use of a pre-printed periop­
erative physician order form is an 
effective method for modifying phy­
sician behaviour in prescribing peri­
operative antimicrobial prophylaxis. 
We believe that such a control 
strategy should be part of a coordi­
nated antimicrobial utilization pro­
gram combining both educational 
and control mechanisms and over­
seen by an antibiotic committee
with multidisciplinary hospital rep­
resentation.
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Correction
In the June 1990 issue of the jour­
nal, there was an omission in the 
article “Post-traumatic microvascu- 
lar reconstruction: Toronto’s 500th 
reattachment” by D.P. Ewart and 
R.M. Zuker (pages 239 to 242). On 
page 239, second column, the name 
of Dr. Brian Boyd should be added 
to the listing of Toronto’s microvas- 
cular team. The journal and the 
authors apologize to Dr. Boyd for 
this omission.
388 CJS, VOL. 33, NO. 5, OCTOBER 1990
ORIGINAL ARTICLES
Factors Influencing the Effectiveness 
of Extracorporeal Shock-Wave Lithotripsy 
of Biliary Duct Calculi
Richard W. Norman MD, FRCSC;* Lazio A. Fried, MD, FRCPC;+ G. Paul LeBrun, MD, FRCPC;t Mark 
C. Taylor, MD, FRCSCJ
The authors examined the effectiveness of extracorporeal shock-wave lithotripsy on 
patients who had bile-duct stones. Thirty-eight patients were treated with an 
unmodified HM-3 Dornier lithotripter; 35 (92%) patients either passed the stone 
fragments spontaneously or had them reduced to a size which allowed removal by 
percutaneous or endoscopic techniques.
As stone size increased so did the number of shocks required for satisfactory 
fragmentation, the number of treatments and the rate of post-treatment 
manipulation.
The number of stones was not as important a variable as the authors expected. 
Pre-treatment sphincterotomy was not always necessary and was of no benefit in 
terms of spontaneous passage of fragments. Complications were minor. 
Extracorporeal shock-wave lithotripsy of stones throughout the biliary tree is a safe, 
effective and invaluable adjunct in the managment of bile-duct stones.
Les auteurs ont etudie Tefficacite de la lithotripsie par ondes de choc chez des 
patients qui souffraient de calculs biliaires. Trente-huit patients on ete traites a 
l’aide d’un lithotritreur HM-3 Dornier non modifie; 35 patients (92%) ont, soit passe 
les fragments calculeux de fa?on spontanee, ou leur taille fut reduite suffisammnent 
pour qu’ils puissent etre retires par des techniques percutanees ou endoscopiques.
Avec la taille des calculs, ont augmente le nombre de chocs requis pour obtenir 
une fragmentation satisfaisante, le nombre de traitements et le taux de manipula­
tions post-therapeutiques.
Le nombre de calculs n’a pas represente une variable aussi importante que les 
auteurs Tavaient anticipe. Une sphincterotomie pretherapeutique n’a pas toujours 
ete necessaire et n’a aucunement contribue au passage spontane des fragments. Les 
complications ont ete benignes. La lithotripsie extracorporelle par ondes de choc des 
calculs dans tout l’arbre biliaire est un adjuvant sur, efficace et important du 
traitement des calculs biliaires.
E xtracorporeal shock-wave litho­tripsy (ESWL) has revolution­
ized the management of upper uri­
nary tract stones. Because of its 
success and safety, there has been 
much interest in expanding its indi­
cations. Many centres have devel­
oped programs for the lithotripsy of 
gallbladder stones. These calculi 
can be satisfactorily broken up, but 
there remain questions about the 
fate of residual fragments and long­
term recurrence rates.1-3 A more 
clear-cut indication for this treat­
ment is in the management of bili­
ary duct calculi.45 Although these 
are often amenable to basket ex­
traction through matured T-tube 
tracts, percutaneous transhepatic 
tracts and endoscopically placed 
catheters following endoscopic ret­
rograde cholangiopancreatography 
(ERCP) and endoscopic sphinc­
terotomy, there remains a group of 
patients in whom these techniques 
fail, are technically impossible or 
are unduly hazardous.4 In these 
patients ESWL has been an impor­
tant adjunct to solving many of 
these complex problems and avoid­
ing further open surgery.5
During our experience with 
ESWL of biliary duct calculi, it has 
become apparent that several fac­
tors related to calculi and anatomy 
influence the effectiveness of the 
therapy. This paper reviews these 
issues.
Patients and Methods
Over a 2-year period, 38 patients 
(16 men, 22 women) with residual 
or de novo gallstones in the cystic 
(4 patients), hepatic (7) or common 
bile ducts (32) were treated using 
an unmodified HM-3 Dornier litho­
tripter (Dornier Medical Systems, 
Marietta, Ga.). (Five patients had 
stones in more than one duct.) The 
patients ranged in age from 23 to
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92 years (mean 63 years, median 68 
years).
All patients were initially operat­
ed upon or assessed by a general 
surgeon and subsequently by an 
interventional radiologist. The time 
from open biliary surgery to ESWL 
in 36 patients ranged from 8 days 
to 22 years (mean 4.8 years, median 
2 months). All stones were consid­
ered inappropriate for percutaneous
or endoscopic manipulation because 
they were too large or the patient 
had an anatomical abnormality 
(e.g., duodenal diverticulum) (15 
patients), because the patient had 
undergone unsuccessful attempts at 
such procedures (12) or because the 
stones were impacted postoperative- 
ly (11). Stone size was measured as 
the greatest diameter of the largest 
stone and varied from 2 to 35 mm
(mean 16 mm); one was opaque and 
the remainder were lucent. Sixteen 
patients had multiple stones. Either 
epidural (33) or general (5) anesthe­
sia was used for all patients. Imag­
ing was made possible by introduc­
ing dye through a cholecystostomy 
(2 patients) or transhepatic (8), na- 
sobiliary (11) or T tubes (17). All 
patients were positioned supine ini­
tially, but it was necessary to repo­
sition some (14 patients) prone for 
satisfactory visualization.
Twenty-six patients were treated 
once, 11 twice and 1 three times.
The average number of shocks 
required for satisfactory fragmenta­
tion was 2995 (range 575 to 8000 
shocks) at 18 to 25 kV. The maxi­
mum number of shocks used during 
one session was 3200. The influ­
ence on treatment of stone size, 
multiplicity and location are shown 
in Tables I to III. Tube cholangio- 
grams were obtained 24 hours after 
ESWL and later when necessary to 
assess stone fragmentation and 
clearance.
Results
Of the 38 patients, 35 (92%) 
either passed the fragments sponta­
neously (25) or had them reduced 
to a size which could be removed by 
percutaneous or endoscopic tech­
niques (10) (Table IV). Two patients 
subsequently underwent open sur­
gery. One was found to have a
Table 1. In fluence o f Size o f Stones on Treatm ent
Stone size, mm
1 -1 0 1 1 -2 0 2 1 -3 0
Trealm enl (n =  10) (n =  23) (n =  5)
Mean no. o f shocks 
No. o f treatm ents
1720 3246 4 590
1 10 14 2
2 0 9 2
3 0 0 1
Table II. Influence o f N um ber o f S tones on Size and T reatm ent
S ize/treatm ent
Single 
(n =  22)
M ultiple  
(n =  16)
M ean size, m m 15 14
Mean no. o f shocks 3104 2845
No. o f treatm ents
1 13 13
2 8 3
3 1 0
Table III. In fluence o f Ductal Loca tion  o f Stones on T reatm ent
Duct
Treatm ent
Common
bile
(n =  32)
Hepatic 
(n =  7)
Cystic 
(n =  4)
M ean no. o f shocks 
No. o f trea tm ents
2720 1882 2900
1 24 6 3
2 7 1 1
3 1 0 0
Table IV. Variables In fluencing  the E ffectiveness o f Extracorporea l Shock-W ave L itho tripsy (ESWL)
Size, mm Number Sphincterotomy
V ariab le
Overall, 
no. (% )
1 -1 0  
no. (% )
1 1 -2 0  
no. (% )
2 1 -3 5  
no. (% )
Single 
no. (% )
Multiple 
no. (% )
No
no. (% )
Yes 
no. (% )
No. o f patients 38 10 23 5 22 16 26 12
S pontaneous passage o f
fra g m e n ts 25(66) 8 (80 ) 15(65) 2(40) 15(68) 10(62) 17(65) 8 (67)
at 24 h 14(37) 5 (50 ) 8(35) 1(20) 9 (41) 5(31) 10(38) 4 (33 )
at 1 m o 11(29) 3(30) 7(30) 1(20) 6(27) 5(31) 7(27) 4 (33 )
Extraction  o f residual
fra g m e n ts 10(26) 1(10) 7(30) 2(40) 7(32) 3(19) 8(31) 2(17)
P ost-S W L 2( 5) 1(10) 0( 0) 1(20) 0( 0) 2(13) 0( 0) 2(17)
U nknow n 1( 3) 0( 0) 1( 4) 0( 0) 0( 0) 1( 6) 1( 4) 0( 0)
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common-bile-duct tumour, which 
precluded passage of stone frag­
ments and the other was an elderly 
man who had a large (35 X 20 mm) 
common-bile-duct stone, which did 
not fragment well on a single treat­
ment, and who refused repeat 
ESWL. Another man’s T tube fell 
out after the ESWL, and follow-up 
cholangiography was not possible; 
he remained asymptomatic.
Patients with smaller stones 
passed the fragments more fre­
quently and earlier and required 
fewer manipulations after ESWL 
than those with larger stones (Table 
IV). Single stones passed more fre­
quently and earlier than multiple 
stones. Extraction of residual frag­
ments was required after ESWL for 
more single than multiple stones, 
but both patients requiring an open 
common-duct exploration for defini­
tive therapy had multiple stones 
(Table IV).
Sphincterotomy did not improve 
spontaneous clearance rates or re­
duce the likelihood of subsequent 
open surgery but it did decrease the 
rate of post-treatment manipula­
tions (Table IV).
Spontaneous passage (66% to 
75%) and post-treatment manipula­
tion (25% to 29%) rates were similar 
for all three parts of the biliary tree. 
Stones from the hepatic ducts 
seemed to clear slower than those 
from the common bile and cystic 
ducts (Table V).
In the 11 patients with impacted 
stones postoperatively and imma­
ture T-tube tracts, the stones all
cleared spontaneously after ESWL 
— 5 within 24 hours and 6 within 1 
month.
Extracorporeal shock-wave litho­
tripsy was well tolerated and the 
majority of complications were 
minor (Table VI). There was no 
correlation between complications 
and the stone size, number or loca­
tion or the presence of sphinc­
terotomy, with the exception of 
postrtreatment diarrhea — 90% of 
patients in this group had under­
gone spincterotomy. Cardiac arrest 
occurred 2 hours after ESWL in a 
man with known cardiac disease 
who had suffered a myocardial in­
farction 5 months previously. He 
was successfully resuscitated.
Discussion
Until recently, retained biliary 
tract calculi have been removed 
either endoscopically or by percuta­
neous basket extraction. The latter 
requires a 5- to 7-week waiting 
period for maturation of the T-tube 
tract. When these techniques failed 
or were impossible, further open 
biliary surgery was often required. 
Our series offers a new approach 
and confirms that ESWL can be a 
safe and an effective adjunct in the 
management of these stones.56 An 
impressive overall success (stone 
free) rate was achieved in 92% of 
patients. In two-thirds of the group 
no further intervention was re­
quired after ESWL. This is particu­
larly important for the elderly pa­
tients treated, many of whom had a 
variety of other major medical prob­
lems. It is evident that stone burden 
is an important variable influencing 
treatment and success. As stone 
size increases, so does the number 
of shocks required for satisfactory 
fragmentation, the number of re­
quired ESWLs and the rate of post­
treatment manipulations.
Multiplicity of stones was not as 
important a variable as expected 
since it was associated with only a 
slightly decreased spontaneous pas­
sage rate and a similar rate of 
post-treatment intervention (extrac­
tion or surgery) as compared with 
single stones. In most cases of 
multiple stones there was a single 
obstructing calculus at the bottom 
of a column of stones, and when it 
was successfully treated, passage of 
or access to the remainder were 
possible.
In this series our experience with 
different stone compositions was 
limited, but the one calcified stone 
fragmented and cleared extremely 
well.
Although it has been implied pre­
viously that sphincterotomy is 
necessary before ESWL in all these 
patients,6 it is clear that this is not 
required and that many patients can 
be treated successfully without the 
risk of undergoing routine ERCP 
and endoscopic papillotomy before 
ESWL. In fact, this procedure did 
not offer any benefit in terms of 
spontaneous passage of fragments.
Although there were some initial 
concerns, it is clear that stones 
throughout the biliary tree, includ­
ing the intrahepatic ducts, can be
Table VI. Complications Occurring After 
Extracorporeal Shock-Wave Lithotripsy
Complication No.
Elevated liver enzyme levels 31
Diarrhea 12
Sepsis 6
Hemobilia 3
Pancreatitis 1
Cardiac arrest 1
Table V. Influence of Ductal Location on Effectiveness of Extracorporeal Shock-Wave Lithotripsy
Variable
Duct, no. (%)
Common
bile
(n =  32)
Hepatic 
(n =  7)
Cystic 
(n =  4)
Spontaneous passage of fragments 21(66) 5(71) 3(75)
at 24 h 14(44) 2(29) 2(50)
at 1 mo 7(22) 3(43) 1(25)
Extraction of residual fragments 8(25) 2(29) 1(25)
Post-ESWL 2( 6) 0( 0) 0( 0)
Unknown 1( 3) 0( 0) 0( 0)
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safely and effectively managed with 
ESWL.
Complications were minor. Al­
though most patients had elevated 
liver enzyme levels after ESWL, 
these changes were transient. We 
are now pursuing further studies to 
determine whether there is any evi­
dence of long-term hepatic dysfunc­
tion in this group. Postoperative 
diarrhea is secondary to the intro­
duction of hypertonic contrast 
media during the visualization proc­
ess. It usually resolves within 24 
hours. More dye was required in 
patients with a sphincterotomy be­
cause of rapid transit into the duo­
denum and as a result most of the 
diarrhea occurred in this group. An 
attempt was made to reduce the 
severity of this by using half­
strength dye and this seemed bene­
ficial. The incidence of postopera­
tive bacteremia and sepsis would 
likely be higher if tubes were not 
available for drainage and visualiza­
tion. Antibiotics are now given rou­
tinely before ESWL and possibly 
will reduce the risk of this compli­
cation further. Although some con­
troversy is likely to continue with 
respect to the usefulness of this 
treatment for gallbladder stones, it
A
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is clear from our experience that 
extracorporeal shock-wave lithotrip­
sy is a safe, effective and invaluable 
adjunct in the management of bili­
ary duct calculi.
view. J Lithotripsy Stone Dis 1989; 1: 3- 
15
2. S auerbruch T, Delius M, Paumcartner 
G, et al: Fragmentation of gallstones by 
extracorporeal shock-waves. N Engl J 
Med 1986: 314: 818-822
923-926
5. T aylor MC, Marshall JC, Fried LA et al: 
Extracorporeal shock wave lithotripsy 
(ESWL) in the management of complex 
biliary tract stone disease. Ann Surg 
1988; 208: 586-592
R eferences
1. Ferrucci JT: Biliary lithotripsy. A pre-
3. S ackmann M, Delius M, S auerbruch T et 
al: Shock-wave lithotripsy of gallbladder 
stones. N Engl J Med 1988; 318: 393- 
397
4. Fried LA, LeB run GP, Norman RW et al: 
Extracorporeal lithotripsy in the manage­
ment of bile duct stones. AJR 1988; 151:
6. S auerbruch T, S tern M: Fragmentation 
of bile duct stones by extracorporeal 
shock waves. Gastroenterology 1989; 96: 
146-152
7. B urhenne HJ: Percutaneous extraction of 
retained biliary stones: 661 patients. AJR 
1980; 134: 888-898
EXPERIENCE COUNTS
COUNT ON
(sterile cefoxitin sodium, MSD Std.)
Documented clinical efficacy in 
COMMUNITY-ACQUIRED 
INTRA-ABDOMINAL INFECTIONS
Full prescribing information enclosed . . . see page 408
©Trademark Merck & Co., Inc./Merck Frosst Canada Inc., R.U. 
MFI-90-CDN-3386-JA
MSD
MERCK
SHARP&
DOHME
C A N A D A
ORIGINAL ARTICLES
Is Tube Repair of Aortic Aneurysm 
Followed by Aneurysmal Change 
in the Common Iliac Arteries?
John L. Provan, MB, MS, FRCS, FRCSC, FACS;* Jeffrey Fialkov, MD;f
F. Michael Ameli, MB, ChB, FRCS(Edin), FRCSC, FACS;* Eugene L. St. Louis, MD, FRCPCJ
To address the concern that tube repair of an abdominal aortic aneurysm might be 
followed by aneurysmal change in the common iliac arteries, 23 patients who had 
undergone the operation were re-examined 3 to 5 years later. Although 9 had had 
minimal ectasia of these arteries preoperatively, in none of the 23 was there 
symptomatic or radiologic evidence of aneurysmal change on follow-up. 
Measurements of the maximum intraluminal diameters were made by computed 
tomography; they indicated no significant differences between the preoperative and 
follow-up sizes of the common iliac arteries. The variation in time to follow-up also 
showed no significant correlation with change in artery diameter.
Afin de verifier si la reparation vasculaire d’un anevrisme de l’aorte abdominale est 
susceptible d’entratner des alterations anevrismales des arteres iliaques communes, 
23 patients qui avaient subi cette operation ont ete reexamines de 3 a 5 ans plus 
tard. Meme si 9 d’entre-eux presentaient, en preoperatoire, une ectasie minime de 
ces arteres, aucun des 23 n’a montre de symptomes ou de signe radiologiques 
d’alterations anevrismales a l’examen de controle. Des mesures des diametres 
endoluminaux maximaux ont ete faites par tomographie axiale; elles n’ont revele 
aucune difference significative entre les diametres preoperatoires des arteres 
iliaques communes et ceux qui ont ete mesures a l’examen de controle. Les 
variations dans le temps de suivi n’ont montre aucune correlation significative avec 
les changements de diametre arteriel.
A fter the first reported repair of an abdominal aortic aneurysm 
by Dubost in 1952,1 it was conven­
tional teaching that such aneu­
rysms should be repaired with a 
bifurcation graft to the common 
iliac arteries or, when the common 
iliac arteries were themselves aneu­
rysmal or subject to severe athero­
sclerotic disease, by means of a
graft to the common femoral arter­
ies on each side, excluding the iliac 
arteries, which were usually over­
sewn or ligated. Recently, vascular 
surgeons have tended to use a tube 
prosthesis rather than a bifurcated 
one to repair aneurysms of the 
infrarenal abdominal aorta, the dis­
tal anastomosis being made to the 
aorta immediately above its bifurca­
tion. However, no study has been 
carried out to investigate the subse­
quent fate of the common iliac 
arteries not repaired at the time of 
insertion of the tube prosthesis. It 
is not known, for example, whether 
the common iliac arteries dilate or 
develop aneurysmal change that 
may necessitate a second operation 
for correction. To this end, we 
studied patients who had minimal 
or no aneurysmal disease in the 
common iliac arteries at the time of 
tube repair of an aneurysm of the 
infrarenal abdominal aorta to inves­
tigate any change in size of the 
common iliac arteries over a 3- to 
5-year period after repair of the 
original aneurysm.
Patients and Methods
Between 1981 and 1984, 205 
abdominal aortic aneurysms were 
repaired by two surgeons; 87 of 
them were repaired by means of an 
aortobifemoral bypass, 15 by con­
ventional bifurcation grafting to 
each common iliac artery and 103 
by tube repair. Of the 103 patients 
treated by placement of a tube 
prosthesis, 18 had not undergone 
computed tomography before the 
operation. Only 83 of the 85 re­
maining patients could be contacted 
for follow-up, and 23 (28%) of them 
had died after discharge from hospi­
tal. This left 60 patients who were
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available for follow-up. Of these, 24 
refused to return to the hospital for 
follow-up computed tomography for 
reasons such as age, sickness or 
distance from the hospital. Of the 
remaining 36 patients who were 
interviewed and had computed to­
mography, both pre- and postopera­
tive computed tomography scans 
were available for only 23. Unfortu­
nately, all scans obtained in 1981 
were discarded, so the follow-up 
was reduced to a maximum of 5 
years (3 years in 11 patients, 4 
years in 9 and 5 years in 3).
The 36 patients who were avail­
able for follow-up were interviewed 
in July and August 1987 and ques­
tioned about symptoms that could 
have been associated with common 
iliac aneurysms. The 23 patients 
who had retrievable preoperative 
scans underwent non-contrast- 
enhanced computed tomography of 
the abdomen and pelvis in August 
1987.
Before 1985, an EMI 5005 se­
cond-generation whole-body scan­
ner (EMI, Northbrook, 111.) was 
used. Follow-up scanning per­
formed in this study in 1987 was 
carried out using the GE 9800 
third-generation whole-body scan­
ner (G.E. Medical Services, Milwau­
kee, Wise.) which replaced the EMI 
5005 in 1985. To correct for the 
discrepancy in scale that resulted 
from the use of two different scan­
ners we measured the anteroposteri­
or length of a designated vertebral 
body for a given patient on both 
preoperative and follow-up films. 
The ratio of the two measured 
lengths was then used to scale 
preoperative diameters to follow-up 
proportions. The margin scale on 
the GE 9800 scanner was then used 
to scale all measurements to actual 
size in centimetres. The difference 
in resolution and image quality be­
tween the second- and third-genera­
tion scanners is known.2 Improved 
factors, such as increased matrix 
size from 256 X 256 to 512 X 512
(262, 144 pixels), reduced scanning 
time (from 20 to 2 seconds), and 
new resolution algorithm options 
allowed for much better visualiza­
tion of the follow-up images. It was 
possible to make appropriate calcu­
lations, but the degree of error due 
to the difference between the two 
scanners was not quantifiable.
Maximum common iliac artery 
diameters were obtained on both 
the preoperative (Fig. 1) and follow­
up (Fig. 2) computed tomography 
scans, measured from intima to inti- 
ma. These were intraluminal diame­
ters which were easy to obtain 
despite the resolution difference be­
tween the two scanners. The right 
and left arteries were analysed sepa­
rately because they were of different 
sizes preoperatively (1.4809 versus 
1.2904 cm, p > 0.025).
The change in maximum diame­
ter over a 3- to 5-year period for 
both right and left common iliac 
arteries was assessed for statistical 
significance. Differences between 
initial artery size or period of fol­
low-up (3 versus 4 versus 5 years) 
and the change in maximum diame­
ter of the common iliac arteries 
were analysed by analysis of vari­
ance. The mean of three measure­
ments was obtained for each pa­
tient. Mean values for each group 
of diameters (right and left, preop­
erative and postoperative) were then 
calculated. The average standard 
error was 7%.
Results
Of the 36 patients interviewed, 
none had experienced symptoms, 
such as abdominal pain, that have 
been associated with common iliac 
artery aneurysms.3-5 Of the 23 pa­
tients for whom both pre- and post­
operative computed tomography 
scans were available, 14 (61%) had 
had no evidence of ectasia of the 
common iliac arteries before sur-
A U G  I S  -  1 9 8 4/•* • • -
FIG. 1. Preoperative computed tomography scan of common iliac arteries.
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FIG. 2. Computed tomography scan of common iliac arteries at follow-up.
FIG. 3. Preoperative computed tomography scan showing ectasia of right common 
iliac artery.
gery, ectasia being defined as a 
generalized dilatation of a common 
iliac artery to more than 1.5 cm 
(but less than 3.0 cm) in diameter. 
The follow-up of these patients 
showed that they remained free of 
aneurysmal change in the common 
iliac arteries.
The remaining nine patients had 
had minimal ectasia (up to 3 cm in 
maximum diameter) preoperatively 
(Fig. 3) and on follow-up examina­
tion. None had had aneurysmal 
change greater than 3 cm.
Analysis indicated no significant 
change between the preoperative 
and follow-up maximum diameters 
for all 46 common iliac arteries. 
This was true both for the right 
(1.4089 versus 1.5204 cm) and left 
arteries (1.2904 versus 1.2835 cm) 
(Fig. 4). Furthermore, the time be­
tween preoperative and follow-up 
measurements showed no signifi­
cant correlation with change in di­
ameter (p > 0.05, f =  0.149) (Fig. 
5).
CONDITION
FIG. 4. Mean common iliac artery 
diameters for 23 right and 23 left 
arteries measured pre- and postopera- 
tively show no significant change. 
PREL = preoperative, left, POSTL =  
postoperative, left, PRER =  preopera­
tive, right, POSTR = postoperative, 
right.
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Discussion
Aneurysms of the common iliac 
arteries are, more often than not, 
associated with abdominal aortic 
aneurysm.3-6 Isolated common iliac 
artery aneurysms have an etiologic 
association with atherosclerosis and 
share with other atherosclerotic an­
eurysms a tendency to rupture.3'5 7"9 
There is no evidence, however, that 
aneurysmal change develops in nor­
mal common iliac arteries, even 
though occlusive disease may occa­
sionally develop.
Since 1978 surgeons at The 
Wellesley Hospital have used tube 
repair for aortic aneurysms, unless 
there is occlusion, serious stenosis 
or aneurysmal change in one or 
both common iliac arteries.
There are several advantages to 
the use of a tube prosthesis. The 
operation is simpler and hence 
quicker and is attended by less 
blood loss and a lower risk of 
damage to the hypogastric plexus.
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FIG. 5. Mean common iliac artery 
diameters show no significant increase 
on either side, regardless of whether 
follow-up was at 3, 4 or 5 years.
It can very easily be performed 
extraperitoneally. The disadvan­
tages of the procedure lie in the 
risks of not treating serious athero­
sclerosis or of leaving dilatation in 
these arteries. Subsequent aneurys­
mal change would require a further 
operation. In our experience further 
surgery has never been necessary, 
nor have there been complications 
because of atherosclerotic occlusive 
disease in these arteries.
Our study has addressed the con­
cern that aneurysmal change of the 
common iliac arteries might occur 
after repair of an abdominal aortic 
aneurysm with a tube prosthesis. 
We found no tendency for the com­
mon iliac arteries to dilate during 3 
to 5 years after tube repair of the 
abdominal aorta, even if the com­
mon iliac arteries had been some­
what dilated preoperatively.
Occasionally, we actually record­
ed a small decrease in size of the 
iliac arteries at follow-up examina­
tion. Obviously, some reduction in 
intraluminal diameter might occur 
as a result of progression of athero­
sclerotic occlusive disease, but in no 
case was such disease clinically im­
portant.
It can be argued that those pa­
tients who had significant athero­
sclerotic occlusive disease and those 
in whom aneurysmal change is like­
ly had already been excluded from 
our series, by virtue of having had 
an aortobifemoral bypass. This does 
not, however, affect the conclusion 
that tube repair of the abdominal 
aortic aneurysm is appropriate in 
selected patients.
The lack of a marked increase in 
diameter suggests that whatever 
the factors are that lead to iliac 
dilatation in the presence of an
abdominal aortic aneurysm they 
may not be as important once the 
aneurysm has been repaired.
This study therefore supports the 
use of the more conservative tube 
repair for aortic aneurysms by sug­
gesting that it is not followed by 
marked aneurysmal change in the 
common iliac arteries for up to 5 
years postoperatively.
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Cefizox
sterile ceftizoxime sodium
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from inhibition of 
cell-wall synthesis in aerobic and anaerobic gram-positive and gram-negative organisms. In 
vitro, ceftizoxime shows a strong affinity for penicillin-binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the infections 
listed below when caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (including S. 
pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis; Escherichia coli; 
Haemophilus influenzae (including ampicillin-resistant strains); Staphylococcus aureus 
(including penicillinase-producing but excluding methicillin-resistant strains); Serratia sp.; 
and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis; 
Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia marcescens; and 
Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to Pseudo­
monas in fections of the urinary tract, a good clinical response accompanied by bacterial 
eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis; 
Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides sp. (including B. 
fragilis); Peptococcussp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S. pneu­
moniae)-, Staphylococcus aureus (excluding methicillin-resistant strains); Escherichia coli; 
Bacteroides sp. (including 8. fragilis); Klebsiella sp.; and Serratia marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding methicillin- 
resistant strains); Staphylococcus epidermidis; Escherichia coli; Klebsiella sp., (including K. 
pneumoniae); Streptococcus sp. (excluding enterococci but including Group A B-hemolytic 
Streptococcus pyogenes); Proteus mirabilis; Serratia sp.; Enterobacter sp.; Bacteroides sp. 
(including 8. fragilis); Peptococcus sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding methicillin- 
resistant strains); Proteus mirabilis; Peptococcus sp.; and Peptostreptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to identify 
the causative organisms and to determine their susceptibilities to ceftizoxime. Therapy with 
CefizoxTM may be initiated before results of the susceptibility studies are known. However, 
modification of the treatment may be required once these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have shown 
hypersensitivity to ceftizoxime or other members of the cephalosporin group of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful inquiry 
should be made to determine whether the patient has had previous hypersensitivity 
reactions to cephalosporins, penicillins, or other drugs. CefizoxTM should be given 
cautiously to  penicillin-sensitive patients. Antibiotics, including CefizoxTM, should be 
administered with caution to any patient who has demonstrated some form of allergy, 
particularly to drugs. If an allergic reaction to CefizoxTM occurs, its administration should 
be discontinued. Serious acute hypersensitivity reactions may require epinephrine and other 
emergency measures.
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other anti­
biotics). Therefore, it is important to consider this diagnosis in patients administered 
CefizoxTM who develop diarrhea.
Treatment w ith broad-spectrum antibiotics alters normal flora of the colon and may permit 
overgrowth o f Clostridia. Studies indicate a toxin produced by Clostridium d iffic ile  is one 
primary cause of antibiotic-associated colitis.
Mild cases o f colitis may respond to drug discontinuance alone. Moderate to severe cases 
should be managed with fluid, electrolyte and protein supplementation as indicated. When 
the colitis  is not relieved by drug discontinuance or when it is severe, consideration may be 
given to the administration of oral vancomycin or other suitable therapy. Other possible 
causes of co litis  should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in clinical 
studies. However, there is no other evidence that CefizoxTM (sterile ceftizoxime sodium) has 
produced alterations in renal function. Renal status should be periodically evaluated, 
especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible organisms 
including species originally sensitive to the drug. Careful observation of the patient is 
essential. If superinfection occurs during therapy, appropriate measures should be taken. 
CefizoxTM should be administered with caution to individuals with a history of gastro­
intestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine, patients with 
impaired renal function (i.e., creatinine clearance ^1 .32 mL/s or S  79 mL/min) should be 
placed on a special dosage schedule recommended under DOSAGE AND ADMINISTRATION. 
Normal dosages in these individuals are likely to produce excessive serum concentrations 
of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and amino­
glycosides has caused nephrotoxicity. The effect of administering CefizoxTM concomitantly 
with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM jn pregnancy has not been established. The use of 
CefizoxTM in pregnant women requires that the likely benefit from the drug be weighed 
against the possible risk to the mother and fetus. The pharmacokinetics of CefizoxTM jn 
pregnant patients has not been investigated. Reproduction studies performed in rats and 
rabbits have revealed no evidence of imoaired fertility or harm to the fetus caused by cefti­
zoxime. Animal reproduction studies, however, are not always predictive of human 
response.
Labour and Delivery: The safety and efficacy of CefizoxTM Use during labour and delivery 
has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations (less than 
4% of serum concentrations at 1 hour after dosing). The clinical significance of this is 
unknown; therefore caution should be exercised if CefizoxTM is to be administered to a 
nursing woman.
Infants and Children: The safety of CefizoxTM in infants less than 6 months of age has not 
been established. In children six months of age and older, treatment with CefizoxTM has ^  
been associated with transient elevated levels of eosinophils, SGOT, SGPT and CPK 
(creatine phosphokinase). The CPK elevation may be related to intramuscular 
administration. ^
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age-dependent 
reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Reaction
Incidence
< 1 %
Incidence 
>1%  but <5%
Hypersensitivity: Rash
Pruritus
Fever
Liver: Transient elevation of SGOT, 
SGPT and alkaline phosphatase
Blood: Neutropenia Transient eosinophilia
Leukopenia Thrombocytosis
Thrombocytopenia Positive direct Coombs' test
Renal: Transient elevation 
of BUN and creatinine
Local: Injection site: burning, cellulitis, 
phlebitis (with IV administration), 
pain, induration, tenderness, 
parasthesia
Genitourinary: Vaginitis
Gastro­
intestinal:
Diarrhea, Nausea, Vomiting, Pseudomembranous colitis
4
*
*
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No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no specific > . 
information available on symptoms or treatment. In cases of suspected overdosage, 
supportive therapy should be instituted according to symptoms. Serum ceftizoxime levels 
can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION ^
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly or intra­
venously after reconstitution.
Dosage and route of administration should be determined by the condition of the patient, 4  
severity of the infection and susceptibility of the causative organism(s). The intravenous 
route may be preferable for patients with bacterial septicemia, or other severe or life 
threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at least 48 
hours after evidence of bacterial eradication has been obtained. For B-hemolytic strepto­
coccal infections, a minimum of 10 days of treatment is recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM js 1 to 12 grams administered in 
equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
Type of Infection Daily Dose 
(Grams)
Frequency and Route
Uncomplicated 
Urinary Tract
1 500 mg q12h, IV or IM
Other Sites 2-3 1 gq8h orq12h, IVorIM
Severe or 3-6 1 g q8h, IV or IM, to
Refractory 2gq8h or q12h, IV or IM*
Life-Threatening 9-12 3 or 4 gq8hIV
‘ When administering 2 g intramuscularly, the dose should be divided and injected into 
different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas aeruginosa 
and because many strains are only moderately susceptible to CefizoxTM, higher dosage 
may be appropriate when urinary tract infections are caused by these organisms. Other 
therapy should be instituted if the response is not prompt.
Adults with Impaired Renal Function: In patients in whom the creatinine clearance is 
1.32 mL/s (79 mL/min) or less, the dosage of CefizoxTM must be reduced. Following an initial 
loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing schedule presented in 
Table 2 should be followed in patients with reduced renal function.
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TABLE 2 Reconstitution Table for Standard Vials -  I.M. Injection
Renal
Function
Creatinine 
Clearance 
mUs mL/min
Less Severe 
Infections
Life-Threatening
Infections
Mild
Impairment
0.83-1.32 50-79 500 mg 
q8h
750 mg to 1.5 g 
q8h
Moderate to severe 
impairment
0.08-0.82 5-49 250 or 500 mg 
q12h
500 mg to 1.0 g 
q12h
Hemodialysis
patients*
0-0.07 0-4 500 mg q48h or 
250 mg q24h
500 mg to 1.0g 
q48h or 500 mg 
q24h
*ln patients undergoing hemodialysis no additional supplemental dosing is required. 
DOSING, HOWEVER, SHOULD BE SCHEDULED SO THAT THE PATIENT RECEIVES THE 
DOSE AT THE END OF THE DIALYSIS. When started 24 hours after administration of 1 g of 
CefizoxTM, hemodialysis has been shown to reduce serum levels by 50%.
When only the serum creatinine level is available, creatinine clearance may be calculated 
from the following formulae (for patients 18 years and over only). The serum creatinine level 
should represent renal function at the steady state.
Males:
Creatinine Clearance _ Weight (kg) x (140 • age)_________
(mL/min) 72 x serum creatinine (mg/100 mL)
Creatinine Clearance 
(mUs)
Weight (kg )x(140-age)
49 x serum creatinine ( ^mol/L)
Females: 0.85 of the above values
Infants and Children: The following dosage schedule is recommended:
TABLE 3
Age Group Unit Dosage Frequency and Route
Infants (6 mo-2 yrs.), 
and 50 mg/kg IV or IM q6h orq8h, IV or IM
Children (2-12 yrs.)
The pediatric dosage should not exceed the maximum adult dosage for serious infections.
ADMINISTRATION
Intramuscular: The reconstituted solution of CefizoxTM should be injected well within the 
body of a relatively large muscle, such as the gluteus. When administering 2 g IM doses, the 
dose should be divided equally and then injected into different large muscle masses.
Intravenous: Injection (bolus): The reconstituted solution of CefizoxTM should be injected 
slowly over 3 to 5 minutes, directly or through the tubing system by which the patient is 
receiving another compatible intravenous solution. During administration of the solution 
containing CefizoxTM, it is desirable to temporarily discontinue administration of the other 
solution.
Intermittent or continuous infusion: The further diluted reconstituted solution of CefizoxTM 
should be administered over a 20 to 30 minute period,
NOTE: CefizoxTM solutions should not be physically mixed with any other drug. There is a 
known incompatibility with aminoglycoside antibiotics. Therefore, they should not be 
physically mixed with CefizoxTM solutions nor administered at the same site.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFIZOXTM 
Proper Name: Ceftizoxime Sodium
Chemical Name: Sodium[6R-(6<*, 7 6 (Z )]]-7 -[((2 ,3 -d ihydro -2 -im in o-4 -th iazo ly l) 
(methoxyim ino)acetyl]am ino]-8-oxo - 5 - th ia - 1 -azabilcyclo[4.2.0] o c t-2 -e n e -2 -  
carboxylate
Structural Formula:
COONa
XT•C-CONM— 1------
Molecular Formula: C i3 H i2 Ns0 5 S2 Na 
Molecular Weight: 405.38
Description: Ceftizoxime Sodium is a white to pale yellow crystalline powder.
Composition: CefizoxTM vials contain ceftizoxime sodium (expressed in terms of free 
acid). The sodium content of each gram of CefizoxTM is approximately 60 mg (2.6 mEq 
sodium ion).
Solutions of CefizoxTM range from colourless to pale yellow, depending upon the diluent 
and volume used. The solution should be discarded if it becomes cloudy. The pH of 
freshly reconstituted solutions usually ranges from 6.0 to 8.0.
A solution of 1 g CefizoxTM in 13 mL Sterile Water tor Injection is isotonic. 
RECONSTITUTION
STANDARD VIALS (1 GRAM and 2 GRAMS)
For Intramuscular Injection: Reconstitute with Sterile Water for Injection or Bacteriosta­
tic Water for Injection.
Approximate Approximate
Vial Diluent to be Available Average
Size Added to Vial Volume Concentration
3.0 mL 3.7 mL 270 mg/mL
2g 6.0 mL 7.4 mL 270 mg/mL
Shake well un til dissolved.
For Intravenous Injection: Reconstitute only with Sterile Water for Injection.
Reconstitution Table for Standard Vials - I.V. Injection
Approximate Approximate
Vial Diluent to be Available Average
Size Added to Vial Volume Concentration
1 9 10 mL 10.7 mL 95 mg/mL
2g 20 mL 21.4 mL 95 mg/mL
Shake well until dissolved.
For Intravenous Infusion: Reconstitute as for intravenous injection. Further dilute the 
reconstituted solution to 50 to 100 mL w ith one o f the “ Solutions for Intravenous 
Infusion”  (see below).
TABLE 4: Solutions for Intravenous Infusion
Sodium Chloride Injection 
5% or 10% Dextrose Injection
5% Dextrose and 0.9%, 0.45% or 0.2% Sodium Chloride Injection
Ringer's Injection
Lactated Ringer’s Injection
10% Invert Sugar in Sterile Water for Injection
5% Sodium Bicarbonate in Sterile Water for Injection
5% Dextrose in Lactated Ringer's In jection ONLY when reconstitu ted with 4% Sodium 
Bicarbonate Injection.
STABILITY OF SOLUTIONS
Storage: All reconstitu ted solutions and those further diluted should be used w ithin 24 
hours if stored at room temperature or w ith in  48 hours if refrigerated. These storage lim its 
are from the tim e o f the initial reconstitution.
Incompatibility: CefizoxTM should not be added to blood products, protein hydrolysates 
or amino acids. CefizoxTM should not be mixed together w ith an aminoglycoside.
DOSAGE FORMS
Availability: CefizoxTM jS available as a sterile powder in Standard Vials o f 1 gram or 
2 grams, containing ceftizoxime as sodium salt.
Storage: CefizoxTM powder for injection should be stored at room temperature (15°-30°C).
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I
H o t -Tip Laser Angioplasty for Peripheral 
Vascular Disease: Clinical Experience 
With 18 Patients
Yves-Marie Dion, MD, MSc, FRCSC; Guy Dionne, MD
Between May 1988 and March 1989, the authors treated 18 patients who suffered 
from disabling claudication or rest pain. They used the laser hot-tip angioplasty 
technique, in which a metal tip on the laser transforms laser energy into heat. 
Nineteen lower extremities were so treated. Six patients had suffered iliac occlusion, 
11 had disease in the superficial femoral artery and 1 in the popliteal artery.
Laser angioplasty was successful in 7 of 13 lower limbs with infrailiac lesions and 
in 4 of the 6 limbs with iliac artery occlusion; the other 2 underwent bypass grafting 
(aortoiliac in 1 and aortobifemoral in the other). No loss or limb or death occurred, 
but immediate complications of perforation or dissection were frequent.
De mai 1988 a mars 1989, les auteurs ont traite 18 patients souffrant de 
claudication intermittente ou douleur de repos. Ils ont employe la technique connue 
sous le nom de “angioplastie thermique au laser” qui consiste a employer en embout 
metallique place a l’extremite d’une fibre optique et qui transforme l’energie laser en 
chaleur. Dix-neuf membres inferieurs ont ete traites. Six patients presentaient une 
occlusion iliaque, 11 une maladie de l’artere femorale superficielle et 1 une lesion de 
l’artere poplite.
L’angioplastie au laser a ete effectuee avec succes chez 7 des 13 lesions 
infrailiaques et chez 4 des 6 occlusions iliaques, les deux autre patients ayant du 
subir un pontage (aortoiliaque pourun et aortobifemoral pour l’autre). Aucune perte 
de membre ni mortalite n’est survenue, mais les complications immediates de 
perforation ou dissection furent frequentes.
I n 1980, Macruz and colleagues' reported on the use of laser 
energy to ablate atherosclerotic 
plaques. Interest in laser angioplas­
ty was further stimulated by Choy 
and associates23 who reported their 
in-vitro studies on coronary arteries 
of cadavers and in-vivo studies on 
animals using flexible fiberoptics. 
Ginsburg and associates4 were the 
first to report a successful clinical 
laser angioplasty procedure, per­
formed on a severely stenosed deep 
femoral artery. In February 1987, 
the American Food and Drug Ad­
ministration (FDA) gave its approval
to the use of laser thermal recanali­
zation of occluded arteries.5 In this 
technique an optic fibre with a 
metal tip transforms laser energy 
into heat. In this paper, we describe 
our experience with this technique 
in 18 patients with atherosclerotic 
peripheral vascular disease.
Patients and Methods
Patient Selection
The study group included 15 
men, ranging in age from 46 to 77
years (mean 59 years), and 3 
women ranging in age from 45 to 
85 years (mean 64 years) (Table I). 
Criteria for selection included any 
or all of the following: (a) disabling 
claudication of thigh or calf or pain 
at rest; (b) minor tissue loss (e.g., 
nonhealing ulcer or focal gangrene 
with diffuse pedal ischemia).
Patients were classified according 
to the clinical categories of chronic 
limb ischemia described by Ruther­
ford6 (Table I).
Equipment
A continuous wave neodymium: 
yttrium-aluminum-garnet (Nd:YAG) 
laser (Heraus, LaserSonics Inc., 
Santa Clara, Calif.) was used in all 
cases, and all procedures were done 
using a mobile x-ray unit (BV-25, 
Phillips Medical Systems, Shelton, 
Conn.).
Two types of delivery system 
were used: Laserprobe-SLR 2.5 
(Trimedyne, Santa Ana, Calif.) and 
Laserprobe-PLR 2.5 Flex (Trime­
dyne). The optical adaptor between 
the laser and the delivery system 
was from Dynetech, Toronto, Ont.
Laser Angioplasty
In 12 patients, the lower extremi­
ty was entered through the femoral 
artery. Surgical dissection of the 
artery was favoured over the percu­
taneous technique in obese patients 
or when iliac occlusion prevented 
palpation of a femoral pulse. After 
systemic heparinization (100 
units/kg), the femoral artery was 
punctured with a Seldinger needle. 
A no. 8 French introducer (Cordis
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LASER ANGIOPLASTY
Corp., Miami, Fla.) was then insert­
ed in either a cephalad or a caudad 
direction according to which arteri­
al segment was occluded. It was 
connected to a constant pressure 
perfusion system. A baseline angio­
gram was then obtained.
The PLR-2.5 Flex laser probe 
was used for stenoses or when the 
guide wire (Terumo 0.035; Terumo 
Corp., Tokyo, Japan) could cross 
the occluded segment. A no. 5 
French straight catheter (Cook Inc., 
Bloomington, Ind.) was then insert­
ed over the guide wire which was 
replaced by a soft-tipped Bentson 
guide wire measuring 0.089 cm 
(0.035 inch) in diameter (Cook 
Inc.). The SLR-2.5 probe was used 
when the guide wire could not cross 
an occlusion.
Laser output was set at 13 W. 
Upon activation of the laser, the 
probe was sequentially placed in 
contact with the lesion and moved 
away from it, using a back and 
forth action, in order to avoid burn­
ing the arterial wall.
Balloon Angioplasty
After recanalization of the artery, 
balloon angioplasty was performed 
at the lased site. Conventional tech­
niques were employed, using the 
femoral artery sheath already in 
place. The size of the balloon cathe­
ter (Bard, USCI Division, Billerica, 
Mass.) was determined by the diam­
eter of the vessel measured on 
arteriography proximal to the oc­
clusion. When a surgical approach 
was used, bleeding was controlled 
by a single suture of 5-0 Prolene 
placed after introducer withdrawal.
Patients were maintained on hep­
arin for 24 hours postoperatively. 
One capsule of Entrophen-10 
(Frosst) was then given daily.
Vessel Patency
Vessel patency was determined 
preoperatively by measurement of 
the ankle/arm pressure index. De­
terminations were repeated at post­
procedure follow-up, which ranged
from 6 to 15 months. This indicated 
whether achieved improvement had 
been maintained in the appropriate 
limb segment. The criteria for con­
tinued patency were a normalized 
segmental limb pressure index or 
one at least 0.1 above the preopera­
tive index and no more than 0.1 
less than the maximum postopera­
tive index; the former without the 
latter was considered as “deteriora­
tion” rather than “ failure” .
Results
Patient Experience
One of the 18 patients underwent 
hot-tip laser angioplasty on the con­
tralateral limb 5 months after the 
first intervention. The actual laser 
procedure usually took no more 
than 3 to 5 minutes, although total 
operative time was, on average, 116 
minutes. Local anesthesia was used 
in two patients who complained of 
moderate pain at the operative site.
T a b le  1. P a tie n t Data
Age,
yf
C lin ica l
ca teg o ries S tenosis
R esidual
stenosis,
%
Type
of
C o m p lic a tio n s
C ase Sex G rade Group A rte ry % Length, cm A p p ro ach probe Type T re a tm e n t
1 61 M II 4 R S F .R P 100 3 .4 90 S S LR - -
2 64 M II 4 RSF 100 5 80 P PLR -
3 65 M I 3 LS F 100 4 NP P S LR P e rfo ra tio n O b s e rv a tio n
4 54 M I 1 LI 100 8 < 1 0 P P LR - -
5 76 M I 3 RSF 100 3 < 1 0 P P LR M l M e d ic a l
6 77 M I 2 LS F 100 4 30 P S LR - -
7 63 F I 2 RP 98 2 5 S P LR H e m a to m a E va cu a tio n
8 85 F 1 3 RSF 100 2 0 P S LR - -
9 45 F 1 3 LI 100 9 < 1 0 s P LR - -
10 53 M 1 1 LS F 100 5 NP s S LR P e rfo ra tio n FPB
11 64 M II 4 LS F 100 4 < 1 0 s S LR H e m a to m a
d is s e c tio n
O b s e rv a tio n
12 46 M I 1 Rl 100 6 NP p S L R P e rfo ra tio n A IB
13 48 M I 3 RSF 100 9 NP s N P O c c lu s io n  n o t 
v isu a lize d
FPB
14 53 M 1 3 LI 100 8 NP s S L R P e rfo ra tio n ABF
15 53 M 1 3 Rl 100 8 < 1 0 s P LR -
16 60 M 1 3 LSF 99 9 < 1 0 s P LR - -
17 51 M 1 2 LSF 100 6 NP P - S S L R H e m a to m a
d is s e c tio n
E n d a rte re c to m y
18 77 M II 4 RSF 100 20 NP s S L R P e rfo ra tio n FPB
19 57 M 1 3 Rl 99 2 < 1 0 s P LR E m b o lis m O b s e rv a tio n
Rl = r ig h t ilia c  a rte ry , LI =  le f t  ilia c  a rte ry , RSF =  r ig h t  s u p e rf ic ia l fe m o ra l a rte ry , LS F  = le ft s u p e r f ic ia l fe m o ra l a rte ry , RP =  r ig h t p e ro n e a l a r te ry , N P
=  n o t p e rfo rm e d , S = 
a o rto b ife m o ra l bypass .
su rg ica l, P =  p e rcu ta n e ou s , M l = m yo ca rd ia l in fa rc t io n , FPB = fe m o ro p o p li te a l b yp a ss , A IB  =  a o r to il ia c  b yp a ss , A B F  =
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However, pain ceased when the 
laser was turned off, and the proce­
dure was not interrupted.
Laser Angioplasty
Sixteen of the 19 limbs treated 
had complete arterial occlusion and 
3 had severe stenosis (98% to 99%) 
(Table I). Eleven (58%) limbs were
FIG. 1. Occlusion (arrows) of 6-cm 
segment of right superficial femoral 
artery.
successfully treated (Figs. 1 and 2).
Complications during the laser 
procedure included the following: 
perforation of the vessel wall by the 
Laserprobe, documented by angiog­
raphy (five instances) (Fig. 3); local 
hematomas (three); dissection of the 
arterial wall with no distal recanali­
zation, demonstrated at angiogra­
phy (two) (Fig. 4); greater than 50% 
residual stenosis at the site of angi­
oplasty (two); inability to find the 
actual point of occlusion because of 
the proximity of a collateral vessel
FIG. 2. Successful recanalization im­
mediately after laser assisted balloon 
angioplasty.
FIG. 3. Perforation of right superficial 
femoral artery by laser probe. Note 
localization of contrast material by 
surrounding tissues at site of perfora­
tion.
(one); myocardial infarction (one); 
distal embolism (one).
Except for one dissection related 
to the percutaneous technique, the 
perforations and the other dissec­
tion occurred when the Laserprobe- 
SLR (without a guide wire) was 
used (Table I).
The patients received treatment 
appropriate to the complications 
they suffered (Table I). The two 
who had iliac perforation- underwent 
a bypass procedure (aortobifemoral 
and aortoiliac respectively). In one 
the iliac perforation resulted in a 
localized hematoma; in the other a 
larger retroperitoneal hematoma de­
veloped. The site of iliac perforation 
was sutured before each bypass.
Among the three patients who 
had perforation of the superficial 
femoral artery, two had a femoropo- 
pliteal bypass and the other was 
followed up by observation. Superfi­
cial femoral artery perforation was 
treated expectantly in each case.
FIG. 4. Subintimal dissection (between 
arrows) leading to failure of laser- 
assisted balloon angioplasty. Laser 
probe entered plane of least resistance 
at site of occlusion (upper arrow). 
Subintimal plane is route often chosen 
by laser probe or guide wire to cross 
occlusion. In this case, despite appar­
ent good result, thrombosis occurred 
peroperatively. It was impossible to 
cross dissected segment with either 
laser probe guide wire.
A
A
A
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For the patient in whom the exact 
origin of the occlusion could not be 
localized, femoropopliteal bypass 
was performed. The patient who 
suffered dissection of the distal iliac 
and common femoral arteries un­
derwent iliofemoral endarterectomy 
with a venous patch. The patient 
who had dissection at the site of 
angioplasty was treated expectantly 
(Fig. 4).
The results for the balloon dilata­
tions are reported in Table I. The 
two patients who had residual ste­
noses of 90% and 80% were diabet­
ic. They underwent femorotibial by­
pass for pain at rest 6 and 12 
months after angioplasty. All other 
patients had residual stenoses of 
10% or less with the exception of 
one who had 30% residual stenosis.
Distal embolism was diagnosed in 
the recovery room in one patient 
and the clinical findings were con­
firmed by Doppler examination. 
Symptoms and signs disappeared 1 
hour later, probably owing to frag­
mentation of the embolus. The em­
bolism could have been caused ei­
ther by the balloon dilatation or by 
the laser procedure itself.
Two hematomas developed after 
surgical dissection of the artery and 
one after the percutaneous ap­
proach. One was sufficiently severe 
to require reoperation and hemosta­
sis; the other two were treated 
expectantly.
Pre- and postoperative determina­
tions of ankle/arm pressure indices 
were used as determinants of im­
proved blood flow and continued 
vessel patency of the treated ex­
tremity. A persistent elevation of 
the ankle/arm index above 0.1 
from the preoperative value, signify­
ing improvement, was noted in the 
four patients who had successful 
iliac recanalization and who noted a 
marked improvement in their clini­
cal status (Fig. 5). However, only 
two of the seven patients followed 
up after femoropopliteal laser angi­
oplasty had a rise of 0.1 or more in 
their ankle/arm index (Fig. 6). The 
length of occlusion of the recanal­
ized femoropopliteal segments var­
ied from 2 to 9 cm. Three of our 
patients were classified as grade I, 
category 1, before angioplasty. 
Their preoperative ankle/arm indi­
ces were 0.77, 0.64 and 0.63. We 
believed that these younger, active 
patients, who were incapacitated by 
claudication, might benefit from 
laser angioplasty. However, only 
one had a successful outcome. The 
two other patients suffered perfora­
tion and therefore underwent by­
pass grafting.
Discussion
Although balloon angioplasty 
alone has proven an effective means 
of treating most patients with local­
ized stenotic or occlusive lesions, 
the possibility of ablating athero­
sclerotic plaque rather than merely 
expanding the arterial lumen has 
intrigued investigators.7
The laser studies of Sanborn, 
Cumberland and Greenfield,8-11 
aroused considerable interest in 
laser thermal angioplasty. Specific 
advantages have been reported
FIG. 5. Follow-up serial ankle/arm  
index determinations of four patients 
who had successful femoropopliteal 
laser-assisted balloon angioplasty.
when the laser is used as an adjunct 
to angioplasty,1112 including the 
ability of the laser to traverse diffi­
cult lesions, such as long-segment 
occlusions, thus extending the use 
of angioplasty. Ablation and “de- 
bulking” of atheromatous plaque 
by laser has been proposed as a 
method to enhance both immediate 
and long-term results of balloon 
angioplasty.13 Ablation of plaque 
and a reduction in platelet adhe­
sions at the angioplasty site14 may 
reduce the release of potent 
smooth-muscle-cell mitogens which 
stimulate restenosis. Thermally in­
duced changes of smooth muscle 
cells and collagen in vessel walls 
may alter vessel compliance and 
reduce arterial responsiveness to re­
leased vasoconstrictors, thus in­
creasing luminal diameter.15 Al­
though these factors may contrib­
ute to the efficacy of laser angio­
plasty, the actual biologic mecha­
nisms remain to be assessed.7
To date, no randomized prospec­
tive trials have addressed the ques­
tion of whether the adjunctive use 
of lasers in balloon angioplasty of­
fers any advantage over standard 
guide-wire techniques.7 Clinical effi­
cacy, therefore, must be assessed 
on comparisons between various
FIG. 6. Follow-up serial ankle/arm  
index determinations of seven patients 
who had successful iliac laser-assisted 
balloon angioplasty.
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studies that have used one method 
or the other.7
Cragg and associates7 compared 
balloon angioplasty for femoropo- 
pliteal occlusions to laser-assisted 
angioplasty of similar lesions. The 
immediate angiographic and clinical 
success rates appeared to be similar 
(72%). Comparison of long-term 
patency after angioplasty of vessel 
occlusions also showed similar out­
comes. Recently, Morgenstern and 
associates16 reported an immediate 
technical success rate of 91% for 
recanalization of femoropopliteal 
occlusions 1 to 10 cm long, using 
the conventional guide-wire tech­
nique.
Timbadia and colleagues17 recent­
ly reported their 2-year experience 
with 1380 laser-assisted peripheral 
angioplasties performed on 671 pa­
tients. Their recanalization rate was 
76% which is comparable to that of 
other series. The immediate patency 
rate in our series was 58%. Factors 
that may account for the difference 
are the learning curve for adequate 
performance of the technique and 
the type of laser probe used to cross 
the occlusion. Timbadia and col­
leagues attempted to cross the oc­
clusion with a guide wire before 
proceeding to laser angioplasty. 
The number of patients treated 
using the guide wire was not stated.
In our series, all perforations oc­
curred when the Laser probe was 
used without the guide wire. Our 
perforation/dissection rate (37%, 7 
of 19) was higher than that general­
ly reported (12%). However, Perbel- 
lini and colleagues,18 in a study of 
85 patients, reported a perforation/ 
dissection rate of 25.4%. Seeger 
and associates19 described a perfora­
tion rate of 22% among a group of 
46 patients.
White, White and Kopchok20 
noted that the unguided laser probe 
tends to follow the path of least 
resistance. Tobis and associates21 
attempted to recanalize arterial seg­
ments of excised human peripheral 
arteries using a 1.5 mm laser probe 
heated by an argon laser, producing 
10 to 12 W. The arterial segments 
were 5 to 10 cm long and complete 
occlusion was documented by angi­
ography. Transmural perforation 
occurred in 8 of 11 (73%) arterial 
segments treated with a laser-heat­
ed probe. Arterial perforation oc­
curred in one of five (20%) artery 
segments approached without heat­
ing, using a standard 0.089 cm 
(0.035 inch) guide wire and cathe­
ter technique. In 10 of 11 (91%) 
heated and all 5 non-heated artery 
segments, the wire and probe ap­
peared mechanically to deflect away 
from hard fibrocalcific plaque and 
to dissect between the intima and 
media. According to Tobis and col­
leagues,21 mechanical dissection 
may be an important factor during 
laser thermal artery recanalization.
Timbadia and colleagues17 report­
ed a 67% patency rate after iliac 
artery recanalization for occlusive 
disease and 77% after recanalization 
of an occluded superficial femoral 
artery at follow-up ranging from 6 
to 24 months. In our series, at 
follow-up ranging from 6 to 15 
months, the four patients who had 
their iliac artery successfully reca­
nalized were clinically much im­
proved as a result of iliac laser 
angioplasty (Fig. 5).
Of seven patients followed up 
from 6 to 15 months after success­
ful femoropopliteal laser angioplas­
ty (Fig. 6), only 2 (29%) had 
a consistently elevated ankle/ 
arm index. At 3-month follow-up 
five (71%) of the seven manifested 
an increase in their ankle/arm 
index of 0.1 or more.
The length of the occlusion may 
be an important prognostic factor. 
White and White4 reported that 
treatment of occlusive lesions 1 to 3 
cm long resulted in a 1-year paten­
cy rate of 90% to 95% in contrast to 
a 46% patency after treatment of
occlusions longer than 7 cm. In our 
series, two patients who maintained 
their ankle/arm index had occlu­
sions 2 and 3 cm long. Three 
patients had occlusions of 4 cm, 
one of 9 cm and one patient had a 
stenosis of the popliteal artery 2 cm 
long.
More frequent recurrences at the 
femoropopliteal level than at the 
iliac region are explained in part by 
the size of the vessel.5 Disappoint­
ing patency rates of 20% to 30% 
have been reported for laser angio­
plasty at the level of the tibial 
vessels.5 Furthermore, Datena and 
associates22 noted that the pattern 
of restenosis corresponded to the 
length of vessel exposed to the 
thermal probe rather than to the 
original lesion. They concluded that 
because of the high rate of recur­
rent stenosis and the pattern of 
apparent thermal injury, extreme 
caution is warranted if use of the 
thermal probe is to be continued.
To document the follow-up of 
these patients and the pattern of 
recurrence better, Fehrenbacher in­
dicated that the FDA has recently 
recommended follow-up angiogra­
phy 6 months after laser angioplas­
ty in at least 50% of the patients 
subjected to the procedure.22
Rienk and colleagues23 suggested 
that laser recanalization of a non- 
calcified obstruction is more effec­
tive with a sapphire contact probe 
than with a metal tip probe because 
the former produces higher flow 
and larger channels. Lammer and 
Pilger24 compared sapphire tip and 
metal laser probes and concluded 
that the saphire probe enabled abla­
tion of a larger volume of tissue 
surrounded by only a small zone of 
thermal necrosis. Coupled to a con­
tinuous wave Nd:YAG laser, the 
delivery system consists of an optic 
fibre at the end of which is placed 
an specially devised sapphire.25-29 In 
an Austrian multicentre trial30 286 
patients with femoropopliteal occlu-
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sions were studied. Immediate reca­
nalization rates (84%), and patency 
rates at 2 years (74%) were compa­
rable to hot (metal) tip laser angio­
plasty.
In contrast to continuous wave 
lasers, pulsed lasers achieve tissue 
vaporization with less thermal dam­
age to the surrounding arterial 
wall.31-34 Also, thrombogenicity ap­
pears to be reduced at the irradiated 
site.35 The excimer laser (308 nm) 
would allow vasodilatation of an 
irradiated arterial segment, d con­
tinuous wave lasers, through a 
thermal effect, may cause arterial 
spasm.36 The excimer laser pro­
duces a photoablative rather than a 
photothermal effect and can pene­
trate calcified atheroma.37'43 Other 
pulsed lasers currently under inves­
tigation include dye (480 nm), 
argon (514 nm), Nd:YAG (355, 
532, 1064 nm) and Er:YAG (2940 
nm) lasers.37
Conclusions
Our results confirm the feasibility 
of hot-tip laser-assisted balloon an­
gioplasty for obstructed arteries of 
the iliac and femoropopliteal seg­
ments. Although complications did 
not endanger the life or limbs of 
our patients, their frequency, partic­
ularly when no guide wire was 
used, raises concern. Prospective 
randomized trials are needed. La­
sers should remain investigational 
devices until their clinical useful­
ness has been established.
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coated tablets of 275mg in bottles of 100, 500 and 
1000 tablets.
Anaprox® DS is available in OVAL-SHAPED, BLUE 
film-coated tablets of 550 mg in bottles of 100 tablets. 
Dosage:
Anaprox® 275 mg: Two tablets (550 mg) followed by 
one tablet (275mg) every 6 - 8  hours as required. 
Anaprox® DS: One tablet (550 mg) twice daily.
Maximum daily dose: 1375 mg.
Product monograph available on request.
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Spontaneous Rupture of Splenic Artery 
Aneurysm: Maternal and Fetal Survival
W. Dunlop, MD;* S. Iwanicki, MD;t A. Akierman, MD;$ J. Pasieka, MD, RIV;§ J.R. Higgin, MDt
Because the diagnosis of ruptured splenic artery aneurysm in pregnancy is seldom 
made before operation, maternal and fetal mortality continues to be high. The 
authors describe the case of a 22-year-old woman who had a ruptured splenic artery 
aneurysm at 32 weeks’ gestation. The attending obstretician considered this 
condition in the differential diagnosis and it was confirmed by ultrasonography, 
leading to a successful outcome.
Comme le diagnostic des ruptures d’anevrismes de l’artere splenique durant la 
grossesse est rarement pose avant la chirurgie, la mortality maternelle et foetale 
continue d’etre elevee. Les auteurs decrivent le cas d’une femme de 22 ans qui a subi 
une rupture de l’artere splenique au cours de la 32e semaine de gestation. Cette 
possibility ayant ete envisagee par l’obstetricien dans son diagnostic differentiel, 
puis confirmee l’echographie, Tissue fut heureuse.
Rupture of splenic artery aneu­rysm in pregnancy, although 
an uncommon condition, is associ­
ated with a very high maternal 
mortality and only occasional fetal 
survival. The most recent published 
report of maternal and fetal survival 
was in 1986.' Very rarely is the 
diagnosis of ruptured splenic artery 
aneurysm made before operation. 
This case report documents the 
preoperative diagnosis and the 
prompt surgical intervention that 
resulted in the eighth reported suc­
cessful maternal and fetal outcome.
Case Report
A 22-year-old primagravida was 
seen in the emergency room at 32 
weeks’ gestation with a 24-hour 
history of continuous, dull, low 
back pain. On admission, vital signs 
were stable and the fetal heart rate 
was 132 beats/min. The non-stress 
test was reactive. Abdominal exami­
nation revealed epigastric tender­
ness and a soft, nontender uterus. 
The cervix was closed, uneffaced, 
with the presenting part at — 3 sta­
tion. Initial routine blood and urine
tests gave normal results. Shortly 
after the patient received a dose of 
Demerol intramuscularly, her blood 
pressure fell to 80 /50  mm Hg. A 
repeat complete blood count (90 
minutes after admission) revealed a 
hemoglobin of 90 g /L  and a 
test now showed repetitive late de­
celerations with a loss of baseline 
variability. Immediate ultrasonogra­
phy done by the attending obstetri­
cian demonstrated free fluid in the 
upper abdomen with a vaguely out­
lined mass in the left upper quad­
rant. The uterus appeared intact. 
Fetal tone was reduced and no body 
movements were observed. In- 
traperitoneal hemorrhage, likely 
secondary to splenic artery aneu­
rysm with resulting fetal distress, 
was diagnosed.
Immediate laparotomy for a ce­
sarean section was performed and a 
general surgeon was called urgently 
for definitive surgery. On entering 
the abdomen, approximately 1500 
ml of free blood was found as well 
as a massive hematoma obscuring 
the entire left upper quadrant. A 
standard cesarean delivery was 
made of a 2240-g female infant who 
had an Apgar score of 3 and 5 at 1 
and 5 minutes respectively.
Intraperitoneal bleeding was 
massive and required aortic com­
pression before splenectomy and 
distal pancreatectomy could be 
accomplished. The patient’s condi­
tion on completion of surgery was 
stable. She was discharged 13 days
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postoperatively. The infant required 
a longer hospitalization because of 
her prematurity.
Pathological examination showed 
a splenic artery aneurysm.
Discussion
Nearly 100 ruptured splenic ar­
tery aneurysms in pregnancy have 
been reported. The outlook for 
mother and fetus apparently contin­
ues to be poor. A relatively recent 
case report of maternal death from 
this condition would suggest that 
the passage of time, improvements 
in antenatal care and technologic 
advances have not reduced the like­
lihood of a poor result. “The diag­
nosis depends ultimately on think­
ing of the condition.”2 
The differential diagnosis after 
initial assessment usually includes 
abruptio placentae or a ruptured 
uterus even though neither history 
nor physical examination suggests 
that either of these entities are 
present. Early operation with cesar­
ean section does not guarantee a 
definitive diagnosis, and subsequent 
maternal deaths have been report­
ed.3
Previous exposure to a similar 
case led the obstetrician involved in 
this case to perform the ultrasonog­
raphy, which confirmed his clinical 
impression. The presence of a gen­
eral surgeon and immediate defini­
tive surgery at the time of cesarean 
section undoubtedly contributed to 
reduced blood loss and the survival 
of both mother and fetus.
References
1. L owry SM, O'D ea TP. Callacher D1 et 
al: Splenic artery aneurysm rupture: the 
seventh instance of maternal and fetal 
survival. J Obstet Gynecol 1986: 67: 
291-292
2. Ho WC: Rupture of splenic artery aneu­
rysm in pregnancy (C). Can Med Assoc J 
1977; 117: 123, 126
3. M acFarlane JR. T horriarnarson B: 
Rupture of splenic artery aneurysm dur­
ing pregnancy. Am J Obstet Gvnecol 
1966: 95: 1025-1037
13 0liefoxin*g
(sterile cefoxitin sodium, MSD Std.) 
ANTIBIOTIC
ACTION
In vitro studies demonstrate that the bactericidal 
action of cefoxitin, a cephamycin derived from 
cephamycin C, results from the inhibition of 
bacterial cell wall synthesis. Evidence suggests 
that the methoxy group in the 7a position is 
responsible for the resistance of cefoxitin to 
degradation by bacterial beta-lactamases.
INDICATIONS AND CLINICAL USES 
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo­
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia 
spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t in fections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies 
should be performed to determine the suscepti- 
b il ity  of the causative organism (s) to 
MEFOXIN®. Therapy may be started while 
awaiting the results of these tests, however, 
modification of the treatment may be required 
once these results become available.
Organisms particularly appropriate for therapy 
with MEFOXIN® are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci 
Gram negative (beta-lactamase producing and 
non-producing strains)
Escherichia coli
Klebsiella species (including K. pneumoniae) 
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species 
Anaerobes 
Bacteroides fragilis
MEFOXIN® may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas 
spp., most strains of enterococci, many strains 
of Enterobacter cloacae, and methicillin- 
re s is ta n t s ta p h y lo c o c c i and L is te ria  
monocytogenes.
Clinical experience has demonstrated that 
MEFOXIN® can be administered to patients who 
are also receiving carbenicillin, gentamicin, 
tobramycin, or amikacin (see PRECAUTIONS 
and ADMINISTRATION).
PROPHYLACTIC USE
MEFOXIN® may be administered periopera- 
tively (preoperatively, intraoperatively and post­
operatively) to patients undergoing vaginal or 
abdominal hysterectomy and abdominal surgery 
when there is a significant risk of postoperative 
infection or where the occurrence of post­
operative infection is considered to be especially 
serious.
In patients undergoing cesarean section, intra­
operative (after clamping the umbilical cord) 
and postoperative use of MEFOXIN® may 
reduce the incidence of surgery related post­
operative infections.
®Trademark Merck & Co., Inc./ 
Merck Frosst Canada Inc., R.U.
Effective prophylactic use depends on the time 
of administration. MEFOXIN® usually should be 
given one-half to one hour before the operation. 
Prophylactic administration should usually be 
stopped within 12 hours. It has been generally 
reported that continuing administration of any 
antibiotic beyond 24 hours following surgery 
increases the possibility of adverse reactions 
but, in the majority of surgical procedures, does 
not reduce the incidence of subsequent 
infection.
If signs of postsurgical infection should appear, 
specimens for culture should be obtained for 
identification of the causative organism(s) so 
that appropriate treatment may be instituted.
CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics.
WARNINGS
Before therapy with MEFOXIN® is instituted, 
careful inquiry should be made to determine 
whether the patient has had previous hyper­
sensitivity reactions to MEFOXIN®, cepha­
losporins, penicillins or otherdrugs. MEFOXIN® 
should be given with caution to penicillin- 
sensitive patients.
There is some clinical and laboratory evidence 
of partial cross-allergenicity between cepha- 
mycins and the other beta-lactam antibiotics, 
penicillins and cephalosporins. Severe reactions 
(including anaphylaxis) have been reported 
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported 
w ith  v ir tu a lly  a ll a n tib io tic s  in c lu d in g  
MEFOXIN®. This colitis can range from mild to 
life threatening in severity. Antibiotics should 
therefore be prescribed with caution in indi­
viduals with a history of gastrointestinal disease, 
particularly colitis. It is important to consider a 
diagnosis of pseudomembranous colitis in 
patients who develop diarrhea in association 
with antibiotic use. While studies indicate that a 
toxin produced by Clostridium dilficile is one 
primary cause of antibiotic-associated colitis, 
other causes should also be considered.
Any patient who has demonstrated some form of 
allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs, 
administration of the drug should be dis­
continued. Serious hypersensitivity reactions 
may require treatment with epinephrine and 
other emergency measures.
PRECAUTIONS
The total daily dosage should be reduced when 
MEFOXIN® is administered to patients with 
transient or persistent reduction of urinary 
output due to renal insufficiency (see DOSAGE 
AND ADMINISTRATION) because high and 
prolonged serum antibiotic concentrations can 
occur from usual doses.
In patients treated with MEFOXIN® a false­
positive reaction to glucose in the urine may 
occur with Benedict's or Fehling's solutions but 
not with the use of specific glucose oxidase 
methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occur if serum concen­
trations of cefoxitin exceed 100 pg/mL. Serum 
samples from patients treated with MEFOXIN® 
should not be analyzed for creatinine if with­
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine 
may interfere with measurement of urinary 17- 
hydroxy-corticosteroids by the Porter-Silber 
reaction, and produce false increases of modest 
degree in the levels reported.
Increased nephrotoxicity has been reported 
fo llow ing  concom itant adm inistration of 
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient's condition is 
essential and if super-infection occurs during 
therapy, appropriate measures should be taken. 
Should an organism become resistant during 
antibiotic therapy, another antibiotic should be 
substituted.
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Use In Pregnancy
The safety of MEFOXIN® in the treatment of 
infections during pregnancy has not been 
established. If the administration of MEFOXIN® 
to pregnant patients is considered necessary, its 
use requires that the anticipated benefits be 
weighed against possible hazards to the fetus. 
Reproductive and teratogenic studies have been 
performed in mice and rats and have revealed no 
evidence of impaired fertility or harm to the fetus 
due to MEFOXIN®.
Nursing Mothers
Cefoxitin is excreted in human milk.
Children
In children 3 months of age or older, higher 
doses of MEFOXIN® (100 m g/kg/day and 
above) have been associated with an increased 
incidence of eosinophilia and elevated SGOT.
ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse 
reactions rarely required cessation of treatment 
and usually have been mild and transient.
Local Reactions
Thrombophlebitis has occurred with intra­
venous administration. Some degree of pain and 
tenderness is usually experienced after intra­
muscular injections using water. Induration has 
occasionally been reported.
Allergic
M aculopapular rash, u rtica ria , pruritus, 
eosinophilia, fever and other allergic reactions 
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo­
lytic anemia, and thrombocytopenia and bone 
marrow depression have been reported. Some 
individuals, particularly those with azotemia, 
may develop positive direct Coombs tests 
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDFI, and serum alkaline phosphatase and 
jaundice have been reported.
Cardiovascular Function 
Hypotension.
Renal Function
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure has 
been reported rarely. The role of MEFOXIN® in 
changes in renal function tests is difficult to 
assess, since factors predisposing to prerenal 
azotemia or to impaired renal function have 
often been present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN® can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously 
or intramuscularly as required. (See complete 
m onograph on A D M IN IS TR A T IO N  and 
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients 
with bacteremia, bacterial septicemia, or other 
severe or life-threatening infections, or for 
patients who may be poor risks because of 
lowered resistance resulting from such debili­
tating conditions as m alnutrition, trauma, 
surgery, diabetes, heart failure, or malignancy, 
particularly if shock is present or impending.
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2 g of 
MEFOXIN® every 6 to 8 hours. Dosage and 
route of administration should be determined by 
severity of infection, susceptib ility  of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
Type of Dally Frequency
infection Dosage and Route
Uncomplicated 3-4 g 1 g every 6-8 h
forms* of in- I.V. or I.M.
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection
Moderately 6-8 g 1 g every 4 h
severe or severe or
infections 2 g every 6-8 h I.V.
Infections 12 g 2 g every 4 h
commonly or
needing anti- 3 g every 6 h I.V.
biotics in higher
dosage (e.g. gas
gangrene)
’ Including patients in whom bacteremia is absent or 
unlikely
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infections should be maintained 
for at least 10 days to guard against the risk of 
rheumatic fever or glom erulonephritis. In 
staphylococcal and other infections involving a 
collection of pus, surgical drainage should be 
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with 
reduced renal function but a reduced dosage 
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. After 
a loading dose, the following recommendations 
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF 
MEFOXIN® IN ADULTS 
WITH REDUCED RENAL FUNCTION
RENAL
FUNCTION
CREATININE
CLEARANCE
mL/min
DOSE FREQUENCY
Mild
impairment 50-30 1-2 g every 8-12 h
Moderate
impairment 29-10 1 -2  g every 12-24 h
Severe
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
In patients undergoing hemodialysis, the 
loading dose of 1 - 2 g should be given after each 
hemodialysis, and the maintenance dose should 
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants 
and Children (See WARNINGS for Neonates 
under ADMINISTRATION in the complete
m onograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 mg/kg every 12 h I.V.
Neonates
0- 1 week of age
1- 4 weeks of age
20-40 mg/kg every 12 h I.V. 
20-40 mg/kg every 8 h I.V.
Infants
1 month to 2 years 
of age
20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
Children 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day. 
MEFOXIN® is not recommended for the therapy 
of meningitis. If meningitis Is suspected, an 
appropriate antibiotic should be used.
At present the re  is in s u ff ic ie n t data to 
recommend a specific dosage for children with 
impaired renal function. However, if the adminis­
tration of MEFOXIN® is deemed to be essential 
the dosage should be modified consistent with 
the recommendations for adults (see Table 
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN® is recommended as follows: 
Vaginal or abdominal hysterectomy and 
abdominal surgery
2g  administered in tram uscularly or in tra­
venously just prior to surgery (approximately 
one-half to one hour before initial incision). 
The second and th ird 2 g doses should be 
administered at 2-6 hour intervals after the 
initial dose.
Cesarean Section
The first dose of 2 g should be administered 
intravenously as soon as the umbilical cord has 
been clamped. The second and third 2 g doses 
should be given intravenously or intramus­
cularly four hours and eight hours after the first 
dose.
AVAILABILITY
MEFOXIN® is supplied as sterile powder in 
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN® in the dry state should be stored 
below 30°C. The dry material as well as 
solutions tends to darken, depending on storage 
conditions; product potency, however, is not 
adversely affected.
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Cholesterol Granuloma of the Peritoneum
A.F. Al-Amer, MB, FRCS;* H.S. Walia, MB, MS, FRCS(Edin), FRCS;* J.P. Madda, MRCPathf
Cholesterol granulomas are common in the mastoid region but have rarely been 
reported in other areas. The authors report the case of a 40-year-old man who had a 
cholesterol granuloma of the peritoneum. They discuss the morphology of the 
condition and the difficulties of diagnosis. It is likely that chronic or recurrent 
inflammation plays a major role in the pathogenesis and that, when dealing with 
such lesions preoperatively or intraoperatively, a radical approach may not be 
necessary.
Les granulomes de cholesterol sont frequemment observes dans la region mastol- 
dienne mais ils ont rarement ete signales dans d’autres regions. Les auteurs 
decrivent le cas d’un homme de 40 ans presentant un granulome de cholesterol dans 
le peritoine. Ils commentent la morphologie de ce granulome et les difficulty de 
diagnostic. II est vraisemblable qu’une inflammation chronique ou recurrente joue 
un role important dans sa pathogenese et que, face a une telle lesion, avant ou 
durant une intervention chirurgicale, une approche radicale ne soit pas necessaire.
C holesterol granuloma is essen­tially a foreign-body reaction in 
response to cholesterol crystals.1 
This is a well-defined entity in the 
otology literature but has rarely 
been reported in other areas.2"4 The 
biologic benignity of the lesion is 
well established; a few studies have 
recorded its destructive character.4-5 
The lesion often simulates malig­
nant disease in the abdomen6-7 and 
has posed a problem for both pa­
thologists and surgeons.
This report describes the occur­
rence and morphogenesis of an un­
usual form of an intra-abdominal 
lesion and the difficulties in estab­
lishing its diagnosis.
Case Report
A 40-year-old Arab man gave a 
history of upper abdominal pain for 
6 months and weight loss of 7 kg in 
the previous 3 months in spite of
having a normal appetite. The pain 
was colicky, moderate to severe, 
lasting a few minutes to 90 min­
utes, radiating to the back and not 
accompanied by nausea or vomit­
ing. There was no history of hema- 
temesis, melena or jaundice. The 
patient was a nonsmoker, con­
sumed a moderate amount of alco­
hol and was known to have glu- 
cose-6-phosphate dehydrogenase 
deficiency.
Examination revealed a healthy- 
looking patient with no cyanosis, 
jaundice or pallor. There was no 
lymphadenopathy and the thyroid 
and pulses were normal. Systemic 
physical examination revealed no 
abnormality and the abdominal ex­
amination gave normal findings, 
apart from mild tenderness in the 
epigastrium.
Laboratory investigations showed 
a hemoglobin value of 111.1 g/L  
and an erythrocyte sedimentation 
rate of 14 mm/h. Hematologic indi­
ces indicated hypochromic micro­
cytic anemia. The biochemical pro­
file revealed a serum iron level of 
12.1 /umol/L (normal 14 to 31 
ixmol/L) and a total iron-binding 
capacity of 4.8 g /L  (normal 2.5 to 
4.2 g/L), but the rest of the profile 
was normal. Serum amylase concen­
tration was 103 U/L (normal up to 
85 U/L). Upper gastrointestinal en­
doscopy showed only a deformed 
bulb. Computed tomography scan­
ning showed that the head of the 
pancreas was swollen and edema­
tous, the wall of the second part of 
the duodenum was thickened and 
the lower end of the common bile 
duct was slightly dilated. The pa­
tient did not appear for the sched­
uled endoscopic retrograde cholan­
giopancreatography (ERCP). Rou­
tine urinalysis and stool culture 
examination, x-ray films of the 
chest and abdomen and ultrasonog­
raphy gave normal results.
The patient returned with similar 
complaints 2 months later. Repeat 
ultrasonography showed a 6 X 3 
cm cystic mass in the head of the 
pancreas, suggesting a pseudopan- 
creatic cyst. Computed tomography 
suggested a mass, likely cystic, but 
could not eliminate a fluid collec­
tion or a malignant lesion. Repeat 
endoscopy showed a polypoid mass 
1 cm above the ampulla of Vater, 
highly suggestive of a periampul­
lary carcinoma. Biopsies were tak­
en, but only inflammatory tissue 
was found. Endoscopic retrograde 
cholangiopancreatography revealed 
normal common bile, pancreatic 
and cystic ducts and gallbladder. 
Barium meal examination and hypo­
tonic duodenography suggested a 
thickened and rigid second part of 
the duodenum with destroyed or 
irregular mucosa, highly suggestive
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of a malignant condition. In view of 
these findings a presumptive diag­
nosis of ampullary carcinoma was 
made.
At operation through a long mid­
line incision, a mass 5 X 6 cm 
involving the head of the pancreas 
and second part of the duodenum 
was seen. There were 1- to 2-mm 
seedlings, transparent to pearl 
white, involving most of the upper 
abdomen (i.e., peritoneum and liver 
surfaces). There were heaped mass­
es of these in the subphrenic recess­
es and a few scattered over the 
small bowel and peritoneum of the 
lower abdomen. A duodenotomy re­
vealed a 3 X 4 cm ulcerated lesion 
with a fistulous track leading into 
the head of the pancreas. It was our 
opinion that the head of the pancre­
as was carcinomatous with second­
ary lesions. Biopsies were taken 
from the ulcerated lesion inside the 
head of the pancreas, the peritone­
um, surface of the liver and the 
heaped masses. Frozen section (Fig. 
1) was interpreted as containing 
malignant tissue, possible from the 
pancreas, but this was subsequently 
shown to be incorrect.
On the basis of this report a 
bypass procedure, consisting of an 
antecolic gastrojejunostomy, chole- 
cystojejunostomy and jejunojeju- 
nostomy was carried out. The pa­
tient’s postoperative course was un­
complicated. On postoperative day 
10, the revised diagnosis was re­
ceived with surprise.
Pathological Findings
Paraffin sections (Fig. 2) from 
the liver and peritoneum revealed 
the true nature of the lesions. They 
showed multinucleated giant cells 
encircling cholesterol crystals in 
some areas of fat tissue. Empty 
clefts were also seen in the fibrotic 
areas of the fat tissue.
The tears within the tissue on 
frozen section contributed to the
error in histologic interpretation. 
They imparted an appearance simi­
lar to epithelial lining, a papillary 
structure. The dissolution of cho­
lesterol crystals during staining of 
the frozen section gave spaces com­
pletely surrounded by multinucleate 
cells a duct-like appearance. The 
lack of basement membrane to the 
ductular epithelium, so formed, tilt­
ed the diagnosis in favour of adeno­
carcinoma. After being fixed, the 
tissues are firmer and less likely to 
be torn; thus, even if the crystals 
dissolved their shape could be in­
ferred from tissue molds or clefts 
that are left behind.
The pancreatic biopsy showed 
marked periductal infiltration of 
lymphocytes and plasma cells, and
FIG. 1. Frozen section. Appearance of tissue from surface of liver. Note papillary 
structures formed as result of tissue tears caused by presence of cholesterol crystals 
(hematoxylin and eosin, original magnification X 400).
FIG. 2. Paraffin section. Cholesterol crystal (centre) is lying next to multinucleate 
foreign body giant cell (hematoxylin and eosin, original magnification X 400).
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no luminal concretion was present. 
The acinar tissue showed a diffuse 
scattering of polymorphonuclear 
leukocytes together with numerous 
lymphocytes and plasma cells. No 
acinar tissue necrosis or atrophy 
was seen. No fibrosis or calcifica­
tion was present. The islets were 
normal.
The final diagnosis was choles­
terol granulomas of the peritoneum 
and liver, with active chronic pan­
creatitis. Clearly the patient had 
had a pseudocyst in the head of the 
pancreas which had ruptured into 
the duodenum and drained before 
surgery.
Follow-up
At follow-up, 2 months after 
operation, the patient was com­
pletely free of pain and had put on 
10 kg in weight. Ultrasonography 
showed no abnormality and com­
puted tomography revealed further 
regression of the lesion in the head 
of the pancreas.
The patient was admitted 4 
months later with epigastric pain 
radiating to his back and with occa­
sional vomiting. He had resumed 
drinking alcohol, half a bottle a 
day. Clinical examination gave nor­
mal results. However, the serum 
amylase level ranged from 136 to 
150 U /L  (normal less than 85 
U/L) and the 24-hour urinary amy­
lase level was also elevated to 140 
U/L (normal 4 to 37 U/L). Roent­
genography of the abdomen, ul­
trasonography, gallium scanning 
and ERCP gave normal results, but 
the computed tomography scan 
showed persistence of a small cystic 
lesion, less than 1 cm in dimension 
in the head of the pancreas. Endos­
copy revealed the presence of a 
fistulous tract above the ampulla. 
Biopsies taken from the area 
showed only an inflammatory reac­
tion. The patient fitted into a pat­
tern of established chronic pan­
creatitis. So far no evidence of 
malignancy has been found. On 
further follow-up 9 months later, 
repeat endoscopy revealed the per­
sistence of a fistulous tract, but it 
was smaller. The patient still com­
plained of pain, for which analge­
sics were prescribed, and he was 
advised to avoid alcohol consump­
tion.
Discussion
The cholesterol granuloma is a 
known entity in otology, usually 
found in the mastoid region and 
mostly associated with chronic oti­
tis media and cholesteatoma. Rarely 
has this lesion been reported in the 
thyroglossal duct,2 parotid gland,3 
lymph nodes,7 kidneys,8 liver,9 or 
spleen.9 It has never been reported 
before in the peritoneum.
Granulomatous inflammation is a 
common tissue response to a vari­
ety of stimuli, including lipids, 
which may come from exogenous10 
or endogenous11 sources. Rubin­
stein and Brenner9 coined the term 
lipogranulomatosis in preference to 
pseudosarcoid granuloma, because 
the etiology may not be known in 
some cases. Cholesterol granuloma 
is a specific histologic entity con­
sisting of fibrous granulation tissue 
in which a large number of choles­
terol crystals have been deposited 
and surrounded by foreign-body 
giant cells, a condition that requires 
careful differentiation from tubercu­
losis12 and sarcoidosis.13 The cho­
lesterol, according to Friedman,1 
comes from the breakdown of 
blood. Sade and Teitz14 suggested 
hypoxic breakdown of tissue, and 
Aviel and associates2 mention tissue 
breakdown secondary to persistent 
inflammation as the possible 
source.
There is a paucity of reports of 
this condition in the literature; of 
the three case reports of abdominal
lipogranulomatosis only one was of 
cholesterol granuloma.7 The re­
maining two reports were cases of 
idiopathic lipogranulomatosis,9 the 
etiology of which could not be 
established. Most of the reported 
cases were in Caucasians, whereas 
our patient is an Arab. The history 
of ingestion or injection of mineral 
oil or radiographic material is im­
portant. The age of reported cases 
ranged from 35 to 69 years. Pa­
tients usually present with abdomi­
nal pain and weight loss. Only one 
patient had night sweats. Choles­
terol granuloma is often associa­
ted with cholesterol-rich lesions, 
leakage of which would result in 
its ingestion by macrophages, caus­
ing organomegaly and lym- 
phadenopathy. Usually the diagno­
sis is an incidental histologic find­
ing. These features are unhelpful 
since they could be compatible with 
any of the principal differential di­
agnoses. Special investigations like 
barium meal examination, ul­
trasonography, computed tomogra­
phy, angiography or ERCP may not 
reveal the diagnosis. A quick sec­
tion may not be helpful because 
dissolution of cholesterol crystals 
during staining causes spaces sur­
rounded by multinucleate cells, 
which have a duct-like appearance 
and can be misinterpeted as carcino­
ma as in our case. Thus there is no 
one test except histologic examina­
tion of paraffin sections that clearly 
separates cholesterol granuloma 
from its chief differential diagnoses.
Our case of cholesterol granulo­
ma in the peritoneum appears to be 
the only case of its kind in the 
English literature. Morphogenesis 
appears to be secondary to erosion, 
leak and fistulization of the duode­
num by a pseudopancreatic cyst, 
thus evacuating itself. Pseudocysts 
are known to contain a mixture of 
necrotic debris, blood and enzyme 
which subsequently becomes liqui­
fied and has the propensity to leak,
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erode or rupture. This seems to 
have happened in our case, in 
which release of this fluid, rich in 
cholesterol, elicited a mononuclear 
phagocytic and foreign-body granu­
lomatous reaction, resulting in for­
mation of miliary seedlings across 
the upper abdomen, with heaping of 
collections of these lesions in the 
subphrenic spaces. This diagnosis 
must be differentiated from perito­
neal tuberculosis, starch granuloma 
and metastasis from stomach, pan­
creas and ovaries.
In theory no treatment is re­
quired. However, all the tissue is 
invariably removed at the time of 
the surgical procedure when malig­
nancy is suspected or some lesser 
procedure is done. If the diagnosis 
is entertained, pre- or intraopera- 
tively, when dealing with such le­
sions, a radical approach may not 
be necessary. Frozen section in 
such cases may help in reaching the
correct diagnosis, provided the pa­
thologist is aware of the possibility.
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SESAP VI Critique
Item 24
The pathogenesis of peptic ulcer disease is multifactorial. Some patients with peptic ulcer have an increased 
parietal cell mass, which results in acid hypersecretion. Others have increased serum levels of gastrin or an 
increased parietal cell sensitivity to gastrin. Another subgroup is believed to have enhanced vagal tone, which 
increases parietal cell sensitivity to gastrin and the parietal cell mass. The hormone somatostatin may serve as a 
regulator of acid secretion. Therefore, reduced somatostatin could be part of the pathogenesis of ulcer disease. 
However, somatostatin has not been consistently found to be decreased in patients with ulcers. Gastric mucosal 
production of prostacyclin (PGI2) is either normal or reduced in ulcer patients. Although some o f the 
prostaglandins may have a cytoprotective effect, prostacyclin has not been shown to have any effect on ulcer
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ERGAMISOL (levamisole hydrochloride) is indicated as 
adjuvant therapy in poor prognosis malignant melanoma 
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metastatic disease. In such patients, levamisole has been 
shown to produce an improvement in relapse free survival 
and overall survival when compared to observation alone, 
particularly in patients aged 55 years or older. 
ERGAMISOL is also indicated as adjuvant therapy, in com­
bination with 5-fluorouracil, in patients with completely 
resected Dukes’ stage C colon cancer. Evidence of 
metastatic disease must be excluded before initiating 
therapy. In patients with Dukes’ stage C carcinoma of the 
colon, a regimen of levamisole plus 5-fluorouracil has 
been shown to produce significant reductions in both 
cancer recurrence and overall death rate.
CONTRAINDICATIONS
Levamisole is contraindicated in patients with a known 
hypersensitivity to the drug.
WARNINGS
ERGAMISOL (levamisole hydrochloride) has been asso­
ciated with reversible leukopenia and agranulocytosis, 
therefore it is essential that appropriate hematological 
m on ito rin g  be done rou tine ly  during therapy w ith 
ERGAMISOL.
Patients should be instructed to report immediately any 
sudden change in their state of health which may be man­
ifested by influenza-like symptoms (fever, lassitude, sore 
throat, shivering or sweating) so that appropriate hema­
tological testing can be done.
Leukopenia (total WBC below 3000 mm3) is not neces­
sarily a sign of impending agranulocytosis; recovery is 
possible w ithout withdrawal of the drug. However, with 
a reduced neutrophil count (less than 20% of the total 
white blood cell count) levamisole should be discontinued 
permanently. (Agranulocytosis is attributed to antibody 
form ation and absorption of immune complexes. This 
process initiates complement activation and cell lysis; lev­
amisole itself does not directly damage granulopoiesis.) 
The HLA genotype B27 predisposes to the development 
of agranulocytosis, particularly in females with concomi­
tant rheumatoid arthritis. The onset is frequently sudden 
and may be asymptomatic. Following discontinuation of 
levamisole, neutrophil counts normalize within a week to 
10 days. There is no evidence that steroids or WBC trans­
fusions are of significant therapeutic value; prophylaxis 
of infection during the acute phase of agranulocytosis 
should be an important consideration.
PRECAUTIONS
Drug Interactions; The therapeutic effect of levamisole 
may be antagonized by concomitant administration of cor­
ticosteroids.
Additional caution is necessary when levamisole is used 
in combination w ith other drugs potentially affecting 
hemopoiesis.
Levamisole has been reported to produce “ANTABUSE™” - 
like side effects when given concomitantly with alcohol.
ADVERSE REACTIONS
Approximately half of all patients treated with ERGAMISOL 
(levamisole hydrochloride) experience adverse effects of 
the medication. Due to the intermittent nature of the 
dosage schedule, drug discontinuation may not be nec­
essary fo r successful resolution.
The adverse reactions observed when levamisole is used 
in combination w ith 5-fluorouracil are consistent with 
those anticipated if 5-fluorouracil is given alone in a com­
parable dose and schedule.
The incidence of adverse reactions for levamisole alone 
in malignant melanoma patients and for levamisole plus 
5-fluorouracil in colonic cancer patients is presented in 
the following table:
INCIDENCE (%)
LEVAMISOLE LEVAMIS0LE+5-FU 
COLONIC
ADVERSE REACTIONS
MELA­
NOMA
INDUC­
TION
MAINTE­
NANCE
GASTROINTESTINAL
nausea 24 37 56
vomiting 6 8 17
diarrhea 25 47
taste change 10 2 7
anorexia 1
MUCOCUTANEOUS
stomatitis 1 27 28
dermatitis 4 8 22
severe 1 1
alopecia 4 22
conjunctivitis 1 7
hyperpigmentation 2
HEMATOLOGICAL
leukopenia 10
2000 to 4000/mm3 38 38
less than 2000/m m 3 7 2
thrombocytopenia
50000 to 130000 /m m 3 4 18
less than 50000 /m m 3 2 4
agranulocytosis 1.4
MUSCULOSKELETAL
arthralgia/myalgia 8 2 4
NEUROLOGIC
visual change 2
smell change 1 2
headache 1 5
dizziness/vertigo 1 4
ataxia 3
anxiety/irritability 2 2
depression 1 2
insomnia 1
somnolence 1
impaired thinking 1 2
OTHER
fatigue/weakness 5 11
fever 8
impaired liver function 1 2
SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no experience of overdosage with ERGAMISOL 
(levamisole hydrochloride). At high doses ERGAMISOL 
exhibits positive inotropic and chronotropic properties on 
heart muscle as well as convulsant properties. General 
supportive measures are recommended.
DOSAGE AND ADMINISTRATION 
In patients with malignant melanoma
ERGAMISOL (levamisole hydrochloride) should be admin­
istered at a dose of 2.5 mg/kg given as a single daily dose, 
preferably at night, on 2 consecutive days every week. 
Higher doses are not recommended as they are associated 
with increased toxic ity and have not been shown to 
provide any additional therapeutic benefit.
In patients with Dukes' stage C carcinoma of the colon 
Levamisole plus 5-fluorouracil should be administered 
only by or under the supervision of qualified physicians, 
experienced in cancer chemotherapy, and well versed in 
the use of potent antimetabolites.
Therapy with ERGAMISOL may be initiated as soon after 
resection as patients are able to tolerate oral medication, 
but no sooner than one week and no later than five weeks 
after surgery.
ERGAMISOL should be administered orally at a dose of 
50 mg t.i.d., for three consecutive days, every two weeks. 
This therapy should be continued for at least one year. 
Administration of 5-fluorouracil should be timed to begin 
concomitantly with the second three day course of lev­
amisole. The initial dosage of 5-fluorouracil should be 450 
mg/m7day, given intravenously, for five consecutive days. 
Four weeks following the initial five day course of 5-flu- 
orouracil, patients should begin maintenance therapy on 
a once weekly basis with an intravenous injection of 5- 
fluorouracil at a dose of 450 mg/m3. Treatment should 
continue fo r as long as levamisole is administered.
If the patient experiences stomatitis, diarrhea or leukope­
nia, the weekly 5-fluorouracil administrations should be 
deferred until these side effects have subsided. If these 
side effects are moderate to severe in intensity, 5-fluo- 
rouracil should be resumed with a 20% reduction in the 
dose.
Dosage Forms:
Availability: ERGAMISOL tablets 50 mg are available in 
blister packages of 36 tablets.
Storage: ERGAMISOL tablets 50 mg should be stored
at room temperature and protected from 
moisture and light.
Product monograph available on request.
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inImipenem Versus Tobramycin- Antianaerobe Antibiotic Therapy Intra-abdominal Infections
Dan Poenaru, MD; Mary De Santis, RN; Nicolas V. Christou, MD, PhD
The authors compared broad-spectrum monotherapy with imipenem to an 
aminoglycoside-based antibiotic regimen for the management of intra-abdominal 
infections. One hundred and four patients who had intra-abdominal infection were 
randomly allocated to receive imipenem (52) or tobramycin plus clindamycin or 
metronidazole (52). Patients treated with imipenem had fewer febrile episodes and 
occurrences of breakthrough bacteremia, less antibiotic resistance and need for drug 
change; their hospital stay was shorter. The death rate from sepsis was 4% in 
patients who received imipenem and 13% in those who received the combined 
regimen (p = 0.08). Treatment was successful in 79% of patients on imipenem 
versus 67% of those receiving an aminoglycoside. Patient stratification by the 
APACHE II system and probability of death calculation using delayed-type 
hypersensitivity scores predicted a similar death rate for the two treatment groups. 
Imipenem appears to be a safe and efficacious alternative broad-spectrum antibiotic 
for treating patients who are seriously ill with intra-abdominal infection.
Les auteurs ont compare l’imipenem en monotherapie a large spectre, a une 
antibiotherapie renfermant un aminoside dans le traitement des infections intra- 
abdominales. Cent quatre patients souffrant d’infections intra-abdominales ont ete 
assignes de fa?on aleatoire a recevoir de l’imipenem (52) ou de la tobramycine 
associee a la clindamycine ou au metronidazole (52). Les patients qui re$urent 
l’imipenem presentment moins de poussees febriles, de bacteremies, de resistance 
aux antibiotiques et necessiterent moins de changements de medications; leur sejour 
hospitalier fut plus court. La mortalite due aux sepsies fut de 4% chez les patients 
qui re^urent l’imipenem et de 13% pour ceux qui re$urent le traitement dissociation 
(p = 0.08). Une guerison fut enregistree chez 79% des patients traites a I’imipenem 
par rapport a 67% chez ceux qui recurent un aminoside. La stratification des 
patients selon le systeme APACHE II et la probability de deces calculee a l’aide de 
cotes d’hypersensibilite retardee laissaient prevoir un taux de mortalite similaire 
dans les deux groupes. L’imipenem semble etre une alternative sure et efficace dans 
l’antibiotherapie a large spectre des infections intra-abdominales graves.
Intra-abdominal infection is a seri­ous surgical problem associated 
with high morbidity and mortality.1 
Its management includes surgical 
debridement and drainage of ab­
scesses as well as the administra­
tion of antibiotics. The bacteriologic 
findings often include facultative 
gram-negative and anaerobic organ­
isms, with the anaerobes predomi­
nating.2 It has become common 
practice to treat both of these com­
ponents, despite relatively weak 
support for such an approach.1 The 
mainstay of pharmacotherapy in in­
tra-abdominal infection has hence 
become an aminoglycoside to treat 
the gram-negative organisms in 
combination with either clin­
damycin or metronidazole for the 
anaerobes. The well-known adverse 
effects associated with aminoglyco­
side use, such as ototoxicity and 
nephrotoxicity, have led to a search 
for alternatives to the aminoglyco­
side-based regimen. Several second- 
and third-generation cephalosporins 
have been suggested as being equiv­
alent to the combined therapy.3'5 
The emergence of /3-lactamase- 
mediated bacterial resistance to 
these agents6 has prompted the 
development of newer antimicro­
bials, such as the carbapenems, 
monobactams and quinolones.
Imipenem is an amidine derivative 
of thienamycin, a /3-lactam antibiot­
ic produced by Streptomyces cat- 
tleyaJ Because of the drug’s rapid 
metabolism by the renal enzyme 
dehydropeptidase-I, it is adminis­
tered with cilastatin, a specific in­
hibitor of the enzyme. The drug is 
not only resistant to /3-lactamase, 
but is an efficient inhibitor of many 
such enzymes.8 The in-vitro spec­
trum of imipenem is extremely 
wide, including most aerobic and 
anaerobic gram-negative and gram­
positive bacteria; at concentrations 
of 8 m g/L  the drug inhibits over 
98% of clinically important patho­
genic species.9 The only notable
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exceptions to imipenem’s coverage 
are Xanthomonas (Pseudomonas) 
maltophilia. Pseudomonas cepacia, 
Streptococcus faecium, Chlamydia 
trachomatis and Flavobacterium 
spp.10
The clinical efficacy of imipenem 
has been tested in several random­
ized comparative trials, both against 
aminoglycoside-based regimens11-14 
and cephalosporins.1516 However, 
few investigators have specifically 
evaluated the drug in intra-abdomi­
nal infections.121718 The purpose of 
this prospective randomized study 
was to compare the efficacy and 
safety of imipenem with that of an 
aminoglycoside-based regimen in 
patients with intra-abdominal sep­
sis.
Patients and Methods
Patients admitted to the surgical 
wards or the surgical intensive care 
unit of the Royal Victoria Hospital 
in Montreal were entered prospec­
tively into the trial. The study was 
approved by the departmental ethics 
reviews board. Included were pa­
tients admitted for emergency oper­
ation who were suspected, clinical­
ly, of having intra-abdominal infec­
tion on the basis of the history, 
physical examination and laboratory 
or radiographic findings. Those 
who had gynecologic and perianal 
infections, overt renal failure requir­
ing dialysis, concomitant central 
nervous system infection and hyper­
sensitivity to the study drug(s) or 
were pregnant were excluded as 
were patients suffering from un­
complicated acute cholecystitis, ap­
pendicitis without perforation, trau­
matic bowel perforation of less than 
12 hours’ duration or perforated 
peptic ulcers of less than 24 hours’ 
duration. In our opinion the last 
four conditions primarily reflect an 
inflammatory process, not an infec­
tion. Shock, organ failure or ad­
vanced age were not reasons for 
exclusion.
Antimicrobial Therapy
After they had given their in­
formed consent, the patients were 
randomly allocated to receive either 
imipenem/cilastatin (500 mg every 
6 hours intravenously) or tobra­
mycin plus anaerobic coverage. To­
bramycin, 1.5 m g/kg intravenously 
every 8 hours, was given to patients 
whose renal function was normal. 
The dosage interval was adjusted 
according to the creatinine clear­
ance rate in patients whose renal 
function was impaired. Serum to­
bramycin levels were measured be­
fore and after the fourth dose, and 
either dose or interval was adjusted 
to obtain peak drug levels between 
6 and 10 /ug/ml and trough levels 
not less than 1.5 pg/m\.  Anaerobic 
coverage was provided with either 
clindamycin 600 mg every 6 hours 
or metronidazole 500 mg every 6 
hours, both administered intrave­
nously, depending on the origin of 
the infection and the treating physi­
cian’s preference. Treatment was 
continued until there was clinical 
evidence that the infection had re­
solved or that a change of antibiotic 
was required.
Data Collection
Upon entry into the study, a 
clinical history was obtained and 
physical examination performed. 
Changing physical signs and symp­
toms, as well as daily temperature 
charts, were recorded throughout 
the trial. Laboratory data collected 
included the results of hematologic 
and biochemical screening and uri­
nalysis, performed on admission 
and every 3 days during the study. 
The APACHE II score as devised by 
Knaus and colleagues19 was calcu­
lated on admission, using the inten­
sive care research unit APACHE II
scoring sheets. Delayed-type hyper­
sensitivity (DTH) skin testing was 
performed with five common recall 
antigens and the skin-test score 
calculated as described previously.20 
Calculation of the risk of death was 
estimated from formulas and meth­
odologies previously described.19 20
Microbiologic Evaluation
Upon admission, each patient had 
two sets of aerobic and anaerobic 
blood cultures done, as well as 
cultures of all suspected infection 
sites. Gram’s staining of all speci­
mens was performed routinely. Sus­
ceptibility to the study antibiotics 
and to other common antimicrobials 
was tested for by the FDA Stan­
dardized Disk Technique.21
Outcome
Outcome was evaluated by two 
methods. The local infection out­
come was reported using the crit­
eria of Solomkin and others.1 A 
successful outcome required resolu­
tion of the infection without addi­
tional antibiotics. Failure was re­
ported when: (a) lack of objective 
response to therapy necessitated a 
change in antibiotics or additional 
operations; (b) the original infection 
recurred at a site related to the 
initial infection; (c) a change of 
antibiotics was necessitated by an 
adverse reaction, a delayed response 
or in-vitro resistance of an isolate; 
(d) death occurred within a period 
related to the infectious episode and 
infection was a contributing factor. 
Outcome was indeterminate in cases 
of: (a) inadequate surgical proce­
dures; (b) death associated with 
noncontributory infection or within 
72 hours of initiation of therapy; (c) 
superinfection at the initial site, 
with organisms not identified at the 
onset of therapy.
The hospital outcome was re­
corded as alive, dead from sepsis,
4
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and dead from causes other than 
sepsis. Death was considered septic 
related if uncontrolled infection was 
present at the time of death and no 
other independent causative factors 
could entirely account for the out­
come.
Statistical Analysis
Differences between the groups 
were analysed using Student’s two- 
sample 7-test. The a  and /3 limits of 
significant probability were set at
0.05 and 0.1, respectively. Probabil­
ities of death in each group were 
calculated using the logistic regres­
sion formula of Knaus and associ­
ates19 as well as an alternative for­
mula using both APACHE II and 
DTH skin-test scores recently re­
ported.22
Findings
Between September 1985 and 
October 1988, 104 patients were
entered into the study; 52 patients 
received imipenem/cilastatin and 
52 a combined aminoglycoside- 
based regimen (32 tobramycin and 
clindamycin and 20 tobramycin and 
metronidazole). Some of the admis­
sion parameters for each treatment 
arm are shown in Table I. The 
severity of illness (i.e., the septic 
response to infection in the two 
groups) was further estimated by 
the APACHE II score and by cal­
culating the probability of death for 
patients receiving either regimen. 
None of these parameters showed 
statistically significant differences 
between the two groups.
Table II characterizes the various 
infections by type (e.g., peritonitis, 
intra-abdominal abscess) and by site 
of origin. Again the differences 
were not significantly different. The 
six patients who were classified as 
having neither peritonitis nor intra­
abdominal abscess included three 
who had diverticulitis, one who had 
ulcerative colitis and one with a 
bilocutaneous fistula. The break­
down of pathogens into the three 
major classes in each type of infec­
tion is depicted in Fig. 1, and 
according to the site of infection in 
Fig. 2. There were no significant 
differences in the microbiologic 
findings in the two groups.
Table III sets forth the microbial 
resistance to the four antibiotics 
used. Listed are all the resistant 
strains that were encountered, both 
before and during the study. Those 
pathogens that were only partially 
characterized are included under 
the general class to which they 
belong. From the pathogens identi­
fied upon entry to the study ana­
erobes showed higher resistance, 
primarily to Bacteroides fragilis 
(three strains resistant to met­
ronidazole, one to clindamycin), fol­
lowed by Clostridium spp. There 
were no initial strains resistant to 
imipenem. A substantial number of 
gram-positive aerobes were resis-
Table 1. C o m p a riso n  o f A d m iss io n  P a ra m e te rs  in  th e  T w o  T re a tm e n t G rou p s *
Variable
Imipenem
(n =  52)
Combined
treatment
(" =  52)
A ge, y r t 5 2 .0  ±  17 .3 5 7 .6  ±  18.4
S ex
M en 34 26
W o m e n 18 26
S e rum  c rea tin in e , g /L 100 105
S erum  a lb u m in , g / L f 3 1 .6  ± 8 . 7 2 8 .9  ±  6.1
B ac te re m ia  p re -s tu d y , no . (% ) 6 ( 1 2 ) 5 ( 1 0 )
A PAC HE II s c o re t 1 1 .2  ± 9 .1 13.1 ± 7 . 8
DTH sco re , m m t 1 2 .3  ±  1 4 .6 1 0 .8  ± 1 8 .6
A ne rg ic , no. (% ) 2 0  (3 8 ) 2 4  (46 )
P ro b a b ility  o f death
by  APACHE II 0 .1 8 0 .2 3
by  APACHE II and DTH 0 .1 4 0 .2 0
‘ D iffe re n ce s  w e re  n o t s ig n ifica n t. 
tV a lu e s  w ere  m ean  ±  standa rd  d e v ia tio n .
Table II. D is tr ib u tio n  o f In fe c tio n s  b y  T y p e  and S ite  in  th e  T w o  T re a tm e n t G roups
Site/type Imipenem Combined treatment
of no. (%) no. (%)
infection (n =  52) (n =  52)
P e r ito n itis 2 4  (4 6 ) 24  (4 6 )
In tra -a b d o m in a l
a b scess 2 6  (5 0 ) 24  (4 6 )
O the r 2 ( 4 ) 4 ( 8 )
E so p h a g u s /s to m a c h 6 ( 1 2 ) 7 ( 1 3 )
D u o d e n u m /s m a ll bow el 5 ( 1 0 ) 3 ( 6 )
C o lo re c tu m 3 4  (6 5 ) 3 5  (6 7 )
P an c re a tico b ilia ry
tra c t 7 ( 1 3 ) 6 ( 1 2 )
P e ritonea l c a v ity 0 ( 0 ) 1 ( 2 )
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tant to the combined regimen, while 
imipenem covered this bacterial 
class very well. During the therapy, 
resistant strains were identified in 
each treatment arm, with gram­
positive aerobic strains encountered 
most frequently. Table IV shows 
the organisms and outcome for 
each treatment failure associated 
with pathogens resistant to the 
study drugs at the beginning of 
therapy. It can be seen that in the 
combined regimens both failures
centration, we calculated both peak 
and trough tobramycin levels found 
at each sequential serum testing 
(Table VI). These showed a progres­
sive increase in both peak and 
trough levels with each tobramycin 
serum check, approaching target 
levels. There was an inverse correla­
tion between tobramycin serum lev­
els and outcome.
Success of treatment was as­
sessed in terms of both eradication
of the infection (Fig. 3) and hospital 
outcome. There were more treat­
ment successes and fewer failures 
and indeterminate outcomes in the 
imipenem group than in the amino­
glycoside groups, but the differ­
ences were not significant. The ef­
fect of each treatment modality was 
assessed in terms of several parame­
ters. Figure 4 shows the differences 
in five such measurements: occur­
rence of febrile episodes while on
and deaths were encountered in 
patients harbouring resistant organ­
isms.
Superinfections, defined as infec-
Tab le  II I .  A n tim ic ro b ia l R es is ta n ce  P a tte rn s  to  Each S tu d y  Drug
B efore  th e rap y During therapy
O rgan ism N o.* O rganism N o.*
G ra m -p o s itiv e  ae robes 
T o b ra m yc in Streptococcus spp  
Enterococcus
4
2
Streptococcus spp  
Enterococcus
1
2
<tions due to organisms resistant to 
the study drug, and their outcome
are shown in Table V. Imipenem, Staphylococcus
partly due to its well-known resist- epidermidis 2
ance to P . m a l t o p h i l ia ,  contributes Staphylococcusaureus 1
the same number of treatment fail- Im ipenem None S. epidermidis 4
ures as the combined regimens. As G ram -n e g a tive  aerobes
Corynebacterium 2
*  z
one would expect, superinfections T o b ra m yc in N one None k
in the combined regimens were Im ipenem N one Pseudomonas
caused chiefly by aerobic gram-posi­
tive pathogens which are not ade- A naerobes
maltophilia 2 A
quately covered.
In the combined regimens, to-
C lin d am yc in Bacteroides
fragilis
Fusobacterium
1
1
None
k.
4 .
bramycin was given at a median AGPC 1
dose of 80 mg every 8 hours (range M etron id a zo le B. fragilis 3 AGPC 1
from 60 mg to 180 mg), and the perfringens 1 A
interval of administration ranged AGPC 1
from 6 to 36 hours. In order to Im ipenem N one AGPR 1
determine whether we achieved the 'N u m b e r  o f  s p e c im e n s  e n coun te red .
targeted peak aminoglycoside con- AGPC =  a n a e rob ic  g ra m -p o s it iv e  cocc i, AG PR  =  a n a e rob ic  g ra m -p o s it iv e  rods.
FIG. 1. Major bacterial classes encountered by type of FIG. 2. Major bacterial classes encountered by source of
infection. Black bars =  gram-positive, white bars =  gram- infection. Black bars =  gram-positive, white bars = gram­
negative, dotted bars =  anaerobes. negative, dotted bars =  anaerobes.
r-t
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the study, occurrence of break­
through bacteremias (i.e., bac­
teremias caused by pathogens that 
emerged during the therapy), resist­
ance to the study antibiotic and 
need to change it, and length of 
hospital stay. Imipenem fared better 
than the combined regimens in 
every one of these respects, al­
though only for the change in anti­
biotic was the difference significant 
(p = 0.02). Final hospital outcome 
is shown in Fig. 5. Although the 
percentage of imipenem-treated pa­
tients who died of their infection 
was lower than that for the com­
bined regimens (4% versus 13%, p 
= 0.08), non-septic deaths in the 
two groups were similar.
The use of two different severity 
of disease scores has permitted the 
stratification of our patients and 
subsequent study of the effect of 
treatment in relation to illness se­
verity in each subgroup. Figure 6 
shows cumulative failures stratified 
according to the APACHE II score 
on admission, and in Fig. 7 the
stratification is based on the individ­
ual probabilities of death derived 
from the APACHE II score and 
DTH logistic regression formula.22 
These two figures show the wide 
spectrum of distribution of patients 
according to the severity of their 
disease, as well as the differences in 
success between subgroups in the 
two treatment arms.
Only one adverse effect was en­
countered in our study, a transient 
tachycardia reported in the amino­
glycoside group. We did not detect 
any change in serum creatinine lev­
els after the study in these patients 
(pre-study mean serum creatinine 
was 105 g /L , post-study 112 g/L).
Discussion
As concluded by Solomkin and 
colleagues1 in their critical evalua­
tion of antibiotic trials, studies eval­
uating therapy for intra-abdominal 
infections must demonstrate the fol­
lowing: inclusion of infections with 
high failure rates and sufficient 
numbers of patients, effective ran­
domization techniques, stratifica­
tion for other variables affecting 
outcome, precise outcome evalua­
tion criteria and provision of suffi­
cient data to support the outcome 
evaluation. In the design of our 
study we have attempted to follow 
these criteria, and our results gen­
erally reflect this.
The size of the population stud­
ied has always been a concern in 
trials of antibiotics, where small 
differences in drug efficacy require 
large numbers of patients for statis­
tical significance. However, only a 
few reports on imipenem in the 
literature include more than 100 
patients, and none of these have 
compared imipenem prospectively 
to conventional therapies in intra­
abdominal infections. The largest 
study to date, that of Gonzenbach, 
Simmen and Angwerd,18 included
Table IV. Treatment Failures Associated With Pre-therapy Organisms Resistant to Study Drugs
Drug Organism/no. specimens Failed Deaths
Imipenem None 0 0
Tobramycin Streptococcus spp (4) 2 2
Enterococcus (2) 1 1
Clindamycin Bacteroides fragilis (1) 0 0
Fuso bacterium (1) 1 1
AGPC (1) 1 1
Metronidazole B. fragilis (3) 2 0
Clostridium perfringens (1) 0 0
AGPC (1) 0 0
AGPC =  anaerobic gram-positive cocci.
Table V. Treatment Failures Associated With Organisms Resistant to Study Drugs During Therapy
(“ Superinfections” )
Drug Organism No. Failed Deaths
Imipenem Pseudomonas maltophilia 2 1 1
AGPR 1 0 0
Staphylococcus epidermidis 4 1 0
Corynebacterium 2 1 0
Tobramycin AGPC 1 1 1
S. epidermidis 1 0 0
Enterococcus 1 1 0
Clindamycin None 0 0 0
Metronidazole AGPC 1 1 1
AGPC =  anaerobic gram-positive cocci; AGPR =  anaerobic gram-positive rods.
Table VI. Mean Tobramycin Serum Levels (g/m l)
No. Trough ± SEM Peak ± SEM
First testing 48 1.52 ± 0 .17 4.86 ± 0.25
Second testing 32 1.59 ± 0.19 5.80 ± 0.44
Third testing 11 2.05 ± 0 .18 6.13 ±0.41
Successful course 32 1.23 ± 0 .16 4.41 ± 0.25
Failed course 11 1.83 ± 0 .40 * 5.43 ± 0.48*
*p (success versus failure). p =  0.09 p =  0.05
CIS, VOL. 33, NO. 5, OCTOBER 1990 419
POENARU, DE SANTIS, CHRISTOU
Alive Septic death Other death
FIG. 3. Outcome in relation to local infection. Classification 
adapted from Solomkin and associates.1 Black bars =  imipe- 
nem, dotted bars =  aminoglycoside.
FIG. 4. Effect of antibiotic therapy on five study parameters: 
occurrence of febrile episodes while on study drug (F, body 
temperature greater than 38°C), occurrence of breakthrough 
bacteremias (BB), resistance to the study antibiotic (RD) and 
need to change it (AC), and length of hospital stay in days 
(HS). Black bars = imipenem, dotted bars =  aminoglycoside.
Alive Septic death Other death
FIG. 5. Outcome in relation to final disposition for each treatment arm. Black 
bars = imipenem, dotted bars =  aminoglycoside.
93 patients but provided no statisti­
cal analysis.
The admission parameters of our 
study revealed a seriously ill popu­
lation with high APACHE II scores, 
high percentage of anergic and bac- 
teremic cases and many patients 
classified as having major infec­
tions. We predicted overall mortali­
ties in the order of 15% to 20% 
using our stratification formulas; 
the actual death rate was 13%.
In each of the parameters fol­
lowed through the study, imipenem 
fared better than the combined ami- 
noglycoside-based regimens. The 
differences in number of febrile epi­
sodes and length of hospital stay
have been noted by others,1718 but 
we added such factors as the occur­
rence of breakthrough bacteremias, 
an initial resistance to the study 
antibiotic and the need to change 
the antibiotic. The last factor 
showed quite a striking effect: only 
2 patients on imipenem needed to 
be switched to another antibiotic 
compared with 13 patients initially 
receiving an aminoglycoside-based 
regimen. This occurred because of 
bacterial resistance patterns com­
bined with an unfavorable clinical 
impression, usually leading to the 
addition of a /3-lactam antibiotic.
The pre-study resistance patterns 
support the existing evidence in
favour of the extremely efficient 
antibacterial profile of imipe­
nem.8'9'23 With the exception of so- 
called “triple” regimens, which in­
corporate a /3-lactam agent, amino­
glycoside-based regimens cover 
gram-positive aerobes poorly. This 
was evidenced by the considerable 
number of resistant gram-positive 
strains, in keeping with the large 
proportion of this bacterial group in 
our infections. Besides, the substan­
tial number of metronidazole-resist­
ant Bacteroides strains was unsus­
pected and of concern.
When the resistant infections 
were related to eventual outcome, 
no treatment failure or death could 
be attributed to initial bacterial re­
sistance to imipenem. Clindamycin 
and tobramycin, on the other hand, 
appeared commonly linked with re­
sistance and subsequent failure. 
Five patients who had infections 
resistant to these drugs died. It is 
difficult to prove whether such as­
sociations are truly causal, but the 
patterns observed are nevertheless 
suggestive.
Superinfections with resistant or­
ganisms emerged during the treat­
ment in two cases of P. maltophilia 
in our study; this represented 16% 
of all Pseudomonas strains. The 
refractoriness of P. maltophilia to
420 CIS, VOL. 33, NO. 5, OCTOBER 1990
IMIPENEM VERSUS TOBRAMYCIN
< 0 .2  0 .2 - 0 .4  0 .4 - 0 .6  > 0 .6
pldeath
FIG. 6. Cumulative failures in each treatment group with 
patients stratified by APACHE II score. Solid line =  imipe- 
nem, dotted line =  combined regimen.
FIG. 7. Cumulative failures in each treatment group with 
patients stratified by death probability value (p /death /) 
derived from both APACHE II and DTH skin-test scores. Solid 
line = imipenem, dotted line =  combined regimen.
imipenem may have been the cause 
of one treatment failure which even­
tually led to the patient’s death. We 
did not, however, encounter any 
Pseudomonas aeruginosa resistant 
strains emerging during treatment, 
as recently shown by Calandra and 
associates.24 On the other hand, 
there were three superinfections 
with aerobic gram-positive agents 
resistant to tobramycin, one in a 
patient who eventually died of sep­
sis. Hence, superinfections are a 
concern in traditional therapeutic 
regimens also, and their coverage 
with aminoglycosides is far from 
being adequate.
Measurement of aminoglycoside 
serum levels is essential for ensur­
ing adequate treatment and for 
avoiding toxicity. During therapy 
we noted a constant need to change 
dosage and frequency of administra­
tion to achieve adequate tobramycin 
levels, rather than to avoid toxicity. 
Aminoglycoside treatment failures 
cannot be attributed to inadequate 
drug concentrations. Patients 
whose therapy failed had markedly 
higher peak and trough tobramycin 
levels than those with a successful
outcome. Hence, careful amino­
glycoside monitoring can optimize 
the antibiotic dosage without neces­
sarily having prognostic value.
Although superiority of one anti­
biotic regimen over another re­
quires comparison of many varia­
bles, clinical success and final hos­
pital outcome remain the chief pa­
rameters. It is noteworthy that 
every trial of imipenem versus ami­
noglycoside-based combined regi­
mens in intra-abdominal sepsis has 
shown improved outcome with 
imipenem, although none of the 
results have been statistically sig­
nificant.121418'25 Our results clearly 
support this finding, and we were 
able, in the case of septic deaths, to 
approach statistical significance (p 
=  0.08). We had a considerable 
number of treatment failures and 
deaths in keeping with the relatively 
ill patient population that we stud- 
ed. The use of an objective classifi­
cation of outcome, as well as sepa­
rate consideration of septic-related 
and non-septic deaths, enabled us 
to evaluate the antibiotic effect bet­
ter. The overall medical condition of 
the patient remains, however, a
major factor in the success of thera­
py; intra-abdominal infection is a 
surgical condition with a primarily 
surgical treatment strategy, and an­
tibiotics remain an adjunctive thera­
py. Hence, we stratified our patients 
by severity of underlying condition 
in order to identify the subgroup 
most likely to benefit from the 
antibiotics. Stratification of the AP­
ACHE II scores revealed that 
“healthy” patients with scores less 
than 15 had few treatment failures 
and deaths regardless of the regi­
men used; the “sick” group with 
APACHE II scores over 15 was 
associated with most of the morbid­
ity and mortality, and in this sub­
group imipenem-treated patients 
tended to fare better. These data are 
in accord with the findings of So- 
lomkin and colleagues.14 The com­
putation of actual probabilities of 
death for each patient allowed us to 
stratify our population by a compre­
hensive method that takes into ac­
count the state of the patients’ host 
defence as well as physiological 
status, age and long-term health. 
Although hospital outcome would 
naturally be expected to worsen
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with severity of disease, we ob­
served that clinical course success 
followed the same trend. The good- 
outcome patients appeared to be 
those with a probability of death 
less than 0.2, and no differences 
between regimens were found in 
that subgroup; higher probabilities 
of death identified poor-outcome 
patients in whom imipenem again 
seemed to perform better than the 
combined regimens.
Only one adverse effect was seen 
in our study, a surprising finding in 
view of the previous 10% to 20% 
incidence reported by others.141823 
We attribute this to the inclusion in 
our study of only those side-effects 
which appeared related to the anti­
biotic regimen. Most notable was 
the unexpected absence of ne­
phrotoxicity in the aminoglycoside- 
treated group. Solomkin and col­
leagues14 reported a 20% incidence 
of nephrotoxicity with gentamicin 
use and stressed the difficulty in 
avoiding this condition in spite of 
serum level measurements and mul­
tiple dose adjustments. The data 
from our study do not support their 
findings and confirm the view that 
careful maintenance of aminoglyco­
side blood levels within the thera­
peutic range in conjunction with 
the use of the less nephrotoxic drug 
tobramycin can effectively prevent 
renal damage.
In conclusion, we have presented 
here data in support of the use of 
im ipenem /cilastatin in in tra­
abdominal infection. Imipenem com­
pares favourably to aminoglycoside- 
based regimens; it appears more 
effective and is not particularly tox­
ic. Seriously ill patients are the ones 
most likely to benefit from this 
drug, as long as superinfections 
with resistant strains are carefully 
recognized and treated.
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ORIGINAL ARTICLES
Small-Bowel Lipoma: an Uncommon 
Cause of Obstruction
Wojciech Brzezinski, MD;* R.J. Bailey, MD, FRCPC;t Morris Besney, MD, FRCPC;J 
Garth Turner, MD, FRCPC§
Small-bowel tumours are an uncommon cause of small-bowel obstruction. The 
symptoms are unsually nonspecific and intermittent. Contrast studies of the small 
bowel are the best means of delineating the lesion. The authors present a case in 
which obstruction was treated with small-bowel resection, and they give a brief 
account of the occurrence of small-bowel tumours in a major teaching hospital.
Les tumeurs de l’intestin grele sont rarement la cause d’obstruction. Les symptomes 
sont habituellement non specifiques et intermittents. Des examens du grele a l’aide 
de techniques de contraste sont le meilleur moyen de delineer la tumeur. Les 
auteurs decrivent un cas ou une obstruction fut traitee par resection et ils donnent 
un bref aperfu de l’incidence des tumeurs de l’intestin grele dans un hopital 
universitaire important.
Tumours of the small bowel are rare. They make up 1.5% to 
6.5% of all gastrointestinal neo­
plasms.1 Of these, 50% to 75% are 
malignant, accounting for 1% to 3% 
of all gastrointestinal malignant dis­
ease.2 Benign tumours are often 
found at laparotomy performed for 
an unrelated condition. If they be­
come symptomatic, the usual pre­
sentation involves bleeding, abdomi­
nal pain, nausea and vomiting.3
We describe a patient with a 
lipoma of the ileum who presented
fS ta ff Surgeon, Royal Alexandra Hospital
with intermittent obstruction of the 
small bowel.
Case Report
An 82-year-old woman was ad­
mitted with a 3-day history of inter­
mittent upper abdominal pain, nau­
sea and vomiting aggravated by 
eating. She had had similar symp­
toms over the last 2 or 3 years. 
About 30 years earlier she had 
undergone cholecystectomy.
She was found to have mild ab­
dominal distension, with tenderness 
of the upper abdomen. No masses 
or blood was apparent on rectal 
examination. An x-ray film of the 
abdomen showed a number of air- 
fluid levels in the small bowel (Fig. 
1). All symptoms resolved rapidly 
with conservative management. An 
upper-gastrointestinal-tract series 
with small-bowel follow-through 
showed a large intraluminal lesion 
in the ileum (Fig. 2).
At a subsequent laparotomy the 
segment of ileum containing the 
tumour (Fig. 3) was resected. His­
topathologic examination of the le­
sion demonstrated that it was a
FIG. 1. X-ray film of abdomen, patient 
upright, shows air-fluid levels in sev­
eral loops of abnormally distended 
small bowel.
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benign lipoma. The patient’s post­
operative course was uncomplicat­
ed.
Discussion
Small-bowel lipomas account for 
20% to 25% of all gastrointestinal 
lipomas, being second in frequency 
to those of the colon, which consti­
tute 65% to 75% of cases.4-5 Lipo­
mas also account for 8% to 20% of 
all benign neoplasms of the small 
bowel, the most common being lei­
omyomas and adenomatous polyps.
Lipomas are usually single, sub­
mucosal masses. In 10% to 15% of 
cases they are multiple. A few rare 
cases of diffuse lipomatosis have 
been described.6-7 Malignant trans­
formation has not been reported. 
Fewer than half of the patients who 
have intestinal lipoma become
FIG. 2. Spot film from small-bowel 
follow-through shows smooth, non- 
pedunculated lesion, 4 cm in diameter, 
in ileum.
symptomatic because of obstruc­
tion, intussusception or bleeding.8
The diagnosis of small-bowel tu­
mours is not always easy. A small- 
bowel follow-through may reveal 
(as it did in our case) the presence 
of a smooth, rounded filling defect. 
Fluoroscopy may offer additional 
help, showing mobility if the tu­
mour is pedunculated and identify­
ing normal bowel-wall motility. Ex­
cision of the benign tumour can be 
accomplished by enterotomy or a 
segmental resection. Surgical resec­
tion of a malignant lesion would 
have to be more extensive.
Reviewing the records of the 
Royal Alexandra Hospital in Ed­
monton we found that 46 patients 
with small-bowel tumours had been 
operated on between 1970 and 
1988. In 19 patients the tumour
FIG. 3. Gross appearance of lipoma 
removed from small bowel.
was benign and in 27 it was malig­
nant. The most common benign 
tumour in this group was lei­
omyoma (six cases). Among malig­
nant lesions, we found adenocar­
cinomas in 18 cases, carcinoids in 
6, sarcomas in 2 and lymphoma in 
1 case.
We thank the staff of the Medical 
Records Department, Royal Alexandra 
Hospital for assistance in preparing 
data and Miss Brandingen for preparing 
the manuscript.
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ORTHOPEDIC SURGEON: ON -  Applica­
tions are invited for three openings at St. 
Joseph's Health Centre of London, a 500-bed 
teaching hospital affiliated with the University 
of Western Ontario. The successful appli­
cants will become part of a planned five- 
member practice group with a large referral 
area, attractive operating time, inpatient beds, 
outpatient clinics, research facilities, and in­
come. The need is for surgeons with an 
interest in general orthopedics in combination 
with subspecialities in one or more of foot 
and ankle, oncology, upper extremity, adult 
reconstructive/arthroplasty, soft tissue, ar­
throscopy, and medical education. Qualifica­
tions include FRCSC, good clinical skills, an 
academic orientation, an interest and exper­
tise in teaching of medical students, interns 
and residents, and 1 year of post-fellowship 
training. Starting date is preferred January 
1991, and at the latest July 1991. Consider­
ation will also be given to recent FRCSC
graduates taking the position as a 1 year 
locum, or setting up a 1 year fellowship 
January 1991 - December 1991, to then join 
our practice January 1992 on a long-term 
basis. Send enquiries and curriculum vitae to: 
Dr. Tom Phillips, 450 Central Ave., Lon­
don, ON N6B 2E8. -S90-32
FACULTY POSITIONS: US -  The University 
of South Alabama Department of Surgery in 
Mobile, Alabama invites applications for facul­
ty positions in vascular, cardiothoracic, plastic 
and reconstructive surgery, pediatric surgery 
and trauma. The University of South Alabama 
medical system comprises four hospitals 
serving as a tertiary referral centre for a 
regional area of 1.5 million people. Mobile is a 
gulf coast city of 350 000 people, at the 
southern-most tip of Alabama. For further 
information, contact: Dr. J. Raymond
Fletcher, Chairman, Department of Sur­
gery, 2451 Fillingim St., Mobile AL
36617, Tel: (205) 471 -7993 . The Universi­
ty of South Alabama is an affirmative action/ 
equal opportunity educational institution.
-S90-31
DOWNTOWN TORONTO -  Medical office 
available in Class " A "  professional building, 
600 sq. ft., recently decorated facility. Fully 
furnished. Current practitioner retiring after 17 
years at this location. Near hospitals. On 
subway. Ample parking. For further details, 
please contact, in confidence: ROI Corpora­
tion, Mississauga, tel: (416) 820-4145. 
Ref. 315. -S90-30
NEARING RETIREMENT?: -  I am looking 
for a rural general surgeon interested in work­
ing half time, eg: 4 months on and 4 months 
off, starting in 1 or 2 years. Located on the 
beautiful Sunshine Coast. Contact: Dr. Eric 
Paetkau, FRCS, Box 638, Sechelt, BC VON 
3A0 -S90-29
University of Ottawa • Faculty of Medicine 
Chair of Orthopaedics
The University of Ottawa invites applications for the position 
of Chairperson of the University Division of Orthopaedics.
Applicants must be eligible to practise in Ontario and hold certifica­
tion of the Royal College of Physicians and Surgeons of 
Canada in orthopedics. The Faculty is seeking an individual with 
a track record of excellence in clinical and academic practice, 
leadership skills and potential to develop a strong research 
program in orthopedics.
The Department is responsible for directing both undergradu­
ate teaching and postgraduate programs in orthopedics in the 
following affiliated hospitals: Ottawa Civic Hospital, Ottawa 
General Hospital and the Children’s Hospital of Eastern Ontario.
The successful candidate will hold a joint appointment as Chair 
of the University Division of Orthopaedics and Head of one of 
the affiliated teaching hospitals.
The Faculty is seeking an individual who will hold a full-time 
university appointment. Salary and fringe benefits are 
commensurate with qualifications and experience and are in 
accordance with existing scales at the University of Ottawa.
Priority will be given to Canadian citizens and permanent re­
sidents of Canada in accordance with Canadian immigration re­
quirements. Employment equity is university policy.
Applicants are requested to forward their curriculum vitae and the 
names of three referees prior to Nov. 30, 1990 to:
John F. Seely, MD 
Dean, Faculty of Medicine 
University of Ottawa 
451 Smyth Road 
Ottawa, Ontario K1H 8M5
Universite d’Ottawa • Faculte de medecine 
Chaire d’orthopedie
L’Universite d’Ottawa accueille les candidatures a la direction de 
sa chaire d’orthopedie.
Les candidats et candidates doivent etre admissibles a exercer la 
profession en Ontario et posseder I’agrement a titre de specialiste 
du College royal des medecins et chirurgiens du Canada, tout en 
faisant preuve de realisations et d’experience en orthopedie 
Clinique et universitaire. Le poste comporte un role de direction 
dans les milieux universitaire, hospitalier et communautaire et la 
preference sera accordee a une personne competente qui s’est 
engagee dans la voie de I’exce ilence un ive rs ita ire  en 
enseignement et en recherche
Le departement a la responsabilite de fournier un enseignement 
de qualite au niveau prediplome et postdoctoral dans les hopitaux 
affilies offrant une formation en orthopedie soit I’Hopital pour 
enfants de I’Est de I’Ontario, I’Hopital Civic d’Ottawa, I’Hopital 
General d’Ottawa. La personne retenue assumera une double 
affectation a la direction de la chaire d’orthopedie de I’Universite 
et a la direction de I’orthopedie dans un des hopitaux 
d’enseignement mentionnes.
La Faculte est a la recherche d’une personne pour combler un 
post a temps complet. Le traitement et les avantages sont fonction 
de la formation et de I’experience, conformement a I’echelle en 
vigueur a I’Universite d’Ottawa.
En vertu des exigences canadiennes relatives a I’immigration, la 
priorite est accordee aux personnes de citoyennete canadienne et 
de residence permanente au Canada. L’Universite a une politique 
d’egalite en matiere d’emploi.
Priere d’envoyer les demandes, accompagnees d’un curriculum 
vitae et du nom de trois repondants, a I’adresse ci-dessous avant 
le 30 nov. 1990.
John F. Seely, MD 
Doyen, Faculte de medecine 
Universite d’Ottawa 
451, chemin Smyth
Ottawa (Ontario) K1H 8M5 —s90-a
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CARDIOVASCULAR AND THORACIC SURGERY 
ACADEMIC APPOINTMENT
DIVISION OF CARDIOVASCULAR/THORACIC SURGERY 
UNIVERSITY OF SASKATCHEWAN 
SASKATOON, SASKATCHEWAN
Applications are invited for a full-time position with the Division 
of Cardiovascular Surgery in the Department of Surgery at the 
University of Saskatchewan. The successful candidate will be 
appointed to the active staff of the Department of Surgery at 
Royal University Hospital and hold a full-time faculty appointment 
with the College of Medicine at the University of Saskatchewan.
Interested applicants should have clinical experience in adult and 
pediatric cardiovascular surgery. A recorded commitment to 
undergraduate and postgraduate education is essential. A 
background of recent surgical research is desirable.
Candidates must have certification in cardiovascular and thoracic 
surgery from the Royal College of Physicians and Surgeons of 
Canada. They must be eligible for registration with the College 
of Physicians and Surgeons of Saskatchewan. In accordance 
with Canadian immigration requirements, this advertisement is 
directed to Canadian citizens and permanent residents. The 
University of Saskatchewan is committed to the principles of 
employment equity.
Please submit a current curriculum vitae and names of three 
referees by Oct. 31, 1990 to:
Dr. Roger G. Keith 
Professor and Head 
Department of Surgery 
University of Sasktachewan 
Royal University Hospital 
Saskatoon, Saskatchewan 
S7N 0X0
— S90-35
sc o rr& w H iTE TEXAS A&M UNIVERSITY 
College of Medicine
TEMPLE CAMPUS
The Department of Neurologic Surgery o f the Scott 
and White Institutions and Texas A&M University 
College of Medicine is seeking applications for 
senior staff physician faculty in the Sections of 
Pain/Stercotaxic Surgery or Neurosurgical Oncology. 
Residency or post residency experience and a 
defined interest in either subspecialty area together 
with a broad capability and interest in general 
neurosurgical disorders is desired. Basic and clinical 
research opportunities are available commensurate 
with previous experience. Medical student and 
resident teaching/daily responsibilities are required. 
The main campus is located in central Texas, north 
of Austin in the approximate center of the Dallas/ Ft. 
Worth, San Antonio, Houston triangle and benefits 
from easy access to other surrounding universities 
(Southwestern University, Georgetown; University of 
Mary Hardin-Baylor, Belton; Baylor University, 
Waco.)
For further information, please send curriculum 
vitae and references to:
Mitchell Smigicl, M.D.
Chairman, Neurologic Surgery 
Scott and While, Texas A&M University 
College o f  Medicine 
2401 South 31st Street 
Temple, TX 76508
— S90-06
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CHIEF OF NEUROSURGERY
The Sir Mortimer B. Davis —  Jewish 
General Hospital, a 630-bed tertiary 
care teaching hospital of McGill 
University is inviting applications for 
the position of Chief of Neurosurgery. 
P o tentia l cand idates should be 
certified by the Royal College of 
Physicians and Surgeons of Canada (or 
equivalent) and have significant 
academic and research experience in 
teaching hospitals. The successful 
candidate will be offered a university 
appointm ent com m ensurate with 
h is /he r qualifications. Interested 
candidates should send a copy of their 
curriculum vitae to:
Dr. P.L. Heilpern 
Associate Executive Director —  
Professional Services 
Sir Mortimer B. Davis 
Jewish General Hospital 
3755 Cote St. Catherine Road 
Suite A-142
Montreal, Quebec H3T 1E2 —S90-34
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THE SURGEON’S CHOICE
SURGICAL SUTURES FROM SWITZERLAND
ASSUT® BRAND AND SUPERB QUALITY
HSR-needles
1/2 circle, cutting-taper
HSR-18
HSRG-needles ^
1/2 circle, cutting-taper, heavy
HSRG-27
A
HSRG-38
HSRG-45
TSR-needle
3/8 circle, cutting-taper
TSR-14
HS-needles W
1/2 circle, reverse cutting
TS-needles -
3/8 circle, reverse cutting
HSG-needle I
1/2 circle, cutting, heavy 
HSG-24
Introducing the finest quality of sterile double packed surgical 
sutures from Switzerland. Available in Blue Nylon, Black Silk, 
Polypropylene. Also available in Linen, Surgical Steel, Astralen 
as well as Tendon Sutures, Double-Armed Needles, Round 
Bodied and other type needles. A comprehensive catalogue 
''will be furnished upon request with first order. Free suture 
samples are available upon request.
I S pI r s p e w u .'.
SPECIAL $16.95/doz.
REGULAR $23.95
POLYPROPYLENE - SPECIAL S18.95/DOZ. Needles are shown in actual size for 
shape and length, but not for thickness.
ASTRALEN
Green braided polyester with im­
proved tensile strength and knot 
security, siliconized. A modern 
braid ing technique gives the 
strand a smooth and uniform sur­
face that minimizes the trauma.
SUPRAMID
Black monofilament polyamide 
with supersoft core, resulting in 
superior pliability and knot sec­
urity. The uniform and smooth 
surface permits effortless passage 
through tissue with minimum 
trauma. Supramid is extremely 
. well tolerated.
LINEN
Natural white twisted strand very 
smooth and with high knot sec­
urity. This well-known material has 
been used in surgery for many 
years and it is still very 
appreciated.
POLYPROPYLENE
Blue monofilament polypropylene 
is flexible and ties securely. Ex­
tremely well tolerated, its smooth 
and uniform surface allows easy 
passage through tissue with min­
imum trauma.
SUPRAMID W HITE
White monofilament polyamide 
with supersoft core, with the same 
characteristics as Supramid.
SILK
Black braided surgical silk on 
twisted core for greater tensile 
strength. Silicone treatment and 
new braiding technique render 
the silk uniform and smooth and 
facilitate its handling.
SURGICAL S T E E L
Twisted stainless steel with very 
high tensile strength and excellent 
knot security. This strand causes 
minimum tissue reaction.
MONOFIL NYLON
Blue monofilament polyamid with 
high tensile strength. The uniform 
and smooth surface permits effort­
less passage through tissue with 
minimum trauma. Extremely well 
tolerated.
THE ABOVE INFORMATION IS PROVIDED TO ASCERTAIN YOUR B EST AND CORRECT CHOICES.
MAXOM
polyglyconate monofilament absorbable suture
Easier 
handling 
first throw 
to last
Maxon. A softer, more supple suture that offers strength, 
superior handling characteristics and patient benefits.
DG
DAVIS+GECK
MEDICAL DEVICE DIVISION 
Cyanamid Canada Inc.
A  World Leader in Wound Management
